drTarget portfolio target-disease associations for muculoeskeletal and connective diseases DrTarget’s AI-Powered Indication Expansion for Muculoeskeletal and Connective Diseases

DrTarget’s AI-Driven Insights for Musculoskeletal & Connective Tissue Diseases

DrTarget leverages advanced AI and machine learning to uncover target-disease associations for musculoskeletal and connective tissue diseases, integrating data from Open Targets and other public repositories. Our computational models identify novel therapeutic targets and drug repurposing opportunities for conditions such as:

✔ Osteoarthritis & Rheumatoid Arthritis
✔ Osteoporosis & Bone Metabolic Disorders
✔ Muscular Dystrophies & Myopathies
✔ Fibrosis & Connective Tissue Disorders
✔ Joint Degeneration & Cartilage Repair

By combining phenotypic modeling and AI-driven drug discovery, we accelerate the identification of mechanisms driving disease progression, supporting the development of targeted therapies and precision medicine approaches.

Target-disease associations for musculoeskeletal/connective tissue disorders.

Check best scored target-disease associations in table:

BioAssay Name	program	diseaseName	assayType	testedCompounds	activeCompounds	associationScore	numberOfEvidences
Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	cardiomyopathy	targetBased	335239	801	0.738160697713462	1141
Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	cardiomyopathy	targetBased	335238	390	0.738160697713462	1141
Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	dilated cardiomyopathy	targetBased	335239	801	0.696018079292442	92
Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	dilated cardiomyopathy	targetBased	335238	390	0.696018079292442	92
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay	MAPK1	hypertrophic cardiomyopathy	pathwayBased	70898	707	0.638631820518866	20
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF	MAPK1	hypertrophic cardiomyopathy	pathwayBased	131324	544	0.638631820518866	20
Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	hypertrophic cardiomyopathy	targetBased	335239	801	0.926253064265713	1241
Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	hypertrophic cardiomyopathy	targetBased	335238	390	0.926253064265713	1241
Assay for Inhibitors of the beta-Arrestin-Adaptor Protein 2 Interaction That Mediate GPCR Degradation and Recycling	ARRB1_inhibitors	hypertrophic cardiomyopathy	targetBased	338373	1061	0.599404989335178	27
Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn6) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )]	FGB_inhibitors	hypertrophic cardiomyopathy	targetBased	369953	760	0.578848118498312	10
Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn7) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )]	FGB_inhibitors	hypertrophic cardiomyopathy	targetBased	369953	498	0.578848118498312	10
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	hypertrophic cardiomyopathy	targetBased	194628	267	0.723494176407128	465
qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen	IL-1b Inflammasome	juvenile idiopathic arthritis	pathwayBased	362051	17187	0.557333022236428	217
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	psoriatic arthritis	targetBased	217959	2390	0.629378658421174	63
Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	restrictive cardiomyopathy	targetBased	335239	801	0.672321932673797	120
Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	restrictive cardiomyopathy	targetBased	335238	390	0.672321932673797	120
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	osteoporosis	targetBased	86095	1442	0.740989460833532	72
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	osteoporosis	targetBased	86095	1151	0.740989460833532	72
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	osteoporosis	targetBased	394050	3624	0.683681888899659	113
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	osteoporosis	targetBased	86095	1114	0.661909666301374	61
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	osteoporosis	targetBased	405685	308	0.658783124032757	133
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	cutaneous lupus erythematosus	targetBased	343468	734	0.508265156028171	6
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	hip fracture	targetBased	394050	3624	0.560682335264164	17
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	hip fracture	targetBased	335239	991	0.595650699705387	9
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	hip fracture	targetBased	335239	695	0.595650699705387	9
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	postmenopausal osteoporosis	targetBased	86095	1442	0.643509974124573	30
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	postmenopausal osteoporosis	targetBased	86095	1151	0.643509974124573	30
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	postmenopausal osteoporosis	targetBased	394050	3624	0.640838273592233	36
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	postmenopausal osteoporosis	targetBased	86095	1114	0.651434014354781	44
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	postmenopausal osteoporosis	targetBased	405685	308	0.650220587016059	56
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	bone density	targetBased	86095	1442	0.544372294829174	60
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	bone density	targetBased	86095	1151	0.544372294829174	60
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	ankylosing spondylitis	targetBased	217959	2390	0.673282147689306	33
MLPCN ERAP1 Measured in Biochemical System Using Plate Reader - 7016-01_Inhibitor_SinglePoint_HTS_Activity	ERAP1_inhibitors	ankylosing spondylitis	targetBased	335777	499	0.531074016498844	207
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	bone fracture	targetBased	394050	3624	0.565035984166105	29
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	bone fracture	targetBased	335239	991	0.63093617484398	26
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	bone fracture	targetBased	335239	695	0.63093617484398	26
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	bone fracture	targetBased	405685	308	0.626471657003301	21
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	bone fracture	targetBased	316642	617	0.557765397120809	12
uHTS identification of small molecule modulators of NR3A	GRIN3A	bone fracture	targetBased	339772	8480	0.591034537873092	14
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	humerus fracture	targetBased	335239	991	0.577168330395272	6
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	humerus fracture	targetBased	335239	695	0.577168330395272	6
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	humerus fracture	targetBased	316642	617	0.577168330395272	6
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	bone disease	targetBased	86095	1442	0.518297504276273	499
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	bone disease	targetBased	86095	1151	0.518297504276273	499
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	scoliosis	targetBased	335239	991	0.581086621208305	17
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	scoliosis	targetBased	335239	695	0.581086621208305	17
qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen	IL-1b Inflammasome	gout	pathwayBased	362051	17187	0.57690435150965	63
HCS assay for microtubule stabilizers	TUBB	gout	targetBased	195821	1625	0.650695824149268	48
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	bone quantitative ultrasound measurement	targetBased	86095	1442	0.553003830357957	41
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	bone quantitative ultrasound measurement	targetBased	86095	1151	0.553003830357957	41
HTS of Smad transcription factor inhibitors	SMAD3	bone quantitative ultrasound measurement	targetBased	88033	251	0.501865676168539	11
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	osteoarthritis, knee	targetBased	394050	3624	0.579400705699943	14
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	osteoarthritis, knee	targetBased	335239	991	0.644836374558565	48
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	osteoarthritis, knee	targetBased	335239	695	0.644836374558565	48
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	osteoarthritis, knee	targetBased	339297	1446	0.611730200008939	12
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	osteoarthritis, knee	targetBased	316642	617	0.615751427985334	35
Small Molecule Inhibitors of FGF22-Mediated Excitatory Synaptogenesis & Epilepsy Measured in Biochemical System Using RT-PCR - 7012-01_Inhibitor_SinglePoint_HTS_Activity	FGF22_inhibitors	bone development disease	targetBased	339650	5128	0.628351401578255	15
Fluorescence-based biochemical high throughput primary assay to identify inhibitors of phospholipase C isozymes (PLC-gamma1).	PLCG1	bone development disease	targetBased	369953	3123	0.607202180524209	10
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	rickets	targetBased	394050	3624	0.588911011139894	107
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	polycythemia	targetBased	217959	2390	0.547877540544829	613
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	fibromyalgia	targetBased	363803	2412	0.615589784440467	32
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	fibromyalgia	targetBased	335239	991	0.505730515267723	51
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	fibromyalgia	targetBased	335239	695	0.505730515267723	51
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	fibromyalgia	targetBased	359518	300	0.567270683537583	15
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	fibromyalgia	targetBased	335652	1779	0.567270683537583	15
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	fibromyalgia	targetBased	357537	806	0.567270683537583	15
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	fibromyalgia	targetBased	339887	1178	0.567270683537583	15
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	fibromyalgia	targetBased	362274	1056	0.567270683537583	15
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	fibromyalgia	targetBased	336308	6862	0.567270683537583	15
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	arthritis	targetBased	316642	617	0.651046057163841	78
Primary screen for KDM5B Histone Demethylases FDH-coupled qHTS	KDM5B	grip strength measurement	targetBased	217819	5697	0.522906509080935	35
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	sinusitis	targetBased	339297	1446	0.637275760427135	26
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	Fanconi anemia complementation group A	pathwayBased	376029	3978	0.620838562759111	6
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	heel bone mineral density	targetBased	86095	1442	0.559275327168255	59
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	heel bone mineral density	targetBased	86095	1151	0.559275327168255	59
HTS of Smad transcription factor inhibitors	SMAD3	heel bone mineral density	targetBased	88033	251	0.547319979971764	24
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	rib fracture	targetBased	335239	991	0.601285568397495	9
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	rib fracture	targetBased	335239	695	0.601285568397495	9
uHTS identification of small molecule modulators of NR3A	GRIN3A	rib fracture	targetBased	339772	8480	0.569561257660925	6
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	musculoskeletal system disease	targetBased	339297	1446	0.514238155627858	99
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	toothache	targetBased	335239	991	0.532764875117537	11
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	toothache	targetBased	335239	695	0.532764875117537	11
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	toothache	targetBased	316642	617	0.644988505060209	38
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	muscle cramp	targetBased	316642	617	0.619285523949174	12
uHTS identification of TNAP inhibitors in the absence of phosphate acceptor performed in luminescent assay	ALPL_inhibitors	adult hypophosphatasia	targetBased	195560	517	0.939215261483421	551
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	rotator cuff tear	targetBased	290355	265	0.527975236729244	11
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	rotator cuff tear	targetBased	335239	991	0.567119417340278	15
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	rotator cuff tear	targetBased	335239	695	0.567119417340278	15
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	osteoarthritis, hip	targetBased	335239	991	0.61595213184444	18
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	osteoarthritis, hip	targetBased	335239	695	0.61595213184444	18
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	pulpitis	targetBased	335239	991	0.524471038386675	9
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	pulpitis	targetBased	335239	695	0.524471038386675	9
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	pulpitis	targetBased	339297	1446	0.586098907288342	12
HTS of Smad transcription factor inhibitors	SMAD3	connective tissue disease	targetBased	88033	251	0.63854754175007	547
Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R	MC4R	Abnormality of the skeletal system	targetBased	356160	3470	0.654264744820366	73
TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R	MC4R	Abnormality of the skeletal system	targetBased	356160	1703	0.654264744820366	73
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	Osteopenia	targetBased	394050	3624	0.57648010585294	47
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	Osteopenia	targetBased	86095	1114	0.556646138618613	8
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	Abnormal skeletal morphology	targetBased	359207	1432	0.550489496986252	13
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	Sciatica	targetBased	335239	991	0.52560928186248	6
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	Sciatica	targetBased	335239	695	0.52560928186248	6
uHTS identification of TNAP inhibitors in the absence of phosphate acceptor performed in luminescent assay	ALPL_inhibitors	Skeletal dysplasia	targetBased	195560	517	0.624363486174286	11
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	Muscle spasm	targetBased	363803	2412	0.60466648961276	9
High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits	GNAI3	auriculocondylar syndrome	targetBased	204125	876	0.791157912368328	41
qHTS assay for re-activators of p53 using a Luc reporter	TP53	bone marrow failure syndrome	pathwayBased	321427	201	0.737460111393103	73
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	bone marrow failure syndrome	targetBased	54509	528	0.737460111393103	73
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	bone marrow failure syndrome	targetBased	54513	338	0.737460111393103	73
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	bone marrow failure syndrome	targetBased	125394	1890	0.737460111393103	73
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	bone marrow failure syndrome	targetBased	124022	1156	0.737460111393103	73
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	osteoarthritis	targetBased	290355	265	0.629392602569647	41
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	osteoarthritis	targetBased	335239	991	0.657280791256667	97
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	osteoarthritis	targetBased	335239	695	0.657280791256667	97
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	osteoarthritis	targetBased	339297	1446	0.581476497553818	17
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	osteoarthritis	targetBased	316642	617	0.645932652943565	116
Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	cardiomyopathy, familial restrictive, 1	targetBased	335239	801	0.839628176662135	108
Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	cardiomyopathy, familial restrictive, 1	targetBased	335238	390	0.839628176662135	108
qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase)	HPGD	isolated congenital digital clubbing	targetBased	148480	6428	0.710106043082438	116
uHTS Luminescent assay for identification of inhibitors of NALP3 in yeast	NLRP3	familial cold autoinflammatory syndrome 1	targetBased	330392	1295	0.873832417903922	297
qHTS for Inhibitors of TGF-b	TGFB1	Camurati-Engelmann disease	pathwayBased	403345	4970	0.882045406274388	110
Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R1A (PKA-R1A) complex	PRKAR1A	Acrodysostosis 1 with or without hormone resistance	targetBased	343468	285	0.829085639795519	192
qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	pseudohypoparathyroidism type 1A	targetBased	334825	423	0.931191434735326	489
qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	pseudohypoparathyroidism type 1A	targetBased	337446	1356	0.931191434735326	489
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	systemic lupus erythematosus	targetBased	343468	734	0.606714042774157	24
uHTS luminescence assay for the identification of compounds that inhibit NOD2	NOD2	Blau syndrome	targetBased	292323	1836	0.939286992074845	1956
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	metaphyseal chondrodysplasia, Jansen type	targetBased	405685	308	0.870699161633779	171
qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen	IL-1b Inflammasome	Muckle-Wells syndrome	pathwayBased	362051	17187	0.543319270372889	54
uHTS Luminescent assay for identification of inhibitors of NALP3 in yeast	NLRP3	Muckle-Wells syndrome	targetBased	330392	1295	0.894883848273049	515
Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R1A (PKA-R1A) complex	PRKAR1A	amelogenesis imperfecta type 1G	targetBased	343468	285	0.598819185739921	44
Primary cell-based high-throughput screening assay for identification of compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1	KCNJ2	Andersen-Tawil syndrome	targetBased	305610	2592	0.928674186301643	1100
uHTS identification of Gli-Sufu Antagonists in a luminescence reporter assay	GLI1	polydactyly of a biphalangeal thumb	targetBased	338328	2501	0.706647047561123	14
Glucocerebrosidase	GBA1	Gaucher disease type III	targetBased	48118	549	0.843925331047856	164
qHTS Assay for Activators of Human alpha-Glucosidase as a Potential Chaperone Treatment of Pompe Disease	GAA	glycogen storage disease II	targetBased	199169	715	0.960121004133098	4311
qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase Cleavage of Glycogen	GAA_inhibitors	glycogen storage disease II	targetBased	302297	1165	0.960121004133098	4311
HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen	AKT1_inhibitors	Proteus syndrome	targetBased	356517	1139	0.869235310377157	179
Primary cell-based high-throughput screening assay to measure PERK inhibition	PERK_inhibitors	Wolcott-Rallison syndrome	targetBased	217959	370	0.873386417124152	435
Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2	THRB	glycogen storage disease due to glycogen branching enzyme deficiency	targetBased	276265	806	0.758107361832069	338
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	chondrodysplasia Blomstrand type	targetBased	405685	308	0.824076159020484	170
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	Costello syndrome	targetBased	194628	267	0.971682105449753	1184
Primary Cell-based High Throughput Screening assay for activators of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	46,XY complete gonadal dysgenesis	targetBased	64908	1225	0.579738241896345	77
Primary Cell-based High Throughput Screening assay for inhibitors of the nuclear receptor Steroidogenic Factor 1 (SF-1)	NR5A1	46,XY complete gonadal dysgenesis	targetBased	64908	359	0.579738241896345	77
Luminescence-based cell-based primary high throughput screening assay for inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1): repression of SF-1 (NR5A1) activated StAR promoter by full-length DAX-1	NR0B1	46,XY complete gonadal dysgenesis	targetBased	368927	4094	0.714510258851383	372
Luminescence-based primary cell-based high throughput screening assay to identify inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1)	NR0B1	46,XY complete gonadal dysgenesis	targetBased	343468	3417	0.714510258851383	372
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	Eiken syndrome	targetBased	405685	308	0.765164840016023	86
EZH2/PRC2 methyltransferase inhibitors Measured in Biochemical System Using Plate Reader - 2125-01_Inhibitor_SinglePoint_HTS_Activity	EZH2_inhibitors	Weaver syndrome	targetBased	57013	201	0.907269836964628	782
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	Duchenne muscular dystrophy	targetBased	339297	1446	0.514857952397938	8
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	sickle cell anemia	targetBased	335239	991	0.631524990132642	24
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	sickle cell anemia	targetBased	335239	695	0.631524990132642	24
qHTS Assay for Inhibitors of the CtBP/E1A Interaction	RBBP8	Seckel syndrome 2	targetBased	335214	1652	0.795909043926353	35
uHTS identification of HIF-2a Inhibitors in a luminesence assay	HIF-2a_inhibitors	erythrocytosis, familial, 4	targetBased	363840	2624	0.779929786051706	233
uHTS Luminescent assay for identification of inhibitors of NALP3 in yeast	NLRP3	CINCA syndrome	targetBased	330392	1295	0.925563914784182	621
HTS-Luminescent assay for inhibitors of ALR by detection of hydrogen peroxide production Measured in Biochemical System Using Plate Reader - 2036-02_Inhibitor_SinglePoint_HTS	ALR inhibitors	congenital cataract-progressive muscular hypotonia-hearing loss-developmental delay syndrome	targetBased	288728	10857	0.770329660937942	30
HTS-Luminescent assay for inhibitors of ALR by detection of hydrogen peroxide production Measured in Biochemical System Using Plate Reader - 2036-02_Inhibitor_SinglePoint_HTS	ALR activators	congenital cataract-progressive muscular hypotonia-hearing loss-developmental delay syndrome	targetBased	288728	10857	0.770329660937942	30
Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	dilated cardiomyopathy 2A	targetBased	335239	801	0.744453709686017	86
Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	dilated cardiomyopathy 2A	targetBased	335238	390	0.744453709686017	86
Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	dilated cardiomyopathy 1FF	targetBased	335239	801	0.830166550514321	63
Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	dilated cardiomyopathy 1FF	targetBased	335238	390	0.830166550514321	63
qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	pseudohypoparathyroidism type 1C	targetBased	334825	423	0.900125093342387	147
qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	pseudohypoparathyroidism type 1C	targetBased	337446	1356	0.900125093342387	147
qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	pseudopseudohypoparathyroidism	targetBased	334825	423	0.857715919055999	266
qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	pseudopseudohypoparathyroidism	targetBased	337446	1356	0.857715919055999	266
Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	hypertrophic cardiomyopathy 7	targetBased	335239	801	0.885049175732636	144
Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	hypertrophic cardiomyopathy 7	targetBased	335238	390	0.885049175732636	144
HTS of Smad transcription factor inhibitors	SMAD3	aneurysm-osteoarthritis syndrome	targetBased	88033	251	0.88651169542596	492
qHTS assay for inhibitors of human lactate dehydrogenase	lactateDehydrogenaseInhibitors	glycogen storage disease due to lactate dehydrogenase M-subunit deficiency	targetBased	476056	732	0.825949553451582	236
Primary cell-based screen for identification of compounds that inhibit the Choline Transporter (CHT)	SLC5A7	distal hereditary motor neuropathy type 7	targetBased	306502	2634	0.632249836516357	623
Primary cell-based screen for identification of compounds that allosterically activate the Choline Transporter (CHT)	SLC5A7	distal hereditary motor neuropathy type 7	targetBased	306502	1509	0.632249836516357	623
Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	familial restrictive cardiomyopathy	targetBased	335239	801	0.526611777023384	59
Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	familial restrictive cardiomyopathy	targetBased	335238	390	0.526611777023384	59
Screen for inhibitors of the SWI/SNF chromatin remodeling complex (esBAF) in mouse embryonic stem cells with Luciferase reporter assay Measured in Cell-Based System Using Plate Reader - 2141-01_Inhibitor_SinglePoint_HTS_Activity	SMARCA4	Coffin-Siris syndrome	targetBased	344733	7043	0.76887560431398	1260
Primary cell-based high-throughput screening assay for identification of compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1	KCNJ2	periodic paralysis	targetBased	305610	2592	0.68356093063422	449
qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen	IL-1b Inflammasome	cryopyrin-associated periodic syndrome	pathwayBased	362051	17187	0.605771408191478	546
QFRET-based biochemical primary high throughput screening assay to identify exosite inhibitors of ADAM17.	ADAM17_inhibitors	neonatal inflammatory skin and bowel disease	targetBased	369953	3080	0.78132175077845	681
uHTS identification of Gli-Sufu Antagonists in a luminescence reporter assay	GLI1	preaxial polydactyly of fingers	targetBased	338328	2501	0.514204542415849	6
uHTS Luminescent assay for identification of inhibitors of NALP3 in yeast	NLRP3	cryopyrin-associated periodic syndrome	targetBased	330392	1295	0.74279650622679	2442
qHTS Assay for Activators of Human alpha-Glucosidase as a Potential Chaperone Treatment of Pompe Disease	GAA	glycogen storage disease due to acid maltase deficiency, infantile onset	targetBased	199169	715	0.642982582442733	17
qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase Cleavage of Glycogen	GAA_inhibitors	glycogen storage disease due to acid maltase deficiency, infantile onset	targetBased	302297	1165	0.642982582442733	17
HCS assay for microtubule stabilizers	TUBB	familial Mediterranean fever	targetBased	195821	1625	0.637516775910312	23
uHTS Luminescent assay for identification of inhibitors of NALP3 in yeast	NLRP3	familial cold autoinflammatory syndrome	targetBased	330392	1295	0.595263504725513	254
RNA aptamer-based HTS for inhibitors of GRK2	GRK2	Jeune syndrome	targetBased	327939	1924	0.522237752095036	12
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	osteogenesis imperfecta	targetBased	394050	3624	0.527327245164823	65
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	osteogenesis imperfecta	targetBased	405685	308	0.504678620737738	61
uHTS identification of TNAP inhibitors in the absence of phosphate acceptor performed in luminescent assay	ALPL_inhibitors	osteogenesis imperfecta	targetBased	195560	517	0.590018585582101	59
qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	McCune-Albright syndrome	targetBased	334825	423	0.895970037054108	329
qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	McCune-Albright syndrome	targetBased	337446	1356	0.895970037054108	329
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	Fanconi anemia	pathwayBased	376029	3978	0.57760274438034	421
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	AL amyloidosis	targetBased	143816	859	0.524188480440994	22
HTS of Smad transcription factor inhibitors	SMAD3	Loeys-Dietz syndrome	targetBased	88033	251	0.782631949327588	824
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay	MAPK1	Noonan syndrome	pathwayBased	70898	707	0.735833813629442	26
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF	MAPK1	Noonan syndrome	pathwayBased	131324	544	0.735833813629442	26
Assay for Inhibitors of the beta-Arrestin-Adaptor Protein 2 Interaction That Mediate GPCR Degradation and Recycling	ARRB1_inhibitors	Noonan syndrome	targetBased	338373	1061	0.577168330395272	6
Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn6) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )]	FGB_inhibitors	Noonan syndrome	targetBased	369953	760	0.577168330395272	6
Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn7) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )]	FGB_inhibitors	Noonan syndrome	targetBased	369953	498	0.577168330395272	6
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	Noonan syndrome	targetBased	194628	267	0.750196204718814	41
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	Noonan syndrome and Noonan-related syndrome	targetBased	194628	267	0.704710908817553	459
uHTS Luminescent assay for identification of inhibitors of NALP3 in yeast	NLRP3	autoinflammatory syndrome	targetBased	330392	1295	0.702039458685415	1491
uHTS luminescence assay for the identification of compounds that inhibit NOD2	NOD2	autoinflammatory syndrome	targetBased	292323	1836	0.564415235811097	914
Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R1A (PKA-R1A) complex	PRKAR1A	acrodysostosis	targetBased	343468	285	0.781959384313481	152
qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase)	HPGD	hypertrophic osteoarthropathy, primary, autosomal recessive, 1	targetBased	148480	6428	0.798213557362017	135
Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	familial hypertrophic cardiomyopathy	targetBased	335239	801	0.677983200454697	73
Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	familial hypertrophic cardiomyopathy	targetBased	335238	390	0.677983200454697	73
uHTS identification of Gli-Sufu Antagonists in a luminescence reporter assay	GLI1	postaxial polydactyly type A	targetBased	338328	2501	0.523502780989542	13
uHTS identification of Gli-Sufu Antagonists in a luminescence reporter assay	GLI1	polydactyly, postaxial, type A8	targetBased	338328	2501	0.732801265040584	21
uHTS for identification of Inhibitors of Mdm2/MdmX interaction in luminescent format.	MDM4	bone marrow failure syndrome 6	targetBased	331671	10022	0.513043524679079	6
Fluorescence-based primary biochemical high throughput screening assay to identify inhibitors of human diacylglycerol lipase, beta (DAGLB)	DAGLB_inhibitors	osteogenesis imperfecta, type 21	targetBased	343468	202	0.546808807855395	11
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	Fanconi anemia, complementation group S	pathwayBased	376029	3978	0.882895059808289	251
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	myelofibrosis	targetBased	217959	2390	0.707709957175985	1089
Luminescence-based cell-based primary high throughput screening assay to identify activators of the GAA850 frataxin (FXN) promoter	FXN	Friedreich ataxia	targetBased	356160	1985	0.890999212816761	1874
A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells.	GMNN	Ear-patella-short stature syndrome	targetBased	343234	9888	0.76120314187953	15
A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells.	GMNN	Ear-patella-short stature syndrome	targetBased	342279	6233	0.76120314187953	15
qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase)	HPGD	Pachydermoperiostosis	targetBased	148480	6428	0.552231998408656	18
Primary cell-based screen for identification of compounds that inhibit the Choline Transporter (CHT)	SLC5A7	Congenital myasthenic syndromes	targetBased	306502	2634	0.774715316348506	860
Primary cell-based screen for identification of compounds that allosterically activate the Choline Transporter (CHT)	SLC5A7	Congenital myasthenic syndromes	targetBased	306502	1509	0.774715316348506	860
Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the prolyl oligopeptidase-like enzyme (PREPL)	PREPL	Congenital myasthenic syndromes	targetBased	324747	2221	0.727310482862168	891
HTS of Smad transcription factor inhibitors	SMAD3	Aneurysm - osteoarthritis syndrome	targetBased	88033	251	0.818691129384453	60
qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	Albright hereditary osteodystrophy	targetBased	334825	423	0.866673808957289	189
qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	Albright hereditary osteodystrophy	targetBased	337446	1356	0.866673808957289	189
qHTS Assay for Activators of Human alpha-Glucosidase as a Potential Chaperone Treatment of Pompe Disease	GAA	Glycogen storage disease due to acid maltase deficiency, adult onset	targetBased	199169	715	0.551611095948914	11
qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase Cleavage of Glycogen	GAA_inhibitors	Glycogen storage disease due to acid maltase deficiency, adult onset	targetBased	302297	1165	0.551611095948914	11
Glucocerebrosidase	GBA1	Gaucher disease type 1	targetBased	48118	549	0.904732450777115	509
Glucocerebrosidase	GBA1	Gaucher disease type 3	targetBased	48118	549	0.869364153583014	180
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	Hypocalcemic vitamin D-resistant rickets	targetBased	394050	3624	0.924912744974669	399
HTS-Luminescent assay for inhibitors of ALR by detection of hydrogen peroxide production Measured in Biochemical System Using Plate Reader - 2036-02_Inhibitor_SinglePoint_HTS	ALR inhibitors	Congenital cataract - progressive muscular hypotonia - hearing loss - developmental delay	targetBased	288728	10857	0.82172283003768	36
HTS-Luminescent assay for inhibitors of ALR by detection of hydrogen peroxide production Measured in Biochemical System Using Plate Reader - 2036-02_Inhibitor_SinglePoint_HTS	ALR activators	Congenital cataract - progressive muscular hypotonia - hearing loss - developmental delay	targetBased	288728	10857	0.82172283003768	36
Luminescent HTS for small molecule inhibitors of MT1-MMP transcription	MMP14	Torg-Winchester syndrome	targetBased	86733	537	0.633573506874993	23
uHTS identification of inhibitors of MT1-MMP activation in a fluoresence assay	MMP14	Torg-Winchester syndrome	targetBased	361500	222	0.633573506874993	23
qHTS Assay for Activators of Human alpha-Glucosidase as a Potential Chaperone Treatment of Pompe Disease	GAA	Glycogen storage disease due to acid maltase deficiency	targetBased	199169	715	0.916238536169051	4712
qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase Cleavage of Glycogen	GAA_inhibitors	Glycogen storage disease due to acid maltase deficiency	targetBased	302297	1165	0.916238536169051	4712
Primary cell-based high-throughput screening assay for identification of compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1	KCNJ2	Cardiodysrhythmic potassium-sensitive periodic paralysis	targetBased	305610	2592	0.896801261242644	914
Primary cell-based screen for identification of compounds that inhibit the Choline Transporter (CHT)	SLC5A7	Presynaptic congenital myasthenic syndromes	targetBased	306502	2634	0.822381801512511	639
Primary cell-based screen for identification of compounds that allosterically activate the Choline Transporter (CHT)	SLC5A7	Presynaptic congenital myasthenic syndromes	targetBased	306502	1509	0.822381801512511	639
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	Blomstrand lethal chondrodysplasia	targetBased	405685	308	0.71396083712997	35

Some of these associations have also gone through clinical trials, as those in the graph below.

Find clinical trials details in table. Use scroll bar or search funtion to select specific drugs, molecular targets or diseases.

BioAssay Name	program	gene	protName	diseaseName	molname	assayMode	clinicalPhase	clinicalStatus	studyStartDate	url	score	variantEffect	directionOnTrait	studyStopReason
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertrophic cardiomyopathy	VERAPAMIL	targetBased	4	Recruiting	10/08/2022	https://clinicaltrials.gov/study/NCT05569382	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	muscle cramp	VERAPAMIL	targetBased	4	Recruiting	05/06/2024	https://clinicaltrials.gov/study/NCT06447688	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	Marfan syndrome	VERAPAMIL	targetBased	4	Completed	01/07/2006	https://clinicaltrials.gov/study/NCT01295047	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	dilated cardiomyopathy	VERAPAMIL	targetBased	4	Unknown status	01/01/2006	https://clinicaltrials.gov/study/NCT00374465	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertrophic cardiomyopathy	DILTIAZEM	targetBased	2	Completed	01/01/2006	https://clinicaltrials.gov/study/NCT00319982	0.2	LoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ankylosing spondylitis	OLSALAZINE	targetBased	2	Completed	01/05/1996	https://clinicaltrials.gov/study/NCT00004288	0.2	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ankylosing spondylitis	OLSALAZINE	targetBased	2	Completed	01/05/1996	https://clinicaltrials.gov/study/NCT00004288	0.2	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ankylosing spondylitis	OLSALAZINE	targetBased	2	Completed	01/05/1996	https://clinicaltrials.gov/study/NCT00004288	0.2	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ankylosing spondylitis	OLSALAZINE	targetBased	2	Completed	01/05/1996	https://clinicaltrials.gov/study/NCT00004288	0.2	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ankylosing spondylitis	OLSALAZINE	targetBased	2	Completed	01/05/1996	https://clinicaltrials.gov/study/NCT00004288	0.2	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	ankylosing spondylitis	OLSALAZINE	targetBased	2	Completed	01/05/1996	https://clinicaltrials.gov/study/NCT00004288	0.2	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	sickle cell anemia	PROPRANOLOL	targetBased	2	Completed	01/06/2010	https://clinicaltrials.gov/study/NCT01077921	0.2	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Marfan syndrome	PROPRANOLOL	targetBased	2	Unknown status	01/02/2007	https://clinicaltrials.gov/study/NCT00651235	0.2	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	sinusitis	LABETALOL	targetBased	2	Completed	01/03/2017	https://clinicaltrials.gov/study/NCT03661346	0.2	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	myelofibrosis	THALIDOMIDE	targetBased	2	Active, not recruiting	27/02/2017	https://clinicaltrials.gov/study/NCT03069326	0.2	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	myelofibrosis	THALIDOMIDE	targetBased	2	Completed	01/10/2004	https://clinicaltrials.gov/study/NCT00445900	0.2	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	systemic lupus erythematosus	THALIDOMIDE	targetBased	4	Completed	05/06/2017	https://clinicaltrials.gov/study/NCT03122431	1	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	primary systemic amyloidosis	THALIDOMIDE	targetBased	2	Completed	01/09/2002	https://clinicaltrials.gov/study/NCT01527032	0.2	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	sarcoidosis	THALIDOMIDE	targetBased	3	Completed	01/02/2005	https://clinicaltrials.gov/study/NCT00305552	0.7	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	cutaneous lupus erythematosus	THALIDOMIDE	targetBased	4	Completed	05/06/2017	https://clinicaltrials.gov/study/NCT03122431	1	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	ankylosing spondylitis	THALIDOMIDE	targetBased	4	Active, not recruiting	15/03/2022	https://clinicaltrials.gov/study/NCT05527444	1	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	ankylosing spondylitis	THALIDOMIDE	targetBased	2	Completed	01/02/2013	https://clinicaltrials.gov/study/NCT02201043	0.2	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	discoid lupus erythematosus	THALIDOMIDE	targetBased	2	Completed	01/10/1997	https://clinicaltrials.gov/study/NCT00001680	0.2	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	AL amyloidosis	THALIDOMIDE	targetBased	3	Terminated	26/12/2012	https://clinicaltrials.gov/study/NCT01659658	0.7	LoF	protect	Sponsor's decision
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	AL amyloidosis	THALIDOMIDE	targetBased	4	Recruiting	01/01/2020	https://clinicaltrials.gov/study/NCT04612582	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Intervertebral disk degeneration	MORPHINE	targetBased	4	Completed	01/11/2005	https://clinicaltrials.gov/study/NCT00353704	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Intervertebral disk degeneration	MORPHINE	targetBased	4	Completed	01/11/2005	https://clinicaltrials.gov/study/NCT00353704	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Sciatica	MORPHINE	targetBased	4	Unknown status	01/01/2015	https://clinicaltrials.gov/study/NCT02504996	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Sciatica	MORPHINE	targetBased	4	Unknown status	01/01/2015	https://clinicaltrials.gov/study/NCT02504996	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis, hip	MORPHINE	targetBased	4	Unknown status	01/09/2009	https://clinicaltrials.gov/study/NCT01281891	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis, hip	MORPHINE	targetBased	4	Unknown status	01/09/2009	https://clinicaltrials.gov/study/NCT01281891	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	femur fracture	MORPHINE	targetBased	4	Recruiting	04/09/2023	https://clinicaltrials.gov/study/NCT05920642	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	femur fracture	MORPHINE	targetBased	4	Recruiting	04/09/2023	https://clinicaltrials.gov/study/NCT05920642	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	scoliosis	MORPHINE	targetBased	3	Terminated	22/06/2018	https://clinicaltrials.gov/study/NCT03537612	0.7	GoF	protect	Do to our inability to meet recruitment targets - Sponsor stopped funding. Looking for new sponsor and protocol modifications
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	scoliosis	MORPHINE	targetBased	3	Terminated	22/06/2018	https://clinicaltrials.gov/study/NCT03537612	0.7	GoF	protect	Do to our inability to meet recruitment targets - Sponsor stopped funding. Looking for new sponsor and protocol modifications
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	scoliosis	MORPHINE	targetBased	3	Completed	01/12/2006	https://clinicaltrials.gov/study/NCT00737997	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	scoliosis	MORPHINE	targetBased	3	Completed	01/12/2006	https://clinicaltrials.gov/study/NCT00737997	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	scoliosis	MORPHINE	targetBased	2	Completed	18/06/2019	https://clinicaltrials.gov/study/NCT03968146	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	scoliosis	MORPHINE	targetBased	2	Completed	18/06/2019	https://clinicaltrials.gov/study/NCT03968146	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	rib fracture	MORPHINE	targetBased	4	Terminated	01/02/2009	https://clinicaltrials.gov/study/NCT00880529	1	GoF	protect	low enrollment, 2 pts enrolled no data every analyzed investigator left the institution
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	rib fracture	MORPHINE	targetBased	4	Terminated	01/02/2009	https://clinicaltrials.gov/study/NCT00880529	1	GoF	protect	low enrollment, 2 pts enrolled no data every analyzed investigator left the institution
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	rib fracture	MORPHINE	targetBased	4	Unknown status	06/11/2018	https://clinicaltrials.gov/study/NCT03619785	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	rib fracture	MORPHINE	targetBased	4	Unknown status	06/11/2018	https://clinicaltrials.gov/study/NCT03619785	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	rib fracture	MORPHINE	targetBased	3	Terminated	08/08/2016	https://clinicaltrials.gov/study/NCT02749409	0.7	GoF	protect	Case numbers not enough, however, the funding is over
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	rib fracture	MORPHINE	targetBased	3	Terminated	08/08/2016	https://clinicaltrials.gov/study/NCT02749409	0.7	GoF	protect	Case numbers not enough, however, the funding is over
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	rotator cuff tear	MORPHINE	targetBased	2	Unknown status	01/01/2016	https://clinicaltrials.gov/study/NCT03034382	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	rotator cuff tear	MORPHINE	targetBased	2	Unknown status	01/01/2016	https://clinicaltrials.gov/study/NCT03034382	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	multiple bone fractures	MORPHINE	targetBased	2	Completed	01/12/2012	https://clinicaltrials.gov/study/NCT01807429	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	multiple bone fractures	MORPHINE	targetBased	2	Completed	01/12/2012	https://clinicaltrials.gov/study/NCT01807429	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	bone fracture	MORPHINE	targetBased	4	Withdrawn	01/03/2016	https://clinicaltrials.gov/study/NCT02698228	1	GoF	protect	Study did not occur
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	bone fracture	MORPHINE	targetBased	4	Withdrawn	01/03/2016	https://clinicaltrials.gov/study/NCT02698228	1	GoF	protect	Study did not occur
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	bone fracture	MORPHINE	targetBased	4	Completed	01/12/2018	https://clinicaltrials.gov/study/NCT03693404	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	bone fracture	MORPHINE	targetBased	4	Completed	01/12/2018	https://clinicaltrials.gov/study/NCT03693404	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	femoral neck fracture	MORPHINE	targetBased	4	Unknown status	01/09/2010	https://clinicaltrials.gov/study/NCT01219088	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	femoral neck fracture	MORPHINE	targetBased	4	Unknown status	01/09/2010	https://clinicaltrials.gov/study/NCT01219088	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	femoral neck fracture	MORPHINE	targetBased	4	Terminated	01/09/2010	https://clinicaltrials.gov/study/NCT01219062	1	GoF	protect	Surgeon team were not happy with the study protocol, the periarticular injection of local anesthetics
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	femoral neck fracture	MORPHINE	targetBased	4	Terminated	01/09/2010	https://clinicaltrials.gov/study/NCT01219062	1	GoF	protect	Surgeon team were not happy with the study protocol, the periarticular injection of local anesthetics
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	hip fracture	MORPHINE	targetBased	4	Terminated	01/05/2016	https://clinicaltrials.gov/study/NCT02689024	1	GoF	protect	recruitment too slow; intervention was standard care in patients who were not included; acute care pathways changed due to policy regarding hip fracture patients
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	hip fracture	MORPHINE	targetBased	4	Terminated	01/05/2016	https://clinicaltrials.gov/study/NCT02689024	1	GoF	protect	recruitment too slow; intervention was standard care in patients who were not included; acute care pathways changed due to policy regarding hip fracture patients
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	hip fracture	MORPHINE	targetBased	4	Completed	01/10/2008	https://clinicaltrials.gov/study/NCT01904071	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	hip fracture	MORPHINE	targetBased	4	Completed	01/10/2008	https://clinicaltrials.gov/study/NCT01904071	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis, knee	MORPHINE	targetBased	4	Not yet recruiting	01/09/2023	https://clinicaltrials.gov/study/NCT06042426	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis, knee	MORPHINE	targetBased	4	Not yet recruiting	01/09/2023	https://clinicaltrials.gov/study/NCT06042426	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis, knee	MORPHINE	targetBased	4	Completed	01/04/2008	https://clinicaltrials.gov/study/NCT00901628	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis, knee	MORPHINE	targetBased	4	Completed	01/04/2008	https://clinicaltrials.gov/study/NCT00901628	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis, knee	MORPHINE	targetBased	4	Completed	01/11/2007	https://clinicaltrials.gov/study/NCT00562627	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis, knee	MORPHINE	targetBased	4	Completed	01/11/2007	https://clinicaltrials.gov/study/NCT00562627	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis, knee	MORPHINE	targetBased	2	Completed	01/04/2014	https://clinicaltrials.gov/study/NCT02860949	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis, knee	MORPHINE	targetBased	2	Completed	01/04/2014	https://clinicaltrials.gov/study/NCT02860949	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis, knee	MORPHINE	targetBased	2	Unknown status	01/08/2015	https://clinicaltrials.gov/study/NCT02967302	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis, knee	MORPHINE	targetBased	2	Unknown status	01/08/2015	https://clinicaltrials.gov/study/NCT02967302	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis, knee	MORPHINE	targetBased	4	Withdrawn	01/02/2016	https://clinicaltrials.gov/study/NCT02765815	1	GoF	protect	competing protocol
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis, knee	MORPHINE	targetBased	4	Withdrawn	01/02/2016	https://clinicaltrials.gov/study/NCT02765815	1	GoF	protect	competing protocol
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	temporomandibular joint disorder	MORPHINE	targetBased	4	Completed	10/12/2013	https://clinicaltrials.gov/study/NCT04110587	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	temporomandibular joint disorder	MORPHINE	targetBased	4	Completed	10/12/2013	https://clinicaltrials.gov/study/NCT04110587	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	idiopathic scoliosis	MORPHINE	targetBased	2	Completed	01/01/2012	https://clinicaltrials.gov/study/NCT02571491	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	idiopathic scoliosis	MORPHINE	targetBased	2	Completed	01/01/2012	https://clinicaltrials.gov/study/NCT02571491	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis	MORPHINE	targetBased	4	Completed	01/05/2016	https://clinicaltrials.gov/study/NCT02658149	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis	MORPHINE	targetBased	4	Completed	01/05/2016	https://clinicaltrials.gov/study/NCT02658149	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis	MORPHINE	targetBased	4	Completed	01/11/2014	https://clinicaltrials.gov/study/NCT02292082	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis	MORPHINE	targetBased	4	Completed	01/11/2014	https://clinicaltrials.gov/study/NCT02292082	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	sickle cell anemia	MORPHINE	targetBased	4	Terminated	01/03/2011	https://clinicaltrials.gov/study/NCT00880373	1	GoF	protect	The funding withdrawal and early termination of the trial is based upon lack of suitable recruitment figures in order to reach the required trial endpoints.
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	sickle cell anemia	MORPHINE	targetBased	4	Terminated	01/03/2011	https://clinicaltrials.gov/study/NCT00880373	1	GoF	protect	The funding withdrawal and early termination of the trial is based upon lack of suitable recruitment figures in order to reach the required trial endpoints.
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	sickle cell anemia	MORPHINE	targetBased	2	Completed	01/11/2019	https://clinicaltrials.gov/study/NCT04301336	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	sickle cell anemia	MORPHINE	targetBased	2	Completed	01/11/2019	https://clinicaltrials.gov/study/NCT04301336	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	sickle cell anemia	MORPHINE	targetBased	4	Completed	15/03/2015	https://clinicaltrials.gov/study/NCT02222246	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	sickle cell anemia	MORPHINE	targetBased	4	Completed	15/03/2015	https://clinicaltrials.gov/study/NCT02222246	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	sickle cell anemia	MORPHINE	targetBased	4	Withdrawn	01/11/2006	https://clinicaltrials.gov/study/NCT00513864	1	GoF	protect	lack of funding
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	sickle cell anemia	MORPHINE	targetBased	4	Withdrawn	01/11/2006	https://clinicaltrials.gov/study/NCT00513864	1	GoF	protect	lack of funding
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	sickle cell anemia	MORPHINE	targetBased	3	Terminated	13/08/2019	https://clinicaltrials.gov/study/NCT03933397	0.7	GoF	protect	Due to COVID enrollment numbers needed to meet the primary endpoint will not be met.
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	sickle cell anemia	MORPHINE	targetBased	3	Terminated	13/08/2019	https://clinicaltrials.gov/study/NCT03933397	0.7	GoF	protect	Due to COVID enrollment numbers needed to meet the primary endpoint will not be met.
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	Sciatica	CODEINE	targetBased	3	Completed	28/09/2021	https://clinicaltrials.gov/study/NCT05626140	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	tooth disease	CODEINE	targetBased	4	Completed	01/09/2014	https://clinicaltrials.gov/study/NCT02547896	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	tooth disease	CODEINE	targetBased	4	Completed	01/09/2014	https://clinicaltrials.gov/study/NCT02547896	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Sciatica	CODEINE	targetBased	3	Completed	28/09/2021	https://clinicaltrials.gov/study/NCT05626140	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Sciatica	CODEINE	targetBased	3	Completed	28/09/2021	https://clinicaltrials.gov/study/NCT05626140	0.7	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	osteoarthritis	CODEINE	targetBased	4	Completed	01/05/2013	https://clinicaltrials.gov/study/NCT02501564	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	osteoarthritis	CODEINE	targetBased	4	Completed	01/03/2006	https://clinicaltrials.gov/study/NCT00324038	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	osteoarthritis	CODEINE	targetBased	2	Completed	21/07/2016	https://clinicaltrials.gov/study/NCT02845271	0.2	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	Muscle spasm	CODEINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=03cdc2f8-78d1-11dc-8314-0800200c9a66	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	toothache	CODEINE	targetBased	3	Completed	01/06/2008	https://clinicaltrials.gov/study/NCT00694369	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Muscle spasm	CODEINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=03cdc2f8-78d1-11dc-8314-0800200c9a66	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Muscle spasm	CODEINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=03cdc2f8-78d1-11dc-8314-0800200c9a66	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis, knee	CODEINE	targetBased	3	Completed	01/12/2005	https://clinicaltrials.gov/study/NCT00264225	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis, knee	CODEINE	targetBased	3	Completed	01/12/2005	https://clinicaltrials.gov/study/NCT00264225	0.7	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	sickle cell anemia	CODEINE	targetBased	4	Withdrawn	01/11/2006	https://clinicaltrials.gov/study/NCT00513864	1	GoF	protect	lack of funding
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	osteoarthritis, knee	CODEINE	targetBased	3	Completed	01/12/2005	https://clinicaltrials.gov/study/NCT00264225	0.7	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	tooth disease	CODEINE	targetBased	4	Completed	01/09/2014	https://clinicaltrials.gov/study/NCT02547896	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis	CODEINE	targetBased	2	Completed	21/07/2016	https://clinicaltrials.gov/study/NCT02845271	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis	CODEINE	targetBased	2	Completed	21/07/2016	https://clinicaltrials.gov/study/NCT02845271	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis	CODEINE	targetBased	4	Completed	01/03/2006	https://clinicaltrials.gov/study/NCT00324038	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis	CODEINE	targetBased	4	Completed	01/03/2006	https://clinicaltrials.gov/study/NCT00324038	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis	CODEINE	targetBased	4	Completed	01/05/2013	https://clinicaltrials.gov/study/NCT02501564	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis	CODEINE	targetBased	4	Completed	01/05/2013	https://clinicaltrials.gov/study/NCT02501564	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	sickle cell anemia	CODEINE	targetBased	4	Withdrawn	01/11/2006	https://clinicaltrials.gov/study/NCT00513864	1	GoF	protect	lack of funding
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	sickle cell anemia	CODEINE	targetBased	4	Withdrawn	01/11/2006	https://clinicaltrials.gov/study/NCT00513864	1	GoF	protect	lack of funding
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	toothache	CODEINE	targetBased	3	Completed	01/06/2008	https://clinicaltrials.gov/study/NCT00694369	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	toothache	CODEINE	targetBased	3	Completed	01/06/2008	https://clinicaltrials.gov/study/NCT00694369	0.7	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	osteoarthritis	NALOXONE	targetBased	3	Completed	01/05/2009	https://clinicaltrials.gov/study/NCT00902837	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis	NALOXONE	targetBased	3	Completed	01/05/2009	https://clinicaltrials.gov/study/NCT00902837	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis	NALOXONE	targetBased	3	Completed	01/05/2009	https://clinicaltrials.gov/study/NCT00902837	0.7	LoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	Osteopenia	RALOXIFENE	targetBased	4	Completed	31/07/2000	https://clinicaltrials.gov/study/NCT00431431	1		protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	Osteopenia	RALOXIFENE	targetBased	3	Completed	01/02/2004	https://clinicaltrials.gov/study/NCT00310531	0.7		protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	Osteopenia	RALOXIFENE	targetBased	4	Completed	16/12/2020	https://clinicaltrials.gov/study/NCT05386784	1		protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	postmenopausal osteoporosis	RALOXIFENE	targetBased	3	Completed		https://clinicaltrials.gov/study/NCT00046137	0.7		protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	postmenopausal osteoporosis	RALOXIFENE	targetBased	4	Active, not recruiting	30/11/2018	https://clinicaltrials.gov/study/NCT03623633	1		protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	postmenopausal osteoporosis	RALOXIFENE	targetBased	4	Completed	01/11/2004	https://clinicaltrials.gov/study/NCT00079924	1		protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	postmenopausal osteoporosis	RALOXIFENE	targetBased	3	Completed	02/04/2001	https://clinicaltrials.gov/study/NCT00389740	0.7		protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	postmenopausal osteoporosis	RALOXIFENE	targetBased	3	Completed	01/11/1994	https://clinicaltrials.gov/study/NCT00670319	0.7		protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	postmenopausal osteoporosis	RALOXIFENE	targetBased	4	Completed	01/09/2009	https://clinicaltrials.gov/study/NCT01544894	1		protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	postmenopausal osteoporosis	RALOXIFENE	targetBased	4	Completed	01/03/2003	https://clinicaltrials.gov/study/NCT00532246	1		protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	postmenopausal osteoporosis	RALOXIFENE	targetBased	3	Completed	01/10/2006	https://clinicaltrials.gov/study/NCT00383422	0.7		protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	postmenopausal osteoporosis	RALOXIFENE	targetBased	4	Completed	01/08/2002	https://clinicaltrials.gov/study/NCT00191425	1		protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	postmenopausal osteoporosis	RALOXIFENE	targetBased	4	Completed	01/10/2001	https://clinicaltrials.gov/study/NCT00035256	1		protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	postmenopausal osteoporosis	RALOXIFENE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/evista	1		protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	postmenopausal osteoporosis	RALOXIFENE	targetBased	4	Terminated	01/06/2004	https://clinicaltrials.gov/study/NCT00790101	1		protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	postmenopausal osteoporosis	RALOXIFENE	targetBased	4	Completed	01/04/2003	https://clinicaltrials.gov/study/NCT00532428	1		protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	osteoporosis	RALOXIFENE	targetBased	4	Completed	01/09/2006	https://clinicaltrials.gov/study/NCT00371956	1		protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	osteoporosis	RALOXIFENE	targetBased	4	Active, not recruiting	30/11/2018	https://clinicaltrials.gov/study/NCT03623633	1		protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	osteoporosis	RALOXIFENE	targetBased	4	Completed		https://clinicaltrials.gov/study/NCT00035971	1		protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	osteoporosis	RALOXIFENE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fcaaa6dc-74e8-4fb8-800c-5574bf0f8de9	1		protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	osteoporosis	RALOXIFENE	targetBased	4	Completed	01/03/2006	https://clinicaltrials.gov/study/NCT01535027	1		protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	osteoporosis	RALOXIFENE	targetBased	4	Completed	01/09/2010	https://clinicaltrials.gov/study/NCT01166958	1		protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	osteoporosis	RALOXIFENE	targetBased	4	Completed	01/01/2007	https://clinicaltrials.gov/study/NCT00431444	1		protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	osteoporosis	RALOXIFENE	targetBased	3	Completed	01/05/2003	https://clinicaltrials.gov/study/NCT00163137	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Duchenne muscular dystrophy	TAMOXIFEN	targetBased	3	Completed	12/06/2018	https://clinicaltrials.gov/study/NCT03354039	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Duchenne muscular dystrophy	TAMOXIFEN	targetBased	3	Completed	12/06/2018	https://clinicaltrials.gov/study/NCT03354039	0.7		protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	peripartum cardiomyopathy	BROMOCRIPTINE	targetBased	4	Recruiting	27/07/2022	https://clinicaltrials.gov/study/NCT05180773	1	GoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	peripartum cardiomyopathy	BROMOCRIPTINE	targetBased	4	Recruiting	27/07/2022	https://clinicaltrials.gov/study/NCT05180773	1	GoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	peripartum cardiomyopathy	BROMOCRIPTINE	targetBased	4	Recruiting	27/07/2022	https://clinicaltrials.gov/study/NCT05180773	1	GoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	peripartum cardiomyopathy	BROMOCRIPTINE	targetBased	3	Withdrawn	01/01/2017	https://clinicaltrials.gov/study/NCT02590601	0.7	GoF	protect	Not enough patients
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	peripartum cardiomyopathy	BROMOCRIPTINE	targetBased	3	Withdrawn	01/01/2017	https://clinicaltrials.gov/study/NCT02590601	0.7	GoF	protect	Not enough patients
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	peripartum cardiomyopathy	BROMOCRIPTINE	targetBased	3	Withdrawn	01/01/2017	https://clinicaltrials.gov/study/NCT02590601	0.7	GoF	protect	Not enough patients
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	peripartum cardiomyopathy	BROMOCRIPTINE	targetBased	2	Completed	01/06/2010	https://clinicaltrials.gov/study/NCT00998556	0.2	GoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	peripartum cardiomyopathy	BROMOCRIPTINE	targetBased	2	Completed	01/06/2010	https://clinicaltrials.gov/study/NCT00998556	0.2	GoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	peripartum cardiomyopathy	BROMOCRIPTINE	targetBased	2	Completed	01/06/2010	https://clinicaltrials.gov/study/NCT00998556	0.2	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	peripartum cardiomyopathy	BROMOCRIPTINE	targetBased	2	Completed	01/06/2010	https://clinicaltrials.gov/study/NCT00998556	0.2	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	peripartum cardiomyopathy	BROMOCRIPTINE	targetBased	2	Completed	01/06/2010	https://clinicaltrials.gov/study/NCT00998556	0.2	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	peripartum cardiomyopathy	BROMOCRIPTINE	targetBased	2	Completed	01/06/2010	https://clinicaltrials.gov/study/NCT00998556	0.2	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	peripartum cardiomyopathy	BROMOCRIPTINE	targetBased	2	Completed	01/06/2010	https://clinicaltrials.gov/study/NCT00998556	0.2	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	peripartum cardiomyopathy	BROMOCRIPTINE	targetBased	2	Completed	01/06/2010	https://clinicaltrials.gov/study/NCT00998556	0.2	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	peripartum cardiomyopathy	BROMOCRIPTINE	targetBased	2	Completed	01/06/2010	https://clinicaltrials.gov/study/NCT00998556	0.2	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	peripartum cardiomyopathy	BROMOCRIPTINE	targetBased	3	Withdrawn	01/01/2017	https://clinicaltrials.gov/study/NCT02590601	0.7	GoF	protect	Not enough patients
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	peripartum cardiomyopathy	BROMOCRIPTINE	targetBased	3	Withdrawn	01/01/2017	https://clinicaltrials.gov/study/NCT02590601	0.7	GoF	protect	Not enough patients
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	peripartum cardiomyopathy	BROMOCRIPTINE	targetBased	3	Withdrawn	01/01/2017	https://clinicaltrials.gov/study/NCT02590601	0.7	GoF	protect	Not enough patients
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	peripartum cardiomyopathy	BROMOCRIPTINE	targetBased	3	Withdrawn	01/01/2017	https://clinicaltrials.gov/study/NCT02590601	0.7	GoF	protect	Not enough patients
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	peripartum cardiomyopathy	BROMOCRIPTINE	targetBased	3	Withdrawn	01/01/2017	https://clinicaltrials.gov/study/NCT02590601	0.7	GoF	protect	Not enough patients
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	peripartum cardiomyopathy	BROMOCRIPTINE	targetBased	3	Withdrawn	01/01/2017	https://clinicaltrials.gov/study/NCT02590601	0.7	GoF	protect	Not enough patients
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	peripartum cardiomyopathy	BROMOCRIPTINE	targetBased	4	Recruiting	27/07/2022	https://clinicaltrials.gov/study/NCT05180773	1	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	peripartum cardiomyopathy	BROMOCRIPTINE	targetBased	4	Recruiting	27/07/2022	https://clinicaltrials.gov/study/NCT05180773	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	peripartum cardiomyopathy	BROMOCRIPTINE	targetBased	4	Recruiting	27/07/2022	https://clinicaltrials.gov/study/NCT05180773	1	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	peripartum cardiomyopathy	BROMOCRIPTINE	targetBased	4	Recruiting	27/07/2022	https://clinicaltrials.gov/study/NCT05180773	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	peripartum cardiomyopathy	BROMOCRIPTINE	targetBased	4	Recruiting	27/07/2022	https://clinicaltrials.gov/study/NCT05180773	1	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	peripartum cardiomyopathy	BROMOCRIPTINE	targetBased	4	Recruiting	27/07/2022	https://clinicaltrials.gov/study/NCT05180773	1	GoF	protect
Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of Histone Deacetylase 3	HDAC3	HDAC3	Histone deacetylase 3	sickle cell anemia	VORINOSTAT	targetBased	2	Terminated	01/10/2009	https://clinicaltrials.gov/study/NCT01000155	0.2	LoF	protect	The study terminated early due to slow accrual.
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	osteoarthritis, knee	COLCHICINE	targetBased	2	Completed	01/10/2013	https://clinicaltrials.gov/study/NCT02176460	0.2	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	acute myocarditis	COLCHICINE	targetBased	3	Not yet recruiting	22/06/2024	https://clinicaltrials.gov/study/NCT05855746	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	familial Mediterranean fever	COLCHICINE	targetBased	2	Unknown status	01/06/2014	https://clinicaltrials.gov/study/NCT02175589	0.2	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	familial Mediterranean fever	COLCHICINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d6adc880-5499-4691-93f3-27c87902d5fc	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	familial Mediterranean fever	COLCHICINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=95a7ff27-b165-436a-b160-7a0f8ec95d7d	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	familial Mediterranean fever	COLCHICINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=847af9a9-57e3-4474-99ab-89cd0380f125	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	familial Mediterranean fever	COLCHICINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=96ca32da-68cc-d757-e053-2995a90a76d8	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	familial Mediterranean fever	COLCHICINE	targetBased	4	Completed	01/04/2011	https://clinicaltrials.gov/study/NCT02602028	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	familial Mediterranean fever	COLCHICINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4e936802-5b5d-4772-8b1d-4f30867ffa59	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	familial Mediterranean fever	COLCHICINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=153f5af8-827e-4a58-a0bd-5aafcb3b5444	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	familial Mediterranean fever	COLCHICINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5ecaa34e-1bed-49a5-b97c-a8f8c0d885a7	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	familial Mediterranean fever	COLCHICINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c7d013b7-0a67-0953-e053-2a95a90ac47c	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	familial Mediterranean fever	COLCHICINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14d4be16-d355-4baf-b4cd-4d97d4b2dca0	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	familial Mediterranean fever	COLCHICINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=56c130d1-7581-4152-99a2-0014ee9366c0	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	familial Mediterranean fever	COLCHICINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a0688f33-f00f-4a68-abc3-73ec887a471a	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	familial Mediterranean fever	COLCHICINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a80036fe-3016-4541-aa42-6c06cf37ae55	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	gout	COLCHICINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a80036fe-3016-4541-aa42-6c06cf37ae55	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	gout	COLCHICINE	targetBased	2	Completed	01/12/2008	https://clinicaltrials.gov/study/NCT00819585	0.2	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	gout	COLCHICINE	targetBased	2	Completed	01/06/2011	https://clinicaltrials.gov/study/NCT01399008	0.2	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	gout	COLCHICINE	targetBased	2	Recruiting	30/06/2023	https://clinicaltrials.gov/study/NCT05936268	0.2	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	gout	COLCHICINE	targetBased	4	Recruiting	18/01/2023	https://clinicaltrials.gov/study/NCT05698680	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	gout	COLCHICINE	targetBased	3	Completed	01/04/2007	https://clinicaltrials.gov/study/NCT00506883	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	gout	COLCHICINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=847af9a9-57e3-4474-99ab-89cd0380f125	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	gout	COLCHICINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a0567fe6-132b-463b-bc46-9f5a2a2478fb	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	gout	COLCHICINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5ecaa34e-1bed-49a5-b97c-a8f8c0d885a7	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	gout	COLCHICINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=153f5af8-827e-4a58-a0bd-5aafcb3b5444	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	gout	COLCHICINE	targetBased	4	Completed	17/08/2015	https://clinicaltrials.gov/study/NCT02500641	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	gout	COLCHICINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4e936802-5b5d-4772-8b1d-4f30867ffa59	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	gout	COLCHICINE	targetBased	4	Completed	01/10/2011	https://clinicaltrials.gov/study/NCT01451645	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	gout	COLCHICINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a0688f33-f00f-4a68-abc3-73ec887a471a	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	gout	COLCHICINE	targetBased	3	Completed	01/04/2014	https://clinicaltrials.gov/study/NCT02139046	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	gout	COLCHICINE	targetBased	2	Completed	12/02/2020	https://clinicaltrials.gov/study/NCT04130204	0.2	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	gout	COLCHICINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=M04AC01	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	gout	COLCHICINE	targetBased	4	Completed	01/01/2013	https://clinicaltrials.gov/study/NCT02060552	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	gout	COLCHICINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=176af20d-d082-47bd-bc56-a21cc1244a33	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	gout	COLCHICINE	targetBased	4	Recruiting	23/01/2024	https://clinicaltrials.gov/study/NCT04875702	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	gout	COLCHICINE	targetBased	2	Completed	01/03/2014	https://clinicaltrials.gov/study/NCT02063997	0.2	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	gout	COLCHICINE	targetBased	2	Completed	01/04/2015	https://clinicaltrials.gov/study/NCT02330796	0.2	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	gout	COLCHICINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d6adc880-5499-4691-93f3-27c87902d5fc	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	gout	COLCHICINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ebf556e5-7e01-770c-9dc2-4cdfd661c132	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	gout	COLCHICINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=95a7ff27-b165-436a-b160-7a0f8ec95d7d	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	gout	COLCHICINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cb5f9d85-6b81-49f8-bcd6-17b7bfbc10f2	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	gout	COLCHICINE	targetBased	4	Terminated	10/09/2019	https://clinicaltrials.gov/study/NCT03933007	1	LoF	protect	faillure of recrutement
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	gout	COLCHICINE	targetBased	4	Completed	01/01/2014	https://clinicaltrials.gov/study/NCT01994226	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	gout	COLCHICINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=56c130d1-7581-4152-99a2-0014ee9366c0	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	gout	COLCHICINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee1583ac-c308-4beb-b602-9ecac4977026	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	osteoarthritis	COLCHICINE	targetBased	4	Completed	15/05/2019	https://clinicaltrials.gov/study/NCT03913442	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	osteoarthritis	COLCHICINE	targetBased	4	Completed	15/01/2021	https://clinicaltrials.gov/study/NCT04601883	1	LoF	protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	tooth disease	ACETAMINOPHEN	targetBased	4	Completed	04/03/2017	https://clinicaltrials.gov/study/NCT04769557	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	osteoarthritis, hip	ACETAMINOPHEN	targetBased	3	Completed		https://clinicaltrials.gov/study/NCT00240773	0.7		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	humerus fracture	ACETAMINOPHEN	targetBased	4	Terminated	07/06/2021	https://clinicaltrials.gov/study/NCT04905563	1		protect	Clinical evidence supporting the hypothesis of this study has been published
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	humerus fracture	ACETAMINOPHEN	targetBased	4	Recruiting	26/02/2019	https://clinicaltrials.gov/study/NCT03759028	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	humerus fracture	ACETAMINOPHEN	targetBased	4	Enrolling by invitation	15/04/2019	https://clinicaltrials.gov/study/NCT06187584	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	humerus fracture	ACETAMINOPHEN	targetBased	4	Enrolling by invitation	12/09/2023	https://clinicaltrials.gov/study/NCT05640674	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	muscle cramp	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6197eff5-0351-42ef-bb3f-cbc26e6d0d14	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	muscle cramp	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=00eb3e4b-1507-4c9a-83a5-ef50cb312753	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	muscle cramp	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=07c4cc3d-9a68-42a1-801d-5d4ec107ffad	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	muscle cramp	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f5ea858e-76d9-4777-b3dc-5d614f66d485	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	muscle cramp	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9d384e88-5c11-4600-ac6c-a38371570138	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	muscle cramp	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=889c5b6a-879e-425c-a25a-435766e9d601	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	muscle cramp	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=55768b45-fd98-4779-85b6-6a50c628677e	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	muscle cramp	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dad63da3-cd1f-42a8-93d5-44b39aae1268	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	radius fracture	ACETAMINOPHEN	targetBased	4	Completed	02/01/2019	https://clinicaltrials.gov/study/NCT03749616	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	osteoarthritis	ACETAMINOPHEN	targetBased	3	Completed	01/02/2006	https://clinicaltrials.gov/study/NCT00298974	0.7		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	osteoarthritis	ACETAMINOPHEN	targetBased	4	Completed	01/03/2006	https://clinicaltrials.gov/study/NCT00324038	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	osteoarthritis	ACETAMINOPHEN	targetBased	4	Completed	01/10/2012	https://clinicaltrials.gov/study/NCT01699815	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	osteoarthritis	ACETAMINOPHEN	targetBased	4	Recruiting	13/09/2022	https://clinicaltrials.gov/study/NCT05556356	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	osteoarthritis	ACETAMINOPHEN	targetBased	4	Completed	01/09/2016	https://clinicaltrials.gov/study/NCT03540030	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	osteoarthritis	ACETAMINOPHEN	targetBased	3	Completed	01/04/2002	https://clinicaltrials.gov/study/NCT00240786	0.7		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	osteoarthritis	ACETAMINOPHEN	targetBased	3	Completed		https://clinicaltrials.gov/study/NCT00240799	0.7		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	osteoarthritis	ACETAMINOPHEN	targetBased	2	Completed	21/07/2016	https://clinicaltrials.gov/study/NCT02845271	0.2		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	osteoarthritis	ACETAMINOPHEN	targetBased	3	Withdrawn	01/11/2013	https://clinicaltrials.gov/study/NCT01420666	0.7		protect	The study was withdrawn for administrative reason
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	osteoarthritis	ACETAMINOPHEN	targetBased	2	Completed	01/12/2001	https://clinicaltrials.gov/study/NCT00371696	0.2		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	osteoarthritis	ACETAMINOPHEN	targetBased	3	Completed	01/07/1996	https://clinicaltrials.gov/study/NCT00000425	0.7		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	osteoarthritis	ACETAMINOPHEN	targetBased	4	Recruiting	01/01/2019	https://clinicaltrials.gov/study/NCT03781544	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	osteoarthritis	ACETAMINOPHEN	targetBased	4	Completed	14/03/2017	https://clinicaltrials.gov/study/NCT02839876	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	osteoarthritis	ACETAMINOPHEN	targetBased	4	Completed	01/08/2005	https://clinicaltrials.gov/study/NCT01063842	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	osteoarthritis	ACETAMINOPHEN	targetBased	4	Completed	01/05/2007	https://clinicaltrials.gov/study/NCT00635349	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	osteoarthritis	ACETAMINOPHEN	targetBased	4	Completed	01/10/2007	https://clinicaltrials.gov/study/NCT01728246	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	sinusitis	ACETAMINOPHEN	targetBased	4	Completed	01/10/2006	https://clinicaltrials.gov/study/NCT00377403	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	sinusitis	ACETAMINOPHEN	targetBased	2	Completed	01/04/2017	https://clinicaltrials.gov/study/NCT03055507	0.2		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	toothache	ACETAMINOPHEN	targetBased	4	Completed	01/11/2009	https://clinicaltrials.gov/study/NCT01075243	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	toothache	ACETAMINOPHEN	targetBased	3	Completed	01/06/2013	https://clinicaltrials.gov/study/NCT01920386	0.7		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	toothache	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=008c5055-4ae3-498f-a7bf-5bd00f738c6d	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	toothache	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=720366f1-f2d1-6dd6-7bf1-9fdd9378b073	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	toothache	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1f172d58-4050-424b-9743-130d8e618fe8	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	toothache	ACETAMINOPHEN	targetBased	3	Completed	01/04/2013	https://clinicaltrials.gov/study/NCT01420653	0.7		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	toothache	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9d384e88-5c11-4600-ac6c-a38371570138	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	toothache	ACETAMINOPHEN	targetBased	3	Completed	30/04/2016	https://clinicaltrials.gov/study/NCT02735122	0.7		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	toothache	ACETAMINOPHEN	targetBased	4	Completed	01/12/2007	https://clinicaltrials.gov/study/NCT00574015	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	toothache	ACETAMINOPHEN	targetBased	3	Completed	01/06/2008	https://clinicaltrials.gov/study/NCT00694369	0.7		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	toothache	ACETAMINOPHEN	targetBased	2	Completed	31/12/2014	https://clinicaltrials.gov/study/NCT02320708	0.2		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	toothache	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=42e4219a-a4ef-f090-f6a4-2fd2e213d397	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	toothache	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f5ea858e-76d9-4777-b3dc-5d614f66d485	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	toothache	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=07c4cc3d-9a68-42a1-801d-5d4ec107ffad	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	toothache	ACETAMINOPHEN	targetBased	3	Completed	19/07/2017	https://clinicaltrials.gov/study/NCT03224403	0.7		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	toothache	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6197eff5-0351-42ef-bb3f-cbc26e6d0d14	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	toothache	ACETAMINOPHEN	targetBased	4	Completed	01/10/2009	https://clinicaltrials.gov/study/NCT01082081	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	toothache	ACETAMINOPHEN	targetBased	2	Completed	01/10/2013	https://clinicaltrials.gov/study/NCT01960114	0.2		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	toothache	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2321b5fb-9b3a-4435-8deb-e8cfd2208b43	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	toothache	ACETAMINOPHEN	targetBased	2	Completed	25/04/2019	https://clinicaltrials.gov/study/NCT04018612	0.2		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	toothache	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dad63da3-cd1f-42a8-93d5-44b39aae1268	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	toothache	ACETAMINOPHEN	targetBased	2	Terminated	01/08/2016	https://clinicaltrials.gov/study/NCT02862691	0.2		protect	Difficulty recruiting patients
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	toothache	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dd7b5ba3-652a-443f-b0b9-17abda148e67	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	toothache	ACETAMINOPHEN	targetBased	2	Withdrawn		https://clinicaltrials.gov/study/NCT01104844	0.2		protect	The study was withdrawn due to administrative reason
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	scoliosis	ACETAMINOPHEN	targetBased	3	Completed	01/06/2021	https://clinicaltrials.gov/study/NCT04959591	0.7		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	scoliosis	ACETAMINOPHEN	targetBased	2	Completed	18/06/2019	https://clinicaltrials.gov/study/NCT03968146	0.2		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	rib fracture	ACETAMINOPHEN	targetBased	4	Completed	01/09/2015	https://clinicaltrials.gov/study/NCT02432456	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	rib fracture	ACETAMINOPHEN	targetBased	4	Unknown status	06/11/2018	https://clinicaltrials.gov/study/NCT03619785	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	systemic lupus erythematosus	ACETAMINOPHEN	targetBased	3	Recruiting	26/10/2021	https://clinicaltrials.gov/study/NCT04963296	0.7		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	systemic lupus erythematosus	ACETAMINOPHEN	targetBased	2	Completed	10/05/2005	https://clinicaltrials.gov/study/NCT00137969	0.2		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	systemic lupus erythematosus	ACETAMINOPHEN	targetBased	3	Terminated	22/06/2006	https://clinicaltrials.gov/study/NCT00381810	0.7		protect	During a safety review of studies U2970g and U2971g, the Data Monitoring Committee recommended that enrollment in this extension trial be terminated.
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	temporomandibular joint disorder	ACETAMINOPHEN	targetBased	4	Completed	16/07/2019	https://clinicaltrials.gov/study/NCT05529290	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	bone fracture	ACETAMINOPHEN	targetBased	2	Completed	01/12/2015	https://clinicaltrials.gov/study/NCT02521415	0.2		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	bone fracture	ACETAMINOPHEN	targetBased	4	Completed	01/01/2014	https://clinicaltrials.gov/study/NCT02076321	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	bone fracture	ACETAMINOPHEN	targetBased	4	Not yet recruiting	04/11/2022	https://clinicaltrials.gov/study/NCT05425355	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	sickle cell anemia	ACETAMINOPHEN	targetBased	4	Completed	20/02/2018	https://clinicaltrials.gov/study/NCT03541980	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	rotator cuff tear	ACETAMINOPHEN	targetBased	4	Withdrawn	01/01/2015	https://clinicaltrials.gov/study/NCT02153177	1		protect	The study was withdrawn prior to any participants being enrolled.
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	rotator cuff tear	ACETAMINOPHEN	targetBased	4	Completed	01/09/2016	https://clinicaltrials.gov/study/NCT03540030	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	rotator cuff tear	ACETAMINOPHEN	targetBased	2	Completed	22/01/2019	https://clinicaltrials.gov/study/NCT03818919	0.2		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	hip fracture	ACETAMINOPHEN	targetBased	4	Terminated	01/05/2016	https://clinicaltrials.gov/study/NCT02689024	1		protect	recruitment too slow; intervention was standard care in patients who were not included; acute care pathways changed due to policy regarding hip fracture patients
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	hip fracture	ACETAMINOPHEN	targetBased	4	Terminated	01/12/2016	https://clinicaltrials.gov/study/NCT02774148	1		protect	Proved difficult to consent patient population due to comorbidities
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	hip fracture	ACETAMINOPHEN	targetBased	4	Completed	21/04/2021	https://clinicaltrials.gov/study/NCT04837924	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Fabry disease	ACETAMINOPHEN	targetBased	4	Recruiting	10/11/2023	https://clinicaltrials.gov/study/NCT06019728	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	osteoporosis	ACETAMINOPHEN	targetBased	4	Completed	01/06/2007	https://clinicaltrials.gov/study/NCT00489424	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	muscular disease	ACETAMINOPHEN	targetBased	4	Completed	01/02/2013	https://clinicaltrials.gov/study/NCT02113566	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	osteoarthritis, knee	ACETAMINOPHEN	targetBased	4	Not yet recruiting	01/09/2023	https://clinicaltrials.gov/study/NCT06042426	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	osteoarthritis, knee	ACETAMINOPHEN	targetBased	3	Completed	01/10/1999	https://clinicaltrials.gov/study/NCT00568295	0.7		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	osteoarthritis, knee	ACETAMINOPHEN	targetBased	3	Completed	01/05/2000	https://clinicaltrials.gov/study/NCT00110474	0.7		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	osteoarthritis, knee	ACETAMINOPHEN	targetBased	2	Completed	29/06/2018	https://clinicaltrials.gov/study/NCT03570554	0.2		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	osteoarthritis, knee	ACETAMINOPHEN	targetBased	4	Completed	01/09/2010	https://clinicaltrials.gov/study/NCT01105936	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	osteoarthritis, knee	ACETAMINOPHEN	targetBased	3	Completed		https://clinicaltrials.gov/study/NCT00240773	0.7		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	avascular necrosis	ACETAMINOPHEN	targetBased	4	Completed	01/09/2016	https://clinicaltrials.gov/study/NCT03540030	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	arthritis	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=50684514-3226-4395-b695-8c69c29becb4	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	arthritis	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1f172d58-4050-424b-9743-130d8e618fe8	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	arthritis	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d4325b17-23bc-44ac-868d-bb0886853a73	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	arthritis	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dd7b5ba3-652a-443f-b0b9-17abda148e67	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	arthritis	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=02fa9c00-214a-4289-8ab5-d470ce04a70f	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	arthritis	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=42e4219a-a4ef-f090-f6a4-2fd2e213d397	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	arthritis	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=07c4cc3d-9a68-42a1-801d-5d4ec107ffad	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	arthritis	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dad63da3-cd1f-42a8-93d5-44b39aae1268	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	arthritis	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=55768b45-fd98-4779-85b6-6a50c628677e	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	arthritis	ACETAMINOPHEN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9d384e88-5c11-4600-ac6c-a38371570138	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	patellofemoral pain syndrome	ACETAMINOPHEN	targetBased	4	Unknown status	01/02/2014	https://clinicaltrials.gov/study/NCT02241148	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	pulpitis	ACETAMINOPHEN	targetBased	2	Completed	01/09/2015	https://clinicaltrials.gov/study/NCT02601911	0.2		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	pulpitis	ACETAMINOPHEN	targetBased	2	Completed	01/09/2015	https://clinicaltrials.gov/study/NCT02614118	0.2		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Sciatica	ACETAMINOPHEN	targetBased	4	Unknown status	01/03/2016	https://clinicaltrials.gov/study/NCT02777320	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Sciatica	ACETAMINOPHEN	targetBased	4	Unknown status	01/01/2015	https://clinicaltrials.gov/study/NCT02504996	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Inguinal hernia	ACETAMINOPHEN	targetBased	4	Completed	08/03/2016	https://clinicaltrials.gov/study/NCT05919732	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Inguinal hernia	ACETAMINOPHEN	targetBased	4	Completed	08/12/2017	https://clinicaltrials.gov/study/NCT03558555	1		protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	muscle cramp	ROPINIROLE	targetBased	4	Completed	02/09/2016	https://clinicaltrials.gov/study/NCT03176966	1	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	muscle cramp	ROPINIROLE	targetBased	4	Completed	02/09/2016	https://clinicaltrials.gov/study/NCT03176966	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	muscle cramp	ROPINIROLE	targetBased	4	Completed	02/09/2016	https://clinicaltrials.gov/study/NCT03176966	1	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	muscle cramp	ROPINIROLE	targetBased	4	Completed	02/09/2016	https://clinicaltrials.gov/study/NCT03176966	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	muscle cramp	ROPINIROLE	targetBased	4	Completed	02/09/2016	https://clinicaltrials.gov/study/NCT03176966	1	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	muscle cramp	ROPINIROLE	targetBased	4	Completed	02/09/2016	https://clinicaltrials.gov/study/NCT03176966	1	GoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	muscle cramp	ROPINIROLE	targetBased	4	Completed	02/09/2016	https://clinicaltrials.gov/study/NCT03176966	1	GoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	muscle cramp	ROPINIROLE	targetBased	4	Completed	02/09/2016	https://clinicaltrials.gov/study/NCT03176966	1	GoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	muscle cramp	ROPINIROLE	targetBased	4	Completed	02/09/2016	https://clinicaltrials.gov/study/NCT03176966	1	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	fibromyalgia	ROPINIROLE	targetBased	2	Completed	01/11/2004	https://clinicaltrials.gov/study/NCT00256893	0.2	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	fibromyalgia	ROPINIROLE	targetBased	2	Completed	01/11/2004	https://clinicaltrials.gov/study/NCT00256893	0.2	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	fibromyalgia	ROPINIROLE	targetBased	2	Completed	01/11/2004	https://clinicaltrials.gov/study/NCT00256893	0.2	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	fibromyalgia	ROPINIROLE	targetBased	2	Completed	01/11/2004	https://clinicaltrials.gov/study/NCT00256893	0.2	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	fibromyalgia	ROPINIROLE	targetBased	2	Completed	01/11/2004	https://clinicaltrials.gov/study/NCT00256893	0.2	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	fibromyalgia	ROPINIROLE	targetBased	2	Completed	01/11/2004	https://clinicaltrials.gov/study/NCT00256893	0.2	GoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	fibromyalgia	ROPINIROLE	targetBased	2	Completed	01/11/2004	https://clinicaltrials.gov/study/NCT00256893	0.2	GoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	fibromyalgia	ROPINIROLE	targetBased	2	Completed	01/11/2004	https://clinicaltrials.gov/study/NCT00256893	0.2	GoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	fibromyalgia	ROPINIROLE	targetBased	2	Completed	01/11/2004	https://clinicaltrials.gov/study/NCT00256893	0.2	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	systemic lupus erythematosus	PIOGLITAZONE	targetBased	4	Completed	01/03/2007	https://clinicaltrials.gov/study/NCT01322308	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	systemic lupus erythematosus	PIOGLITAZONE	targetBased	4	Completed	01/03/2007	https://clinicaltrials.gov/study/NCT01322308	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	systemic lupus erythematosus	PIOGLITAZONE	targetBased	4	Completed	01/03/2007	https://clinicaltrials.gov/study/NCT01322308	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	systemic lupus erythematosus	PIOGLITAZONE	targetBased	4	Completed	01/03/2007	https://clinicaltrials.gov/study/NCT01322308	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	systemic lupus erythematosus	PIOGLITAZONE	targetBased	4	Completed	01/03/2007	https://clinicaltrials.gov/study/NCT01322308	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	systemic lupus erythematosus	PIOGLITAZONE	targetBased	4	Completed	01/03/2007	https://clinicaltrials.gov/study/NCT01322308	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Friedreich ataxia	PIOGLITAZONE	targetBased	3	Completed	01/12/2008	https://clinicaltrials.gov/study/NCT00811681	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Friedreich ataxia	PIOGLITAZONE	targetBased	3	Completed	01/12/2008	https://clinicaltrials.gov/study/NCT00811681	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Friedreich ataxia	PIOGLITAZONE	targetBased	3	Completed	01/12/2008	https://clinicaltrials.gov/study/NCT00811681	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Friedreich ataxia	PIOGLITAZONE	targetBased	3	Completed	01/12/2008	https://clinicaltrials.gov/study/NCT00811681	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Friedreich ataxia	PIOGLITAZONE	targetBased	3	Completed	01/12/2008	https://clinicaltrials.gov/study/NCT00811681	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Friedreich ataxia	PIOGLITAZONE	targetBased	3	Completed	01/12/2008	https://clinicaltrials.gov/study/NCT00811681	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	bone metastasis	FENTANYL	targetBased	3	Unknown status	01/05/2015	https://clinicaltrials.gov/study/NCT02426697	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	bone metastasis	FENTANYL	targetBased	3	Unknown status	01/05/2015	https://clinicaltrials.gov/study/NCT02426697	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	scoliosis	FENTANYL	targetBased	2	Completed	18/06/2019	https://clinicaltrials.gov/study/NCT03968146	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	scoliosis	FENTANYL	targetBased	2	Completed	18/06/2019	https://clinicaltrials.gov/study/NCT03968146	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	rib fracture	FENTANYL	targetBased	4	Unknown status	06/11/2018	https://clinicaltrials.gov/study/NCT03619785	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	rib fracture	FENTANYL	targetBased	4	Unknown status	06/11/2018	https://clinicaltrials.gov/study/NCT03619785	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	bone fracture	FENTANYL	targetBased	4	Terminated	10/03/2011	https://clinicaltrials.gov/study/NCT02056288	1	GoF	protect	Enrollment was suspended due to the duration of the study and poor follow-up response by participants.
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	bone fracture	FENTANYL	targetBased	4	Terminated	10/03/2011	https://clinicaltrials.gov/study/NCT02056288	1	GoF	protect	Enrollment was suspended due to the duration of the study and poor follow-up response by participants.
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	bone fracture	FENTANYL	targetBased	2	Completed	01/12/2015	https://clinicaltrials.gov/study/NCT02521415	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	bone fracture	FENTANYL	targetBased	2	Completed	01/12/2015	https://clinicaltrials.gov/study/NCT02521415	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	hip fracture	FENTANYL	targetBased	4	Terminated	01/05/2016	https://clinicaltrials.gov/study/NCT02689024	1	GoF	protect	recruitment too slow; intervention was standard care in patients who were not included; acute care pathways changed due to policy regarding hip fracture patients
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	hip fracture	FENTANYL	targetBased	4	Terminated	01/05/2016	https://clinicaltrials.gov/study/NCT02689024	1	GoF	protect	recruitment too slow; intervention was standard care in patients who were not included; acute care pathways changed due to policy regarding hip fracture patients
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis, knee	FENTANYL	targetBased	4	Completed	01/11/2007	https://clinicaltrials.gov/study/NCT00562627	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis, knee	FENTANYL	targetBased	4	Completed	01/11/2007	https://clinicaltrials.gov/study/NCT00562627	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis, knee	FENTANYL	targetBased	4	Completed	01/08/2008	https://clinicaltrials.gov/study/NCT01742897	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis, knee	FENTANYL	targetBased	4	Completed	01/08/2008	https://clinicaltrials.gov/study/NCT01742897	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pulpitis	FENTANYL	targetBased	2	Completed	01/10/2012	https://clinicaltrials.gov/study/NCT01794533	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pulpitis	FENTANYL	targetBased	2	Completed	01/10/2012	https://clinicaltrials.gov/study/NCT01794533	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis	FENTANYL	targetBased	4	Completed	01/10/2008	https://clinicaltrials.gov/study/NCT01774929	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis	FENTANYL	targetBased	4	Completed	01/10/2008	https://clinicaltrials.gov/study/NCT01774929	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis	FENTANYL	targetBased	3	Completed	01/03/2005	https://clinicaltrials.gov/study/NCT00228605	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis	FENTANYL	targetBased	3	Completed	01/03/2005	https://clinicaltrials.gov/study/NCT00228605	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis	FENTANYL	targetBased	4	Completed	01/07/2001	https://clinicaltrials.gov/study/NCT00524160	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis	FENTANYL	targetBased	4	Completed	01/07/2001	https://clinicaltrials.gov/study/NCT00524160	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis	FENTANYL	targetBased	4	Completed	01/06/2002	https://clinicaltrials.gov/study/NCT00236366	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis	FENTANYL	targetBased	4	Completed	01/06/2002	https://clinicaltrials.gov/study/NCT00236366	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	fibromyalgia	NALTREXONE	targetBased	2	Completed	06/01/2021	https://clinicaltrials.gov/study/NCT04270877	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	fibromyalgia	NALTREXONE	targetBased	2	Completed	06/01/2021	https://clinicaltrials.gov/study/NCT04270877	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	fibromyalgia	NALTREXONE	targetBased	2	Completed	01/08/2018	https://clinicaltrials.gov/study/NCT04502251	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	fibromyalgia	NALTREXONE	targetBased	2	Completed	01/08/2018	https://clinicaltrials.gov/study/NCT04502251	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	fibromyalgia	NALTREXONE	targetBased	4	Completed	01/06/2016	https://clinicaltrials.gov/study/NCT02806440	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	fibromyalgia	NALTREXONE	targetBased	4	Completed	01/06/2016	https://clinicaltrials.gov/study/NCT02806440	1	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	interstitial cystitis	NALTREXONE	targetBased	4	Completed	07/09/2021	https://clinicaltrials.gov/study/NCT04313972	1	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	interstitial cystitis	NALTREXONE	targetBased	2	Suspended	08/10/2020	https://clinicaltrials.gov/study/NCT04450316	0.2	LoF	protect	Study temporarily suspended awaiting research personnel to resume recruitment
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	interstitial cystitis	NALTREXONE	targetBased	2	Suspended	08/10/2020	https://clinicaltrials.gov/study/NCT04450316	0.2	LoF	protect	Study temporarily suspended awaiting research personnel to resume recruitment
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	interstitial cystitis	NALTREXONE	targetBased	2	Suspended	08/10/2020	https://clinicaltrials.gov/study/NCT04450316	0.2	LoF	protect	Study temporarily suspended awaiting research personnel to resume recruitment
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	interstitial cystitis	NALTREXONE	targetBased	4	Completed	07/09/2021	https://clinicaltrials.gov/study/NCT04313972	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	interstitial cystitis	NALTREXONE	targetBased	4	Completed	07/09/2021	https://clinicaltrials.gov/study/NCT04313972	1	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	fibromyalgia	NALTREXONE	targetBased	4	Completed	01/06/2016	https://clinicaltrials.gov/study/NCT02806440	1	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	fibromyalgia	NALTREXONE	targetBased	2	Completed	01/08/2018	https://clinicaltrials.gov/study/NCT04502251	0.2	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	fibromyalgia	NALTREXONE	targetBased	2	Completed	06/01/2021	https://clinicaltrials.gov/study/NCT04270877	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Sciatica	MEPERIDINE	targetBased	3	Unknown status	01/12/2004	https://clinicaltrials.gov/study/NCT00163553	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Sciatica	MEPERIDINE	targetBased	3	Unknown status	01/12/2004	https://clinicaltrials.gov/study/NCT00163553	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	scoliosis	MEPERIDINE	targetBased	2	Completed	18/06/2019	https://clinicaltrials.gov/study/NCT03968146	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	scoliosis	MEPERIDINE	targetBased	2	Completed	18/06/2019	https://clinicaltrials.gov/study/NCT03968146	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	dental caries	MEPERIDINE	targetBased	4	Completed	25/06/2019	https://clinicaltrials.gov/study/NCT04068948	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	dental caries	MEPERIDINE	targetBased	4	Completed	25/06/2019	https://clinicaltrials.gov/study/NCT04068948	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	fibromyalgia	TRAZODONE	targetBased	4	Completed	01/04/2008	https://clinicaltrials.gov/study/NCT00791739	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	Chagas cardiomyopathy	AMIODARONE	targetBased	3	Unknown status	12/06/2017	https://clinicaltrials.gov/study/NCT03193749	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	Chagas cardiomyopathy	AMIODARONE	targetBased	3	Unknown status	12/06/2017	https://clinicaltrials.gov/study/NCT03193749	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	Chagas cardiomyopathy	AMIODARONE	targetBased	3	Unknown status	12/06/2017	https://clinicaltrials.gov/study/NCT03193749	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	AL amyloidosis	AMIODARONE	targetBased	2	Terminated	01/01/2012	https://clinicaltrials.gov/study/NCT01511263	0.2	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	AL amyloidosis	AMIODARONE	targetBased	2	Terminated	01/01/2012	https://clinicaltrials.gov/study/NCT01511263	0.2	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	AL amyloidosis	AMIODARONE	targetBased	2	Terminated	01/01/2012	https://clinicaltrials.gov/study/NCT01511263	0.2	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	cardiomyopathy	AMIODARONE	targetBased	3	Completed	01/11/2017	https://clinicaltrials.gov/study/NCT02924285	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	cardiomyopathy	AMIODARONE	targetBased	3	Completed	01/11/2017	https://clinicaltrials.gov/study/NCT02924285	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	cardiomyopathy	AMIODARONE	targetBased	3	Completed	01/11/2017	https://clinicaltrials.gov/study/NCT02924285	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Marfan syndrome	NEBIVOLOL	targetBased	3	Unknown status	01/07/2008	https://clinicaltrials.gov/study/NCT00683124	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	scoliosis	METHADONE	targetBased	3	Completed	01/03/2009	https://clinicaltrials.gov/study/NCT01205256	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	scoliosis	METHADONE	targetBased	3	Completed	01/03/2009	https://clinicaltrials.gov/study/NCT01205256	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	scoliosis	METHADONE	targetBased	4	Completed	01/05/2014	https://clinicaltrials.gov/study/NCT02206685	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	scoliosis	METHADONE	targetBased	4	Completed	01/05/2014	https://clinicaltrials.gov/study/NCT02206685	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	juvenile idiopathic scoliosis	METHADONE	targetBased	4	Recruiting	19/10/2022	https://clinicaltrials.gov/study/NCT05730920	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	juvenile idiopathic scoliosis	METHADONE	targetBased	4	Recruiting	19/10/2022	https://clinicaltrials.gov/study/NCT05730920	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	idiopathic scoliosis	METHADONE	targetBased	2	Completed	01/09/2013	https://clinicaltrials.gov/study/NCT01795495	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	idiopathic scoliosis	METHADONE	targetBased	2	Completed	01/09/2013	https://clinicaltrials.gov/study/NCT01795495	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	fibromyalgia	MIRTAZAPINE	targetBased	2	Completed	01/12/2008	https://clinicaltrials.gov/study/NCT00919295	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	ligament rupture	OXYCODONE	targetBased	4	Completed	16/09/2020	https://clinicaltrials.gov/study/NCT04285853	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	ligament rupture	OXYCODONE	targetBased	4	Completed	16/09/2020	https://clinicaltrials.gov/study/NCT04285853	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	humerus fracture	OXYCODONE	targetBased	4	Recruiting	26/02/2019	https://clinicaltrials.gov/study/NCT03759028	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	humerus fracture	OXYCODONE	targetBased	4	Recruiting	26/02/2019	https://clinicaltrials.gov/study/NCT03759028	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	sinusitis	OXYCODONE	targetBased	2	Completed	01/04/2017	https://clinicaltrials.gov/study/NCT03055507	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	sinusitis	OXYCODONE	targetBased	2	Completed	01/04/2017	https://clinicaltrials.gov/study/NCT03055507	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis, hip	OXYCODONE	targetBased	3	Completed	01/11/2006	https://clinicaltrials.gov/study/NCT00361504	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis, hip	OXYCODONE	targetBased	3	Completed	01/11/2006	https://clinicaltrials.gov/study/NCT00361504	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis, hip	OXYCODONE	targetBased	3	Completed		https://clinicaltrials.gov/study/NCT00399048	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis, hip	OXYCODONE	targetBased	3	Completed		https://clinicaltrials.gov/study/NCT00399048	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	scoliosis	OXYCODONE	targetBased	4	Completed	01/08/2015	https://clinicaltrials.gov/study/NCT02464813	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	scoliosis	OXYCODONE	targetBased	4	Completed	01/08/2015	https://clinicaltrials.gov/study/NCT02464813	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	spondylolisthesis	OXYCODONE	targetBased	4	Completed	01/08/2015	https://clinicaltrials.gov/study/NCT02464813	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	spondylolisthesis	OXYCODONE	targetBased	4	Completed	01/08/2015	https://clinicaltrials.gov/study/NCT02464813	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	joint disease	OXYCODONE	targetBased	3	Completed	01/09/2015	https://clinicaltrials.gov/study/NCT02604446	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	joint disease	OXYCODONE	targetBased	3	Completed	01/09/2015	https://clinicaltrials.gov/study/NCT02604446	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	bone fracture	OXYCODONE	targetBased	4	Completed	01/04/2007	https://clinicaltrials.gov/study/NCT00254631	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	bone fracture	OXYCODONE	targetBased	4	Completed	01/04/2007	https://clinicaltrials.gov/study/NCT00254631	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis, knee	OXYCODONE	targetBased	4	Not yet recruiting	01/09/2023	https://clinicaltrials.gov/study/NCT06042426	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis, knee	OXYCODONE	targetBased	4	Not yet recruiting	01/09/2023	https://clinicaltrials.gov/study/NCT06042426	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis, knee	OXYCODONE	targetBased	3	Completed	01/11/2006	https://clinicaltrials.gov/study/NCT00361504	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis, knee	OXYCODONE	targetBased	3	Completed	01/11/2006	https://clinicaltrials.gov/study/NCT00361504	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis, knee	OXYCODONE	targetBased	2	Completed	01/10/2009	https://clinicaltrials.gov/study/NCT00979953	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis, knee	OXYCODONE	targetBased	2	Completed	01/10/2009	https://clinicaltrials.gov/study/NCT00979953	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis, knee	OXYCODONE	targetBased	2	Completed	04/12/2012	https://clinicaltrials.gov/study/NCT01709214	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis, knee	OXYCODONE	targetBased	2	Completed	04/12/2012	https://clinicaltrials.gov/study/NCT01709214	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis, knee	OXYCODONE	targetBased	3	Completed		https://clinicaltrials.gov/study/NCT00399048	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis, knee	OXYCODONE	targetBased	3	Completed		https://clinicaltrials.gov/study/NCT00399048	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis, knee	OXYCODONE	targetBased	2	Completed	01/06/2011	https://clinicaltrials.gov/study/NCT01366014	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis, knee	OXYCODONE	targetBased	2	Completed	01/06/2011	https://clinicaltrials.gov/study/NCT01366014	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis	OXYCODONE	targetBased	3	Completed	01/10/2008	https://clinicaltrials.gov/study/NCT00784277	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis	OXYCODONE	targetBased	3	Completed	01/10/2008	https://clinicaltrials.gov/study/NCT00784277	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis	OXYCODONE	targetBased	4	Terminated	17/01/2008	https://clinicaltrials.gov/study/NCT00484718	1	GoF	protect	See termination reason in detailed description.
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis	OXYCODONE	targetBased	4	Terminated	17/01/2008	https://clinicaltrials.gov/study/NCT00484718	1	GoF	protect	See termination reason in detailed description.
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis	OXYCODONE	targetBased	3	Completed	01/05/2009	https://clinicaltrials.gov/study/NCT00902837	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis	OXYCODONE	targetBased	3	Completed	01/05/2009	https://clinicaltrials.gov/study/NCT00902837	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis	OXYCODONE	targetBased	3	Terminated	30/10/2009	https://clinicaltrials.gov/study/NCT00985621	0.7	GoF	protect	See termination reason in detailed description.
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis	OXYCODONE	targetBased	3	Terminated	30/10/2009	https://clinicaltrials.gov/study/NCT00985621	0.7	GoF	protect	See termination reason in detailed description.
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis	OXYCODONE	targetBased	3	Terminated	01/04/2004	https://clinicaltrials.gov/study/NCT00312221	0.7	GoF	protect	terminated early for administrative reasons unrelated to safety or efficacy
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis	OXYCODONE	targetBased	3	Terminated	01/04/2004	https://clinicaltrials.gov/study/NCT00312221	0.7	GoF	protect	terminated early for administrative reasons unrelated to safety or efficacy
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	toothache	OXYCODONE	targetBased	2	Completed	01/08/2009	https://clinicaltrials.gov/study/NCT00941304	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	toothache	OXYCODONE	targetBased	2	Completed	01/08/2009	https://clinicaltrials.gov/study/NCT00941304	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	toothache	OXYCODONE	targetBased	2	Terminated	01/08/2016	https://clinicaltrials.gov/study/NCT02862691	0.2	GoF	protect	Difficulty recruiting patients
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	toothache	OXYCODONE	targetBased	2	Terminated	01/08/2016	https://clinicaltrials.gov/study/NCT02862691	0.2	GoF	protect	Difficulty recruiting patients
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Inguinal hernia	OXYCODONE	targetBased	4	Unknown status	01/07/2007	https://clinicaltrials.gov/study/NCT00480142	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Inguinal hernia	OXYCODONE	targetBased	4	Unknown status	01/07/2007	https://clinicaltrials.gov/study/NCT00480142	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	postmenopausal osteoporosis	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a78708cd-04d4-4221-a4e4-53680bbe2912	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	postmenopausal osteoporosis	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a78708cd-04d4-4221-a4e4-53680bbe2912	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	postmenopausal osteoporosis	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=92eafd85-0051-44af-ba5c-9194c8deffe2	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	postmenopausal osteoporosis	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=92eafd85-0051-44af-ba5c-9194c8deffe2	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	postmenopausal osteoporosis	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=966ac064-9eb7-4d15-b271-a7880ed1e79a	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	postmenopausal osteoporosis	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=966ac064-9eb7-4d15-b271-a7880ed1e79a	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Osteopenia	ESTRADIOL	targetBased	3	Completed	01/02/2004	https://clinicaltrials.gov/study/NCT00310531	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Osteopenia	ESTRADIOL	targetBased	3	Completed	01/02/2004	https://clinicaltrials.gov/study/NCT00310531	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	osteoporosis	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=966ac064-9eb7-4d15-b271-a7880ed1e79a	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	osteoporosis	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=966ac064-9eb7-4d15-b271-a7880ed1e79a	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	osteoporosis	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=12fea717-3ee5-47af-ba43-2c6fd4d85d5b	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	osteoporosis	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=12fea717-3ee5-47af-ba43-2c6fd4d85d5b	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	osteoporosis	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a78708cd-04d4-4221-a4e4-53680bbe2912	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	osteoporosis	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a78708cd-04d4-4221-a4e4-53680bbe2912	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	osteoporosis	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=eabc0fb3-da2a-482f-83a7-99b1e823a150	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	osteoporosis	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=eabc0fb3-da2a-482f-83a7-99b1e823a150	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	osteoporosis	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ac676026-14be-486a-9d64-6702bd9e51ea	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	osteoporosis	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ac676026-14be-486a-9d64-6702bd9e51ea	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	osteoporosis	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=70d00600-b8d3-4820-8db6-40d4536a6f9e	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	osteoporosis	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=70d00600-b8d3-4820-8db6-40d4536a6f9e	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	osteoporosis	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=92eafd85-0051-44af-ba5c-9194c8deffe2	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	osteoporosis	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=92eafd85-0051-44af-ba5c-9194c8deffe2	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	osteoporosis	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=09c472c6-a38a-4a3d-b048-6fefd52e2ad3	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	osteoporosis	ESTRADIOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=09c472c6-a38a-4a3d-b048-6fefd52e2ad3	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pulpitis	SUFENTANIL	targetBased	2	Completed	01/01/2010	https://clinicaltrials.gov/study/NCT01572116	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pulpitis	SUFENTANIL	targetBased	2	Completed	01/01/2010	https://clinicaltrials.gov/study/NCT01572116	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	fibromyalgia	CYCLOBENZAPRINE	targetBased	3	Completed	09/12/2019	https://clinicaltrials.gov/study/NCT04172831	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	fibromyalgia	CYCLOBENZAPRINE	targetBased	2	Completed	01/09/2013	https://clinicaltrials.gov/study/NCT01903265	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	fibromyalgia	CYCLOBENZAPRINE	targetBased	3	Completed	01/12/2013	https://clinicaltrials.gov/study/NCT02015234	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	fibromyalgia	CYCLOBENZAPRINE	targetBased	3	Completed	22/07/2020	https://clinicaltrials.gov/study/NCT04508621	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	fibromyalgia	CYCLOBENZAPRINE	targetBased	3	Completed	06/04/2022	https://clinicaltrials.gov/study/NCT05273749	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	fibromyalgia	CYCLOBENZAPRINE	targetBased	3	Terminated	01/08/2015	https://clinicaltrials.gov/study/NCT02589275	0.7	LoF	protect	For business reason unrelated to safety or tolerability,Tonix has discontinued the Fibromyalgia development with TNX102 SL.
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Muscle spasm	CYCLOBENZAPRINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0038f081-a867-43ed-8415-9f0003871291	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Muscle spasm	CYCLOBENZAPRINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=06da53af-5b46-4e32-a64c-9677e27ae229	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Muscle spasm	CYCLOBENZAPRINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ec636fad-9537-4001-a691-c7b4cc2b6a96	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	bone fracture	EPINEPHRINE	targetBased	3	Recruiting	18/04/2024	https://clinicaltrials.gov/study/NCT06381622	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	shoulder impingement syndrome	EPINEPHRINE	targetBased	4	Completed	01/09/2020	https://clinicaltrials.gov/study/NCT04594408	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	osteoarthritis, hip	EPINEPHRINE	targetBased	4	Completed	01/02/2016	https://clinicaltrials.gov/study/NCT03513276	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	osteoarthritis, hip	EPINEPHRINE	targetBased	4	Completed	01/06/2015	https://clinicaltrials.gov/study/NCT02464176	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	stenosing tenosynovitis	EPINEPHRINE	targetBased	4	Completed	01/10/2017	https://clinicaltrials.gov/study/NCT04023695	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	osteoarthritis, knee	EPINEPHRINE	targetBased	4	Withdrawn	01/04/2015	https://clinicaltrials.gov/study/NCT02365727	1	GoF	protect	Protocol not feasible as written
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	osteoarthritis, knee	EPINEPHRINE	targetBased	4	Completed	01/07/2015	https://clinicaltrials.gov/study/NCT02462148	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	osteoarthritis, knee	EPINEPHRINE	targetBased	3	Completed	18/09/2018	https://clinicaltrials.gov/study/NCT03661996	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	osteoarthritis, knee	EPINEPHRINE	targetBased	2	Completed	01/04/2014	https://clinicaltrials.gov/study/NCT02860949	0.2	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	osteoarthritis, knee	EPINEPHRINE	targetBased	4	Completed	01/11/2007	https://clinicaltrials.gov/study/NCT00562627	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	osteoarthritis, knee	EPINEPHRINE	targetBased	4	Completed	01/04/2008	https://clinicaltrials.gov/study/NCT00901628	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	osteoarthritis, knee	EPINEPHRINE	targetBased	4	Terminated	01/10/2015	https://clinicaltrials.gov/study/NCT02570503	1	GoF	protect	Study's primary aims are no longer clinically impactful, as intrathecal morphine has fallen out of favor and replaced with different agents so that outpatient/23 hr surgery is more predictably achievable.
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	osteoarthritis, knee	EPINEPHRINE	targetBased	4	Withdrawn	01/02/2016	https://clinicaltrials.gov/study/NCT02765815	1	GoF	protect	competing protocol
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	rotator cuff tear	EPINEPHRINE	targetBased	2	Unknown status	01/01/2016	https://clinicaltrials.gov/study/NCT03034382	0.2	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	osteoarthritis	EPINEPHRINE	targetBased	4	Completed	21/06/2016	https://clinicaltrials.gov/study/NCT02697955	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	osteoarthritis	EPINEPHRINE	targetBased	4	Completed	01/05/2016	https://clinicaltrials.gov/study/NCT02658149	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	osteoarthritis	EPINEPHRINE	targetBased	4	Withdrawn	30/04/2016	https://clinicaltrials.gov/study/NCT03119038	1	GoF	protect	Investigator no longer actively pursuing this study.
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	dental pulp disease	EPINEPHRINE	targetBased	4	Unknown status	03/01/2018	https://clinicaltrials.gov/study/NCT03368391	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	sinusitis	EPINEPHRINE	targetBased	4	Completed	01/12/2012	https://clinicaltrials.gov/study/NCT01706952	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	sinusitis	EPINEPHRINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7b3d99dc-cb35-4331-96cd-fedb95b96750	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	sinusitis	EPINEPHRINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fd5ede55-10de-491e-a73f-17a77f89891a	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	sinusitis	EPINEPHRINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d785beac-3f68-4df1-926f-34da6773f295	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	sinusitis	EPINEPHRINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0babff47-11ed-47b6-a57d-502ca3c86973	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	sinusitis	EPINEPHRINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8da22eb1-0965-4d4e-b15d-91db7193548e	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	sinusitis	EPINEPHRINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=070d391a-0525-4172-add9-5cb45e0c5d67	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	sinusitis	EPINEPHRINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3ed35d7d-616c-43cd-9776-705821afc1f0	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	sinusitis	EPINEPHRINE	targetBased	3	Unknown status	01/03/2009	https://clinicaltrials.gov/study/NCT00852410	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	sinusitis	EPINEPHRINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=74b3e639-cd9d-46b0-8505-86b0214cb20b	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	sinusitis	EPINEPHRINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=daa651e5-40e1-4e87-9775-3f7cc44dff32	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	sinusitis	EPINEPHRINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0c07b20c-d222-4b42-87b8-9667705a2945	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	sinusitis	EPINEPHRINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f03ce427-2dfa-460c-a1a9-c659d7a35b67	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	pulpitis	EPINEPHRINE	targetBased	3	Completed	01/06/2014	https://clinicaltrials.gov/study/NCT02807298	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	pulpitis	EPINEPHRINE	targetBased	2	Completed	01/01/2010	https://clinicaltrials.gov/study/NCT01572116	0.2	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	pulpitis	EPINEPHRINE	targetBased	2	Completed	01/10/2012	https://clinicaltrials.gov/study/NCT01794533	0.2	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	pulpitis	EPINEPHRINE	targetBased	4	Completed	01/02/2010	https://clinicaltrials.gov/study/NCT01912755	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	pulpitis	EPINEPHRINE	targetBased	2	Recruiting	30/04/2023	https://clinicaltrials.gov/study/NCT05840913	0.2	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	pulpitis	EPINEPHRINE	targetBased	4	Completed	14/02/2022	https://clinicaltrials.gov/study/NCT05227300	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	pulpitis	EPINEPHRINE	targetBased	3	Completed	01/02/2013	https://clinicaltrials.gov/study/NCT02226913	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	pulpitis	EPINEPHRINE	targetBased	4	Withdrawn	01/08/2021	https://clinicaltrials.gov/study/NCT04186299	1	GoF	protect	Study activities never commenced.
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	periodontitis	EPINEPHRINE	targetBased	4	Completed	05/12/2017	https://clinicaltrials.gov/study/NCT03354312	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	musculoskeletal system disease	EPINEPHRINE	targetBased	4	Recruiting	20/09/2023	https://clinicaltrials.gov/study/NCT04397484	1	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	musculoskeletal system disease	EPINEPHRINE	targetBased	2	Recruiting	27/01/2021	https://clinicaltrials.gov/study/NCT05355597	0.2	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	muscle cramp	EPINEPHRINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=76462d55-5448-0fd0-e053-2991aa0aa49f	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pulpitis	FENTANYL CITRATE	targetBased	2	Completed	01/10/2012	https://clinicaltrials.gov/study/NCT01794533	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pulpitis	FENTANYL CITRATE	targetBased	2	Completed	01/10/2012	https://clinicaltrials.gov/study/NCT01794533	0.2	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Osteopenia	ETHINYL ESTRADIOL	targetBased	3	Withdrawn	01/07/2005	https://clinicaltrials.gov/study/NCT00117260	0.7	GoF	protect	Sponsor decision
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Osteopenia	ETHINYL ESTRADIOL	targetBased	3	Withdrawn	01/07/2005	https://clinicaltrials.gov/study/NCT00117260	0.7	GoF	protect	Sponsor decision
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	osteoporosis	ETHINYL ESTRADIOL	targetBased	2	Completed		https://clinicaltrials.gov/study/NCT00320567	0.2	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	osteoporosis	ETHINYL ESTRADIOL	targetBased	2	Completed		https://clinicaltrials.gov/study/NCT00320567	0.2	GoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	proximal spinal muscular atrophy	DALFAMPRIDINE	targetBased	2	Completed	01/06/2012	https://clinicaltrials.gov/study/NCT01645787	0.2	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	proximal spinal muscular atrophy	DALFAMPRIDINE	targetBased	2	Completed	01/06/2012	https://clinicaltrials.gov/study/NCT01645787	0.2	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	proximal spinal muscular atrophy	DALFAMPRIDINE	targetBased	2	Completed	01/06/2012	https://clinicaltrials.gov/study/NCT01645787	0.2	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	spinal cord injury	DALFAMPRIDINE	targetBased	3	Completed	01/07/2002	https://clinicaltrials.gov/study/NCT00041717	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	spinal cord injury	DALFAMPRIDINE	targetBased	3	Completed	01/07/2002	https://clinicaltrials.gov/study/NCT00041717	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	spinal cord injury	DALFAMPRIDINE	targetBased	3	Completed	01/07/2002	https://clinicaltrials.gov/study/NCT00041717	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	spinal cord injury	DALFAMPRIDINE	targetBased	2	Completed	01/06/2012	https://clinicaltrials.gov/study/NCT01621113	0.2	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	spinal cord injury	DALFAMPRIDINE	targetBased	2	Completed	01/06/2012	https://clinicaltrials.gov/study/NCT01621113	0.2	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	spinal cord injury	DALFAMPRIDINE	targetBased	2	Completed	01/06/2012	https://clinicaltrials.gov/study/NCT01621113	0.2	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	spinal cord injury	DALFAMPRIDINE	targetBased	3	Completed	01/07/2002	https://clinicaltrials.gov/study/NCT00041717	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	spinal cord injury	DALFAMPRIDINE	targetBased	3	Completed	01/07/2002	https://clinicaltrials.gov/study/NCT00041717	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	spinal cord injury	DALFAMPRIDINE	targetBased	2	Completed	01/06/2012	https://clinicaltrials.gov/study/NCT01621113	0.2	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	spinal cord injury	DALFAMPRIDINE	targetBased	2	Completed	01/06/2012	https://clinicaltrials.gov/study/NCT01621113	0.2	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	spinal cord injury	DALFAMPRIDINE	targetBased	3	Completed	01/07/2002	https://clinicaltrials.gov/study/NCT00041717	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	spinal cord injury	DALFAMPRIDINE	targetBased	3	Completed	01/07/2002	https://clinicaltrials.gov/study/NCT00041717	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	spinal cord injury	DALFAMPRIDINE	targetBased	2	Completed	01/06/2012	https://clinicaltrials.gov/study/NCT01621113	0.2	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	spinal cord injury	DALFAMPRIDINE	targetBased	2	Completed	01/06/2012	https://clinicaltrials.gov/study/NCT01621113	0.2	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	proximal spinal muscular atrophy	DALFAMPRIDINE	targetBased	2	Completed	01/06/2012	https://clinicaltrials.gov/study/NCT01645787	0.2	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	proximal spinal muscular atrophy	DALFAMPRIDINE	targetBased	2	Completed	01/06/2012	https://clinicaltrials.gov/study/NCT01645787	0.2	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	proximal spinal muscular atrophy	DALFAMPRIDINE	targetBased	2	Completed	01/06/2012	https://clinicaltrials.gov/study/NCT01645787	0.2	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	proximal spinal muscular atrophy	DALFAMPRIDINE	targetBased	2	Completed	01/06/2012	https://clinicaltrials.gov/study/NCT01645787	0.2	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	spinal cord injury	ALBUTEROL	targetBased	2	Completed	01/04/2007	https://clinicaltrials.gov/study/NCT00755079	0.2	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Glycogen storage disease due to acid maltase deficiency	ALBUTEROL	targetBased	4	Completed	01/10/2013	https://clinicaltrials.gov/study/NCT02405598	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	fibromyalgia	QUETIAPINE	targetBased	4	Completed	01/11/2008	https://clinicaltrials.gov/study/NCT00766350	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	fibromyalgia	QUETIAPINE	targetBased	4	Completed	01/01/2008	https://clinicaltrials.gov/study/NCT01458964	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	fibromyalgia	QUETIAPINE	targetBased	4	Completed	01/04/2008	https://clinicaltrials.gov/study/NCT00983320	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	fibromyalgia	QUETIAPINE	targetBased	4	Completed	01/11/2008	https://clinicaltrials.gov/study/NCT00766350	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	fibromyalgia	QUETIAPINE	targetBased	4	Completed	01/11/2008	https://clinicaltrials.gov/study/NCT00766350	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	fibromyalgia	QUETIAPINE	targetBased	4	Completed	01/11/2008	https://clinicaltrials.gov/study/NCT00766350	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	fibromyalgia	QUETIAPINE	targetBased	4	Completed	01/11/2008	https://clinicaltrials.gov/study/NCT00766350	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	fibromyalgia	QUETIAPINE	targetBased	4	Completed	01/11/2008	https://clinicaltrials.gov/study/NCT00766350	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	fibromyalgia	QUETIAPINE	targetBased	4	Completed	01/11/2008	https://clinicaltrials.gov/study/NCT00766350	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	fibromyalgia	QUETIAPINE	targetBased	4	Completed	01/01/2008	https://clinicaltrials.gov/study/NCT01458964	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	fibromyalgia	QUETIAPINE	targetBased	4	Completed	01/01/2008	https://clinicaltrials.gov/study/NCT01458964	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	fibromyalgia	QUETIAPINE	targetBased	4	Completed	01/01/2008	https://clinicaltrials.gov/study/NCT01458964	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	fibromyalgia	QUETIAPINE	targetBased	4	Completed	01/01/2008	https://clinicaltrials.gov/study/NCT01458964	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	fibromyalgia	QUETIAPINE	targetBased	4	Completed	01/01/2008	https://clinicaltrials.gov/study/NCT01458964	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	fibromyalgia	QUETIAPINE	targetBased	4	Completed	01/01/2008	https://clinicaltrials.gov/study/NCT01458964	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	fibromyalgia	QUETIAPINE	targetBased	4	Completed	01/04/2008	https://clinicaltrials.gov/study/NCT00983320	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	fibromyalgia	QUETIAPINE	targetBased	4	Completed	01/04/2008	https://clinicaltrials.gov/study/NCT00983320	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	fibromyalgia	QUETIAPINE	targetBased	4	Completed	01/04/2008	https://clinicaltrials.gov/study/NCT00983320	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	fibromyalgia	QUETIAPINE	targetBased	4	Completed	01/04/2008	https://clinicaltrials.gov/study/NCT00983320	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	fibromyalgia	QUETIAPINE	targetBased	4	Completed	01/04/2008	https://clinicaltrials.gov/study/NCT00983320	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	fibromyalgia	QUETIAPINE	targetBased	4	Completed	01/04/2008	https://clinicaltrials.gov/study/NCT00983320	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Ehlers-Danlos syndrome	CELIPROLOL	targetBased	3	Recruiting	07/11/2022	https://clinicaltrials.gov/study/NCT05432466	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	dilated cardiomyopathy	CARVEDILOL	targetBased	3	Recruiting	27/04/2023	https://clinicaltrials.gov/study/NCT05849766	0.7	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	dilated cardiomyopathy	CARVEDILOL	targetBased	4	Unknown status	01/01/2006	https://clinicaltrials.gov/study/NCT00374465	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	idiopathic dilated cardiomyopathy	CARVEDILOL	targetBased	4	Completed	01/09/2000	https://clinicaltrials.gov/study/NCT01798992	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Duchenne muscular dystrophy	CARVEDILOL	targetBased	4	Unknown status	01/12/2008	https://clinicaltrials.gov/study/NCT00819845	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Duchenne muscular dystrophy	CARVEDILOL	targetBased	4	Unknown status	01/12/2007	https://clinicaltrials.gov/study/NCT00606775	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Becker muscular dystrophy	CARVEDILOL	targetBased	4	Unknown status	01/12/2008	https://clinicaltrials.gov/study/NCT00819845	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	cardiomyopathy	CARVEDILOL	targetBased	2	Withdrawn	01/09/2020	https://clinicaltrials.gov/study/NCT04190433	0.2	LoF	protect	Administratively closed due to low/no accrual
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		spinal stenosis	KETAMINE	targetBased	3	Recruiting	01/12/2023	https://clinicaltrials.gov/study/NCT06140927	0.7	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		osteoarthritis, knee	KETAMINE	targetBased	4	Recruiting	22/01/2024	https://clinicaltrials.gov/study/NCT06267638	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		idiopathic scoliosis	KETAMINE	targetBased	2	Completed	01/01/2012	https://clinicaltrials.gov/study/NCT02571491	0.2	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		dental caries	KETAMINE	targetBased	4	Completed	21/05/2015	https://clinicaltrials.gov/study/NCT02447289	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		dental caries	KETAMINE	targetBased	4	Recruiting	30/01/2020	https://clinicaltrials.gov/study/NCT04119180	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		dental caries	KETAMINE	targetBased	4	Completed	01/06/2008	https://clinicaltrials.gov/study/NCT00902395	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		Inguinal hernia	KETAMINE	targetBased	4	Unknown status	01/01/2016	https://clinicaltrials.gov/study/NCT02646709	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		rib fracture	KETAMINE	targetBased	4	Unknown status	06/11/2018	https://clinicaltrials.gov/study/NCT03619785	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		rib fracture	KETAMINE	targetBased	3	Recruiting	12/06/2021	https://clinicaltrials.gov/study/NCT04928300	0.7	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		rib fracture	KETAMINE	targetBased	4	Recruiting	01/04/2021	https://clinicaltrials.gov/study/NCT04781673	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		rib fracture	KETAMINE	targetBased	4	Completed	01/09/2015	https://clinicaltrials.gov/study/NCT02432456	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		bone fracture	KETAMINE	targetBased	3	Completed	01/01/2016	https://clinicaltrials.gov/study/NCT02402868	0.7	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		bone fracture	KETAMINE	targetBased	4	Terminated	09/09/2019	https://clinicaltrials.gov/study/NCT03781817	1	LoF	protect	Transition/change of primary investigators
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		bone fracture	KETAMINE	targetBased	2	Completed	01/12/2015	https://clinicaltrials.gov/study/NCT02521415	0.2	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		bone fracture	KETAMINE	targetBased	4	Completed	01/06/2007	https://clinicaltrials.gov/study/NCT00490997	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		bone fracture	KETAMINE	targetBased	3	Completed	05/07/2018	https://clinicaltrials.gov/study/NCT03525821	0.7	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		bone fracture	KETAMINE	targetBased	3	Unknown status	01/10/2017	https://clinicaltrials.gov/study/NCT02828566	0.7	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		sickle cell anemia	KETAMINE	targetBased	3	Unknown status	01/07/2016	https://clinicaltrials.gov/study/NCT02801292	0.7	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		sickle cell anemia	KETAMINE	targetBased	4	Terminated	01/06/2004	https://clinicaltrials.gov/study/NCT00252122	1	LoF	protect	Recruitment was very slow.
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		sickle cell anemia	KETAMINE	targetBased	2	Terminated	04/03/2008	https://clinicaltrials.gov/study/NCT00595530	0.2	LoF	protect	Lack of enrollment and patient interest in study
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		sickle cell anemia	KETAMINE	targetBased	2	Completed	01/06/2016	https://clinicaltrials.gov/study/NCT03296345	0.2	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		multiple bone fractures	KETAMINE	targetBased	2	Completed	01/12/2012	https://clinicaltrials.gov/study/NCT01807429	0.2	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		temporomandibular joint disorder	KETAMINE	targetBased	2	Recruiting	18/06/2021	https://clinicaltrials.gov/study/NCT04724759	0.2	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	lumbar disc herniation	ESMOLOL	targetBased	2	Completed	04/02/2020	https://clinicaltrials.gov/study/NCT04260685	0.2	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	sinusitis	ESMOLOL	targetBased	2	Completed	01/03/2017	https://clinicaltrials.gov/study/NCT03661346	0.2	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	hypertrophic cardiomyopathy	ESMOLOL	targetBased	4	Recruiting	06/10/2021	https://clinicaltrials.gov/study/NCT05073094	1	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Duchenne muscular dystrophy	TAMOXIFEN CITRATE	targetBased	3	Completed	12/06/2018	https://clinicaltrials.gov/study/NCT03354039	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Duchenne muscular dystrophy	TAMOXIFEN CITRATE	targetBased	3	Completed	12/06/2018	https://clinicaltrials.gov/study/NCT03354039	0.7		protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	sickle cell anemia	METHYLPHENIDATE	targetBased	3	Completed	01/06/2006	https://clinicaltrials.gov/study/NCT01411280	0.7	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	sarcoidosis	METHYLPHENIDATE	targetBased	4	Completed	01/06/2006	https://clinicaltrials.gov/study/NCT00361387	1	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		systemic lupus erythematosus	MEMANTINE	targetBased	2	Recruiting	23/08/2018	https://clinicaltrials.gov/study/NCT03527472	0.2	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		sickle cell anemia	MEMANTINE	targetBased	2	Recruiting	02/02/2018	https://clinicaltrials.gov/study/NCT03247218	0.2	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		fibromyalgia	MEMANTINE	targetBased	3	Unknown status	01/09/2012	https://clinicaltrials.gov/study/NCT01653457	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	Muscle weakness	GUANIDINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=903fbd33-e5d9-41fb-9414-7bd6f42a8593	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	Muscle weakness	GUANIDINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=903fbd33-e5d9-41fb-9414-7bd6f42a8593	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	Muscle weakness	GUANIDINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=903fbd33-e5d9-41fb-9414-7bd6f42a8593	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	Muscle weakness	GUANIDINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=903fbd33-e5d9-41fb-9414-7bd6f42a8593	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	Muscle weakness	GUANIDINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=903fbd33-e5d9-41fb-9414-7bd6f42a8593	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	Muscle weakness	GUANIDINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=903fbd33-e5d9-41fb-9414-7bd6f42a8593	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	Muscle weakness	GUANIDINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=903fbd33-e5d9-41fb-9414-7bd6f42a8593	1	LoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	carnitine palmitoyltransferase II deficiency	BEZAFIBRATE	targetBased	3	Unknown status	01/06/2006	https://clinicaltrials.gov/study/NCT00336167	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	carnitine palmitoyltransferase II deficiency	BEZAFIBRATE	targetBased	3	Unknown status	01/06/2006	https://clinicaltrials.gov/study/NCT00336167	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	carnitine palmitoyltransferase II deficiency	BEZAFIBRATE	targetBased	3	Unknown status	01/06/2006	https://clinicaltrials.gov/study/NCT00336167	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	carnitine palmitoyltransferase II deficiency	BEZAFIBRATE	targetBased	3	Unknown status	01/06/2006	https://clinicaltrials.gov/study/NCT00336167	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	carnitine palmitoyltransferase II deficiency	BEZAFIBRATE	targetBased	3	Unknown status	01/06/2006	https://clinicaltrials.gov/study/NCT00336167	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	carnitine palmitoyltransferase II deficiency	BEZAFIBRATE	targetBased	3	Unknown status	01/06/2006	https://clinicaltrials.gov/study/NCT00336167	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	carnitine palmitoyltransferase II deficiency	BEZAFIBRATE	targetBased	2	Completed	01/10/2009	https://clinicaltrials.gov/study/NCT00983788	0.2	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	carnitine palmitoyltransferase II deficiency	BEZAFIBRATE	targetBased	2	Completed	01/10/2009	https://clinicaltrials.gov/study/NCT00983788	0.2	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	carnitine palmitoyltransferase II deficiency	BEZAFIBRATE	targetBased	2	Completed	01/10/2009	https://clinicaltrials.gov/study/NCT00983788	0.2	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	carnitine palmitoyltransferase II deficiency	BEZAFIBRATE	targetBased	2	Completed	01/10/2009	https://clinicaltrials.gov/study/NCT00983788	0.2	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	carnitine palmitoyltransferase II deficiency	BEZAFIBRATE	targetBased	2	Completed	01/10/2009	https://clinicaltrials.gov/study/NCT00983788	0.2	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	carnitine palmitoyltransferase II deficiency	BEZAFIBRATE	targetBased	2	Completed	01/10/2009	https://clinicaltrials.gov/study/NCT00983788	0.2	GoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	myelofibrosis	POMALIDOMIDE	targetBased	2	Completed	01/04/2007	https://clinicaltrials.gov/study/NCT00463385	0.2	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	systemic scleroderma	POMALIDOMIDE	targetBased	2	Terminated	09/08/2012	https://clinicaltrials.gov/study/NCT01559129	0.2	LoF	protect	Enrollment was stopped early (see limitations and caveats section).
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	AL amyloidosis	POMALIDOMIDE	targetBased	2	Completed	01/02/2012	https://clinicaltrials.gov/study/NCT01510613	0.2	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	AL amyloidosis	POMALIDOMIDE	targetBased	2	Recruiting	23/06/2021	https://clinicaltrials.gov/study/NCT04895917	0.2	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	AL amyloidosis	POMALIDOMIDE	targetBased	2	Recruiting	14/04/2021	https://clinicaltrials.gov/study/NCT04270175	0.2	LoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	osteopetrosis	CALCITRIOL	targetBased	3	Completed	01/11/1999	https://clinicaltrials.gov/study/NCT00004402	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	X-linked hypophosphatemia	CALCITRIOL	targetBased	4	Recruiting	01/01/2017	https://clinicaltrials.gov/study/NCT03820518	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	osteoporosis	CALCITRIOL	targetBased	3	Completed	01/09/1997	https://clinicaltrials.gov/study/NCT00000412	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	osteoporosis	CALCITRIOL	targetBased	4	Unknown status	01/01/2013	https://clinicaltrials.gov/study/NCT01765010	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	Friedreich ataxia	CALCITRIOL	targetBased	4	Completed	25/08/2021	https://clinicaltrials.gov/study/NCT04801303	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	systemic lupus erythematosus	CALCITRIOL	targetBased	2	Unknown status	01/04/2013	https://clinicaltrials.gov/study/NCT01863641	0.2	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	postmenopausal osteoporosis	CALCITRIOL	targetBased	4	Completed	19/06/2011	https://clinicaltrials.gov/study/NCT01350934	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	renal osteodystrophy	CALCITRIOL	targetBased	2	Completed	01/11/2000	https://clinicaltrials.gov/study/NCT00560300	0.2	GoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	myelofibrosis	LENALIDOMIDE	targetBased	2	Completed	07/07/2006	https://clinicaltrials.gov/study/NCT00352794	0.2	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	myelofibrosis	LENALIDOMIDE	targetBased	2	Completed	01/07/2004	https://clinicaltrials.gov/study/NCT00087672	0.2	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	primary systemic amyloidosis	LENALIDOMIDE	targetBased	2	Completed	01/10/2010	https://clinicaltrials.gov/study/NCT01194791	0.2	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	primary systemic amyloidosis	LENALIDOMIDE	targetBased	2	Completed	01/04/2005	https://clinicaltrials.gov/study/NCT00166413	0.2	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	cutaneous lupus erythematosus	LENALIDOMIDE	targetBased	4	Completed	01/01/2010	https://clinicaltrials.gov/study/NCT01408199	1	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	AL amyloidosis	LENALIDOMIDE	targetBased	3	Terminated	26/12/2012	https://clinicaltrials.gov/study/NCT01659658	0.7	LoF	protect	Sponsor's decision
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	AL amyloidosis	LENALIDOMIDE	targetBased	2	Completed	01/02/2008	https://clinicaltrials.gov/study/NCT00607581	0.2	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	AL amyloidosis	LENALIDOMIDE	targetBased	2	Active, not recruiting	25/08/2017	https://clinicaltrials.gov/study/NCT03252600	0.2	LoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	AL amyloidosis	LENALIDOMIDE	targetBased	2	Completed	01/04/2009	https://clinicaltrials.gov/study/NCT00883623	0.2	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	postmenopausal osteoporosis	BAZEDOXIFENE	targetBased	2	Completed	01/08/2003	https://clinicaltrials.gov/study/NCT00238745	0.2		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	postmenopausal osteoporosis	BAZEDOXIFENE	targetBased	2	Completed	01/08/2003	https://clinicaltrials.gov/study/NCT00238745	0.2		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	postmenopausal osteoporosis	BAZEDOXIFENE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e16705d8-4472-4f83-96ac-69fa2be066cb	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	postmenopausal osteoporosis	BAZEDOXIFENE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e16705d8-4472-4f83-96ac-69fa2be066cb	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	postmenopausal osteoporosis	BAZEDOXIFENE	targetBased	4	Completed	01/05/2013	https://clinicaltrials.gov/study/NCT02090400	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	postmenopausal osteoporosis	BAZEDOXIFENE	targetBased	4	Completed	01/05/2013	https://clinicaltrials.gov/study/NCT02090400	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	postmenopausal osteoporosis	BAZEDOXIFENE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e1b75458-2e5b-46b9-92c6-fa6daba3770f	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	postmenopausal osteoporosis	BAZEDOXIFENE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e1b75458-2e5b-46b9-92c6-fa6daba3770f	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	postmenopausal osteoporosis	BAZEDOXIFENE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bfdd5d5b-7569-4848-afa2-e820fbe3c8fb	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	postmenopausal osteoporosis	BAZEDOXIFENE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bfdd5d5b-7569-4848-afa2-e820fbe3c8fb	1		protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	postmenopausal osteoporosis	BAZEDOXIFENE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e1b75458-2e5b-46b9-92c6-fa6daba3770f	1		protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	postmenopausal osteoporosis	BAZEDOXIFENE	targetBased	4	Completed	01/05/2013	https://clinicaltrials.gov/study/NCT02090400	1		protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	postmenopausal osteoporosis	BAZEDOXIFENE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bfdd5d5b-7569-4848-afa2-e820fbe3c8fb	1		protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	postmenopausal osteoporosis	BAZEDOXIFENE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e16705d8-4472-4f83-96ac-69fa2be066cb	1		protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	postmenopausal osteoporosis	BAZEDOXIFENE	targetBased	2	Completed	01/08/2003	https://clinicaltrials.gov/study/NCT00238745	0.2		protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	osteoporosis	BAZEDOXIFENE	targetBased	3	Completed	01/07/2001	https://clinicaltrials.gov/study/NCT00481169	0.7		protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	osteoporosis	BAZEDOXIFENE	targetBased	3	Completed	01/09/2005	https://clinicaltrials.gov/study/NCT00242710	0.7		protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	osteoporosis	BAZEDOXIFENE	targetBased	3	Completed	01/12/2001	https://clinicaltrials.gov/study/NCT00205777	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	osteoporosis	BAZEDOXIFENE	targetBased	3	Completed	01/12/2001	https://clinicaltrials.gov/study/NCT00205777	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	osteoporosis	BAZEDOXIFENE	targetBased	3	Completed	01/12/2001	https://clinicaltrials.gov/study/NCT00205777	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	osteoporosis	BAZEDOXIFENE	targetBased	3	Completed	01/07/2001	https://clinicaltrials.gov/study/NCT00481169	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	osteoporosis	BAZEDOXIFENE	targetBased	3	Completed	01/07/2001	https://clinicaltrials.gov/study/NCT00481169	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	osteoporosis	BAZEDOXIFENE	targetBased	3	Completed	01/09/2005	https://clinicaltrials.gov/study/NCT00242710	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	osteoporosis	BAZEDOXIFENE	targetBased	3	Completed	01/09/2005	https://clinicaltrials.gov/study/NCT00242710	0.7		protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Glycogen storage disease due to acid maltase deficiency	CLENBUTEROL	targetBased	2	Withdrawn	01/01/2023	https://clinicaltrials.gov/study/NCT04094948	0.2	GoF	protect	hasn't got the funding
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Kennedy disease	CLENBUTEROL	targetBased	2	Recruiting	13/04/2024	https://clinicaltrials.gov/study/NCT06169046	0.2	GoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	Friedreich ataxia	BUPROPION	targetBased	4	Completed	01/10/2012	https://clinicaltrials.gov/study/NCT01716221	1	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	rotator cuff tear	NALBUPHINE	targetBased	2	Unknown status	01/01/2016	https://clinicaltrials.gov/study/NCT03034382	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	rotator cuff tear	NALBUPHINE	targetBased	2	Unknown status	01/01/2016	https://clinicaltrials.gov/study/NCT03034382	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	rotator cuff tear	NALBUPHINE	targetBased	2	Unknown status	01/01/2016	https://clinicaltrials.gov/study/NCT03034382	0.2	GoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	Hypereosinophilic syndrome	IMATINIB	targetBased	2	Terminated	01/09/2002	https://clinicaltrials.gov/study/NCT00171860	0.2	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	Hypereosinophilic syndrome	IMATINIB	targetBased	2	Terminated	12/06/2003	https://clinicaltrials.gov/study/NCT00230334	0.2	LoF	protect	terminated by PI due to insufficient accrual
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	Hypereosinophilic syndrome	IMATINIB	targetBased	2	Recruiting	26/09/2002	https://clinicaltrials.gov/study/NCT00044304	0.2	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	systemic scleroderma	IMATINIB	targetBased	2	Completed	01/12/2007	https://clinicaltrials.gov/study/NCT00479934	0.2	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	systemic scleroderma	IMATINIB	targetBased	2	Completed	02/01/2008	https://clinicaltrials.gov/study/NCT00613171	0.2	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	systemic scleroderma	IMATINIB	targetBased	2	Completed	01/08/2007	https://clinicaltrials.gov/study/NCT00555581	0.2	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	systemic scleroderma	IMATINIB	targetBased	2	Unknown status	01/02/2009	https://clinicaltrials.gov/study/NCT00573326	0.2	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	adult fibrosarcoma	IMATINIB	targetBased	2	Completed	01/05/2004	https://clinicaltrials.gov/study/NCT00084630	0.2	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	localised scleroderma	IMATINIB	targetBased	2	Completed	01/12/2007	https://clinicaltrials.gov/study/NCT00479934	0.2	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	fibromyalgia	PRAMIPEXOLE	targetBased	2	Terminated	01/07/2008	https://clinicaltrials.gov/study/NCT00689052	0.2	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	fibromyalgia	PRAMIPEXOLE	targetBased	2	Terminated	01/07/2008	https://clinicaltrials.gov/study/NCT00689052	0.2	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	fibromyalgia	PRAMIPEXOLE	targetBased	2	Terminated	01/07/2008	https://clinicaltrials.gov/study/NCT00689052	0.2	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	fibromyalgia	PRAMIPEXOLE	targetBased	2	Terminated	01/07/2008	https://clinicaltrials.gov/study/NCT00689052	0.2	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	fibromyalgia	PRAMIPEXOLE	targetBased	2	Terminated	01/07/2008	https://clinicaltrials.gov/study/NCT00689052	0.2	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	fibromyalgia	PRAMIPEXOLE	targetBased	2	Terminated	01/07/2008	https://clinicaltrials.gov/study/NCT00689052	0.2	GoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	fibromyalgia	PRAMIPEXOLE	targetBased	2	Terminated	01/07/2008	https://clinicaltrials.gov/study/NCT00689052	0.2	GoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	fibromyalgia	PRAMIPEXOLE	targetBased	2	Terminated	01/07/2008	https://clinicaltrials.gov/study/NCT00689052	0.2	GoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	fibromyalgia	PRAMIPEXOLE	targetBased	2	Terminated	01/07/2008	https://clinicaltrials.gov/study/NCT00689052	0.2	GoF	protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	myofascial pain syndrome	CAPSAICIN	targetBased	2	Withdrawn	01/11/2009	https://clinicaltrials.gov/study/NCT00795106	0.2		protect	Difficulty finding a monitor
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	osteoarthritis	CAPSAICIN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8820b651-cda0-4318-8ef8-903d1a79034e	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	osteoarthritis	CAPSAICIN	targetBased	2	Completed	01/08/2015	https://clinicaltrials.gov/study/NCT02558439	0.2		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Tendinopathy	CAPSAICIN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2db23534-31bb-4897-b105-95039166f5a7	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Muscle spasm	CAPSAICIN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2db23534-31bb-4897-b105-95039166f5a7	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	lateral epicondylitis	CAPSAICIN	targetBased	2	Completed	01/11/2004	https://clinicaltrials.gov/study/NCT00130949	0.2		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Arthralgia	CAPSAICIN	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=M02AB01	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	osteoarthritis, knee	CAPSAICIN	targetBased	3	Completed	24/01/2018	https://clinicaltrials.gov/study/NCT03429049	0.7		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	osteoarthritis, knee	CAPSAICIN	targetBased	3	Completed	01/06/2007	https://clinicaltrials.gov/study/NCT00471055	0.7		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	osteoarthritis, knee	CAPSAICIN	targetBased	3	Completed	09/09/2018	https://clinicaltrials.gov/study/NCT03660943	0.7		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	osteoarthritis, knee	CAPSAICIN	targetBased	4	Completed	01/07/2016	https://clinicaltrials.gov/study/NCT03124407	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	osteoarthritis, knee	CAPSAICIN	targetBased	3	Completed	18/09/2018	https://clinicaltrials.gov/study/NCT03661996	0.7		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	osteoarthritis, knee	CAPSAICIN	targetBased	2	Completed	01/08/2007	https://clinicaltrials.gov/study/NCT00667654	0.2		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	arthritis	CAPSAICIN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2db23534-31bb-4897-b105-95039166f5a7	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	arthritis	CAPSAICIN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ba11070e-1a36-4d5d-9e48-c37b4e90c037	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	arthritis	CAPSAICIN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aed1e7c1-6197-4152-ae5e-06cf2ec3020f	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	arthritis	CAPSAICIN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=95910cee-0a43-4ac9-aeb9-6a659757b3ba	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	arthritis	CAPSAICIN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b8e3e528-b7cd-e4b7-e053-2995a90a4029	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	arthritis	CAPSAICIN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5dd4fefc-b70a-4850-819c-1cca6f28aa97	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	arthritis	CAPSAICIN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a1eced33-f9ee-4757-ab94-75f238f9b2a9	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	arthritis	CAPSAICIN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d9475b6c-edd1-4ea7-a22c-243e63c4d0f7	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	frozen shoulder	CAPSAICIN	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2db23534-31bb-4897-b105-95039166f5a7	1		protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	spinal stenosis	OXYMORPHONE	targetBased	4	Terminated	01/03/2008	https://clinicaltrials.gov/study/NCT00652093	1	GoF	protect	Removal of Darvocet from US market
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	spinal stenosis	OXYMORPHONE	targetBased	4	Terminated	01/03/2008	https://clinicaltrials.gov/study/NCT00652093	1	GoF	protect	Removal of Darvocet from US market
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	spinal stenosis	OXYMORPHONE	targetBased	4	Terminated	01/03/2008	https://clinicaltrials.gov/study/NCT00652093	1	GoF	protect	Removal of Darvocet from US market
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	sinusitis	REMIFENTANIL	targetBased	4	Completed	01/03/2012	https://clinicaltrials.gov/study/NCT01569048	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	sinusitis	REMIFENTANIL	targetBased	4	Completed	01/03/2012	https://clinicaltrials.gov/study/NCT01569048	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	idiopathic scoliosis	REMIFENTANIL	targetBased	2	Completed	01/01/2012	https://clinicaltrials.gov/study/NCT02571491	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	idiopathic scoliosis	REMIFENTANIL	targetBased	2	Completed	01/01/2012	https://clinicaltrials.gov/study/NCT02571491	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	idiopathic scoliosis	REMIFENTANIL	targetBased	2	Completed	01/09/2013	https://clinicaltrials.gov/study/NCT01795495	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	idiopathic scoliosis	REMIFENTANIL	targetBased	2	Completed	01/09/2013	https://clinicaltrials.gov/study/NCT01795495	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	spinal stenosis	REMIFENTANIL	targetBased	4	Completed	01/03/2010	https://clinicaltrials.gov/study/NCT01052324	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	spinal stenosis	REMIFENTANIL	targetBased	4	Completed	01/03/2010	https://clinicaltrials.gov/study/NCT01052324	1	GoF	protect
Acumen qHTS Assay for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells: Sytravon	MTOR	MTOR	Serine/threonine-protein kinase mTOR	hypertrophic cardiomyopathy	PERHEXILINE	pathwayBased	2	Terminated	01/08/2016	https://clinicaltrials.gov/study/NCT02862600	0.2	LoF	protect	Lack of Efficacy
Acumen qHTS Assay for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells: Sytravon	MTOR	MTOR	Serine/threonine-protein kinase mTOR	hypertrophic cardiomyopathy	PERHEXILINE	pathwayBased	3	Withdrawn	01/03/2016	https://clinicaltrials.gov/study/NCT02431221	0.35	LoF	protect	Lack of efficacy in a preceding study.
Acumen qHTS Assay for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells: Sytravon	MTOR	MTOR	Serine/threonine-protein kinase mTOR	hypertrophic cardiomyopathy	PERHEXILINE	pathwayBased	2	Completed	01/12/2006	https://clinicaltrials.gov/study/NCT00500552	0.2	LoF	protect
Acumen qHTS Assay for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells: Sytravon	MTOR	MTOR	Serine/threonine-protein kinase mTOR	hypertrophic cardiomyopathy	PERHEXILINE	pathwayBased	2	Recruiting	01/12/2020	https://clinicaltrials.gov/study/NCT04426578	0.2	LoF	protect
qHTS Assay for Activators of Human alpha-Glucosidase as a Potential Chaperone Treatment of Pompe Disease	GAA	GAA	Lysosomal alpha-glucosidase	Glycogen storage disease due to acid maltase deficiency	DUVOGLUSTAT	targetBased	2	Completed	31/10/2011	https://clinicaltrials.gov/study/NCT01380743	0.2	GoF	protect
qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase Cleavage of Glycogen	GAA_inhibitors	GAA	Lysosomal alpha-glucosidase	Glycogen storage disease due to acid maltase deficiency	DUVOGLUSTAT	targetBased	2	Completed	31/10/2011	https://clinicaltrials.gov/study/NCT01380743	0.2	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	rickets	CHOLECALCIFEROL	targetBased	4	Completed	01/01/2004	https://clinicaltrials.gov/study/NCT00949832	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	Osteopenia	CHOLECALCIFEROL	targetBased	2	Completed	10/08/2020	https://clinicaltrials.gov/study/NCT04768439	0.2	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	Osteopenia	CHOLECALCIFEROL	targetBased	3	Completed	01/02/2015	https://clinicaltrials.gov/study/NCT02186600	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	Osteopenia	CHOLECALCIFEROL	targetBased	4	Completed	01/01/2003	https://clinicaltrials.gov/study/NCT00160264	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	Osteopenia	CHOLECALCIFEROL	targetBased	3	Completed	01/07/2002	https://clinicaltrials.gov/study/NCT00043719	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	Osteopenia	CHOLECALCIFEROL	targetBased	4	Completed	16/12/2020	https://clinicaltrials.gov/study/NCT05386784	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	juvenile idiopathic arthritis	CHOLECALCIFEROL	targetBased	3	Completed	01/03/1995	https://clinicaltrials.gov/study/NCT00570934	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	bone fracture	CHOLECALCIFEROL	targetBased	2	Completed	21/11/2016	https://clinicaltrials.gov/study/NCT02786498	0.2	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	bone fracture	CHOLECALCIFEROL	targetBased	3	Completed	01/08/2013	https://clinicaltrials.gov/study/NCT01920568	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	bone fracture	CHOLECALCIFEROL	targetBased	3	Unknown status	01/01/2005	https://clinicaltrials.gov/study/NCT00133640	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	bone fracture	CHOLECALCIFEROL	targetBased	3	Completed	01/01/2012	https://clinicaltrials.gov/study/NCT01473602	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	bone fracture	CHOLECALCIFEROL	targetBased	3	Completed	01/02/2012	https://clinicaltrials.gov/study/NCT01473589	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	hip fracture	CHOLECALCIFEROL	targetBased	4	Terminated	01/06/2013	https://clinicaltrials.gov/study/NCT01850251	1	GoF	protect	Recruiting problems.
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	hip fracture	CHOLECALCIFEROL	targetBased	3	Unknown status	01/01/2005	https://clinicaltrials.gov/study/NCT00133640	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	osteitis deformans	CHOLECALCIFEROL	targetBased	3	Completed	01/04/2002	https://clinicaltrials.gov/study/NCT00103740	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	enamel caries	CHOLECALCIFEROL	targetBased	4	Recruiting	12/12/2023	https://clinicaltrials.gov/study/NCT06172764	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	osteoporosis	CHOLECALCIFEROL	targetBased	2	Completed	24/06/2005	https://clinicaltrials.gov/study/NCT00112437	0.2	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	osteoporosis	CHOLECALCIFEROL	targetBased	3	Completed	24/09/2003	https://clinicaltrials.gov/study/NCT00092066	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	osteoporosis	CHOLECALCIFEROL	targetBased	3	Completed	01/06/2008	https://clinicaltrials.gov/study/NCT00692913	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	osteoporosis	CHOLECALCIFEROL	targetBased	3	Completed	02/10/2008	https://clinicaltrials.gov/study/NCT00729183	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	osteoporosis	CHOLECALCIFEROL	targetBased	3	Completed	01/09/2008	https://clinicaltrials.gov/study/NCT00757393	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	osteoporosis	CHOLECALCIFEROL	targetBased	4	Recruiting	01/07/2019	https://clinicaltrials.gov/study/NCT03994172	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	osteoporosis	CHOLECALCIFEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d4a71df1-7488-46a2-8ded-dd0db56de618	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	osteoporosis	CHOLECALCIFEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9f89cb91-bd3b-4103-a8a1-c1c1512fe514	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	osteoporosis	CHOLECALCIFEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c0ec7e75-03b9-4b5b-ca8b-58cb0f65b5d9	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	osteoporosis	CHOLECALCIFEROL	targetBased	2	Recruiting	12/10/2017	https://clinicaltrials.gov/study/NCT03183557	0.2	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	osteoporosis	CHOLECALCIFEROL	targetBased	2	Terminated	01/10/2009	https://clinicaltrials.gov/study/NCT00960934	0.2	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	osteoporosis	CHOLECALCIFEROL	targetBased	2	Completed	03/12/2008	https://clinicaltrials.gov/study/NCT00752557	0.2	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	osteoporosis	CHOLECALCIFEROL	targetBased	3	Completed	01/10/1992	https://clinicaltrials.gov/study/NCT00357643	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	osteoporosis	CHOLECALCIFEROL	targetBased	2	Unknown status	19/01/2017	https://clinicaltrials.gov/study/NCT03040531	0.2	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	osteoporosis	CHOLECALCIFEROL	targetBased	2	Unknown status	01/09/2005	https://clinicaltrials.gov/study/NCT00668941	0.2	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	osteoporosis	CHOLECALCIFEROL	targetBased	4	Completed	01/12/2012	https://clinicaltrials.gov/study/NCT01904110	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	osteoporosis	CHOLECALCIFEROL	targetBased	3	Completed	01/05/2000	https://clinicaltrials.gov/study/NCT00352170	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	osteoporosis	CHOLECALCIFEROL	targetBased	3	Terminated	01/03/2003	https://clinicaltrials.gov/study/NCT00058188	0.7	GoF	protect	Closed by the research committee
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	osteoporosis	CHOLECALCIFEROL	targetBased	3	Unknown status	01/06/2011	https://clinicaltrials.gov/study/NCT02518763	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	osteoporosis	CHOLECALCIFEROL	targetBased	3	Completed	09/06/2010	https://clinicaltrials.gov/study/NCT01120600	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	osteoporosis	CHOLECALCIFEROL	targetBased	3	Completed	01/12/2001	https://clinicaltrials.gov/study/NCT00022087	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	osteoporosis	CHOLECALCIFEROL	targetBased	3	Completed	01/07/2002	https://clinicaltrials.gov/study/NCT00043719	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	osteoporosis	CHOLECALCIFEROL	targetBased	2	Completed	01/11/2009	https://clinicaltrials.gov/study/NCT00996801	0.2	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	osteoporosis	CHOLECALCIFEROL	targetBased	3	Completed	01/05/2000	https://clinicaltrials.gov/study/NCT00138983	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	osteoporosis	CHOLECALCIFEROL	targetBased	3	Completed	01/02/2007	https://clinicaltrials.gov/study/NCT00421343	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	osteoporosis	CHOLECALCIFEROL	targetBased	3	Completed	01/11/2002	https://clinicaltrials.gov/study/NCT00043069	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	osteoporosis	CHOLECALCIFEROL	targetBased	4	Completed	04/07/2011	https://clinicaltrials.gov/study/NCT01675297	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	osteoporosis	CHOLECALCIFEROL	targetBased	2	Completed	13/04/2009	https://clinicaltrials.gov/study/NCT00885170	0.2	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	osteoporosis	CHOLECALCIFEROL	targetBased	4	Unknown status	01/01/2013	https://clinicaltrials.gov/study/NCT01765010	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	osteoporosis	CHOLECALCIFEROL	targetBased	3	Completed	01/01/2004	https://clinicaltrials.gov/study/NCT00092079	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	osteogenesis imperfecta	CHOLECALCIFEROL	targetBased	4	Completed	01/09/2012	https://clinicaltrials.gov/study/NCT01713231	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	systemic lupus erythematosus	CHOLECALCIFEROL	targetBased	3	Completed	03/10/2021	https://clinicaltrials.gov/study/NCT05326841	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	systemic lupus erythematosus	CHOLECALCIFEROL	targetBased	2	Completed	01/11/2008	https://clinicaltrials.gov/study/NCT00710021	0.2	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	systemic lupus erythematosus	CHOLECALCIFEROL	targetBased	2	Completed	01/03/2020	https://clinicaltrials.gov/study/NCT05430087	0.2	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	systemic lupus erythematosus	CHOLECALCIFEROL	targetBased	2	Terminated	01/06/2013	https://clinicaltrials.gov/study/NCT01709474	0.2	GoF	protect	Due to slow enrollment
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	postmenopausal osteoporosis	CHOLECALCIFEROL	targetBased	2	Completed	01/11/2009	https://clinicaltrials.gov/study/NCT00996801	0.2	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	postmenopausal osteoporosis	CHOLECALCIFEROL	targetBased	2	Completed	03/12/2007	https://clinicaltrials.gov/study/NCT00620113	0.2	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	postmenopausal osteoporosis	CHOLECALCIFEROL	targetBased	4	Completed	19/06/2011	https://clinicaltrials.gov/study/NCT01350934	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	postmenopausal osteoporosis	CHOLECALCIFEROL	targetBased	4	Completed	01/03/2006	https://clinicaltrials.gov/study/NCT00271713	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	postmenopausal osteoporosis	CHOLECALCIFEROL	targetBased	2	Completed	05/02/2020	https://clinicaltrials.gov/study/NCT04321837	0.2	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	postmenopausal osteoporosis	CHOLECALCIFEROL	targetBased	4	Completed	20/03/2008	https://clinicaltrials.gov/study/NCT00729651	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	postmenopausal osteoporosis	CHOLECALCIFEROL	targetBased	3	Completed	01/08/1996	https://clinicaltrials.gov/study/NCT00670501	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	postmenopausal osteoporosis	CHOLECALCIFEROL	targetBased	4	Completed	12/07/2012	https://clinicaltrials.gov/study/NCT04609189	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	postmenopausal osteoporosis	CHOLECALCIFEROL	targetBased	3	Withdrawn	01/05/2012	https://clinicaltrials.gov/study/NCT01552122	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	postmenopausal osteoporosis	CHOLECALCIFEROL	targetBased	3	Terminated	13/09/2007	https://clinicaltrials.gov/study/NCT00529373	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	osteoarthritis, knee	CHOLECALCIFEROL	targetBased	4	Recruiting	07/07/2021	https://clinicaltrials.gov/study/NCT04739592	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	osteoarthritis, knee	CHOLECALCIFEROL	targetBased	4	Completed	01/01/2008	https://clinicaltrials.gov/study/NCT00599807	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	osteoarthritis, knee	CHOLECALCIFEROL	targetBased	2	Completed	01/03/2006	https://clinicaltrials.gov/study/NCT00306774	0.2	GoF	protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Arthralgia	ZUCAPSAICIN	targetBased	3			https://www.whocc.no/atc_ddd_index/?code=M02AB02	0.7	GoF	protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	osteoarthritis, knee	ZUCAPSAICIN	targetBased	3	Completed	01/06/2003	https://clinicaltrials.gov/study/NCT00995306	0.7	GoF	protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	osteoarthritis, knee	ZUCAPSAICIN	targetBased	3	Completed	01/11/2003	https://clinicaltrials.gov/study/NCT00077935	0.7	GoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	peripheral primitive neuroectodermal tumor of bone	VINCRISTINE	targetBased	3	Active, not recruiting	22/11/2010	https://clinicaltrials.gov/study/NCT01231906	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	Ewing sarcoma of bone	VINCRISTINE	targetBased	2	Completed	01/02/2008	https://clinicaltrials.gov/study/NCT00516295	0.2	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	spindle cell rhabdomyosarcoma	VINCRISTINE	targetBased	3	Recruiting	14/09/2021	https://clinicaltrials.gov/study/NCT04994132	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	spindle cell rhabdomyosarcoma	VINCRISTINE	targetBased	3	Active, not recruiting	01/06/2016	https://clinicaltrials.gov/study/NCT02567435	0.7	LoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	postmenopausal osteoporosis	RALOXIFENE HYDROCHLORIDE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/evista	1		protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	osteoporosis	RALOXIFENE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fcaaa6dc-74e8-4fb8-800c-5574bf0f8de9	1		protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	osteoporosis	LASOFOXIFENE	targetBased	3	Completed	01/05/2003	https://clinicaltrials.gov/study/NCT00163137	0.7		protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	osteoporosis	LASOFOXIFENE	targetBased	2	Completed	01/06/2004	https://clinicaltrials.gov/study/NCT00143273	0.2		protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	osteoporosis	LASOFOXIFENE	targetBased	3	Completed	01/11/2001	https://clinicaltrials.gov/study/NCT00141323	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	osteoporosis	LASOFOXIFENE	targetBased	3	Completed	01/05/2003	https://clinicaltrials.gov/study/NCT00163137	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	osteoporosis	LASOFOXIFENE	targetBased	3	Completed	01/05/2003	https://clinicaltrials.gov/study/NCT00163137	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	osteoporosis	LASOFOXIFENE	targetBased	2	Completed	01/06/2004	https://clinicaltrials.gov/study/NCT00143273	0.2		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	osteoporosis	LASOFOXIFENE	targetBased	2	Completed	01/06/2004	https://clinicaltrials.gov/study/NCT00143273	0.2		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	osteoporosis	LASOFOXIFENE	targetBased	3	Completed	01/11/2001	https://clinicaltrials.gov/study/NCT00141323	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	osteoporosis	LASOFOXIFENE	targetBased	3	Completed	01/11/2001	https://clinicaltrials.gov/study/NCT00141323	0.7		protect
Primary qHTS assay for inhibitors of human arachidonate 12S-lipoxygenase (ALOX12): Round 2	ALOX12_inhibitors	ALOX12	Polyunsaturated fatty acid lipoxygenase ALOX12	rheumatic disease	BENOXAPROFEN	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=M01AE06	1	LoF	protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	two-pore domain potassium channel	Inguinal hernia	ISOFLURANE	targetBased	3	Withdrawn	01/10/2015	https://clinicaltrials.gov/study/NCT02521831	0.7		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	Potassium channel subfamily K member 3	Inguinal hernia	ISOFLURANE	targetBased	3	Withdrawn	01/10/2015	https://clinicaltrials.gov/study/NCT02521831	0.7		protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Friedreich ataxia	LERIGLITAZONE	targetBased	2	Completed	26/03/2019	https://clinicaltrials.gov/study/NCT03917225	0.2	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Friedreich ataxia	LERIGLITAZONE	targetBased	2	Completed	26/03/2019	https://clinicaltrials.gov/study/NCT03917225	0.2	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Friedreich ataxia	LERIGLITAZONE	targetBased	2	Completed	26/03/2019	https://clinicaltrials.gov/study/NCT03917225	0.2	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Friedreich ataxia	LERIGLITAZONE	targetBased	2	Completed	26/03/2019	https://clinicaltrials.gov/study/NCT03917225	0.2	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Friedreich ataxia	LERIGLITAZONE	targetBased	2	Completed	26/03/2019	https://clinicaltrials.gov/study/NCT03917225	0.2	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	Friedreich ataxia	LERIGLITAZONE	targetBased	2	Completed	26/03/2019	https://clinicaltrials.gov/study/NCT03917225	0.2	GoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	sickle cell anemia	LEVETIRACETAM	targetBased	2	Terminated	23/06/2008	https://clinicaltrials.gov/study/NCT00489281	0.2	LoF	protect	Initiation of CMS BMT study for sickle-cell disease operating under NCT01166009 made further accrual to this study impossible.
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	fibromyalgia	ROTIGOTINE	targetBased	2	Completed	01/03/2007	https://clinicaltrials.gov/study/NCT00464737	0.2	GoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	fibromyalgia	ROTIGOTINE	targetBased	2	Completed	01/03/2007	https://clinicaltrials.gov/study/NCT00464737	0.2	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	fibromyalgia	ROTIGOTINE	targetBased	2	Completed	01/03/2007	https://clinicaltrials.gov/study/NCT00464737	0.2	GoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	fibromyalgia	ROTIGOTINE	targetBased	2	Completed	01/03/2007	https://clinicaltrials.gov/study/NCT00464737	0.2	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	fibromyalgia	ROTIGOTINE	targetBased	2	Completed	01/03/2007	https://clinicaltrials.gov/study/NCT00464737	0.2	GoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	fibromyalgia	ROTIGOTINE	targetBased	2	Completed	01/03/2007	https://clinicaltrials.gov/study/NCT00464737	0.2	GoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	fibromyalgia	ROTIGOTINE	targetBased	2	Completed	01/03/2007	https://clinicaltrials.gov/study/NCT00464737	0.2	GoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	fibromyalgia	ROTIGOTINE	targetBased	2	Completed	01/03/2007	https://clinicaltrials.gov/study/NCT00464737	0.2	GoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	fibromyalgia	ROTIGOTINE	targetBased	2	Completed	01/03/2007	https://clinicaltrials.gov/study/NCT00464737	0.2	GoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	spinal muscular atrophy, type III	AMIFAMPRIDINE	targetBased	2	Terminated	07/03/2019	https://clinicaltrials.gov/study/NCT03819660	0.2	LoF	protect	Development of indication not being pursued
Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	spinal muscular atrophy, type III	AMIFAMPRIDINE	targetBased	2	Terminated	07/03/2019	https://clinicaltrials.gov/study/NCT03819660	0.2	LoF	protect	Development of indication not being pursued
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	spinal muscular atrophy	AMIFAMPRIDINE	targetBased	2	Completed	21/01/2019	https://clinicaltrials.gov/study/NCT03781479	0.2	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	spinal muscular atrophy	AMIFAMPRIDINE	targetBased	2	Completed	21/01/2019	https://clinicaltrials.gov/study/NCT03781479	0.2	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	spinal muscular atrophy, type III	AMIFAMPRIDINE	targetBased	2	Terminated	07/03/2019	https://clinicaltrials.gov/study/NCT03819660	0.2	LoF	protect	Development of indication not being pursued
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	spinal muscular atrophy, type III	AMIFAMPRIDINE	targetBased	2	Terminated	07/03/2019	https://clinicaltrials.gov/study/NCT03819660	0.2	LoF	protect	Development of indication not being pursued
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	spinal muscular atrophy, type III	AMIFAMPRIDINE	targetBased	2	Terminated	07/03/2019	https://clinicaltrials.gov/study/NCT03819660	0.2	LoF	protect	Development of indication not being pursued
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	spinal muscular atrophy, type III	AMIFAMPRIDINE	targetBased	2	Terminated	07/03/2019	https://clinicaltrials.gov/study/NCT03819660	0.2	LoF	protect	Development of indication not being pursued
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	spinal muscular atrophy, type III	AMIFAMPRIDINE	targetBased	2	Terminated	07/03/2019	https://clinicaltrials.gov/study/NCT03819660	0.2	LoF	protect	Development of indication not being pursued
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	spinal muscular atrophy	AMIFAMPRIDINE	targetBased	2	Completed	21/01/2019	https://clinicaltrials.gov/study/NCT03781479	0.2	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	spinal muscular atrophy	AMIFAMPRIDINE	targetBased	2	Completed	21/01/2019	https://clinicaltrials.gov/study/NCT03781479	0.2	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	spinal muscular atrophy	AMIFAMPRIDINE	targetBased	2	Completed	21/01/2019	https://clinicaltrials.gov/study/NCT03781479	0.2	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	spinal muscular atrophy	AMIFAMPRIDINE	targetBased	2	Completed	21/01/2019	https://clinicaltrials.gov/study/NCT03781479	0.2	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	spinal muscular atrophy	AMIFAMPRIDINE	targetBased	2	Completed	21/01/2019	https://clinicaltrials.gov/study/NCT03781479	0.2	LoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	McCune-Albright syndrome	FULVESTRANT	targetBased	2	Completed	31/01/2006	https://clinicaltrials.gov/study/NCT00278915	0.2	LoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	systemic lupus erythematosus	FULVESTRANT	targetBased	2	Completed	01/09/2004	https://clinicaltrials.gov/study/NCT00417430	0.2	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	McCune-Albright syndrome	FULVESTRANT	targetBased	2	Completed	31/01/2006	https://clinicaltrials.gov/study/NCT00278915	0.2	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	McCune-Albright syndrome	FULVESTRANT	targetBased	2	Completed	31/01/2006	https://clinicaltrials.gov/study/NCT00278915	0.2	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	systemic lupus erythematosus	FULVESTRANT	targetBased	2	Completed	01/09/2004	https://clinicaltrials.gov/study/NCT00417430	0.2	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	systemic lupus erythematosus	FULVESTRANT	targetBased	2	Completed	01/09/2004	https://clinicaltrials.gov/study/NCT00417430	0.2	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	osteoarthritis	MODAFINIL	targetBased	4	Completed	01/07/2014	https://clinicaltrials.gov/study/NCT02155257	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	fibromyalgia	PSILOCYBINE	targetBased	2	Active, not recruiting	27/09/2023	https://clinicaltrials.gov/study/NCT05128162	0.2	GoF	protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	toothache	SB-705498	targetBased	2	Completed	07/12/2005	https://clinicaltrials.gov/study/NCT00281684	0.2	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	fibrodysplasia ossificans progressiva	SARACATINIB	targetBased	2	Recruiting	05/08/2020	https://clinicaltrials.gov/study/NCT04307953	0.2	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	muscle cramp	NIMODIPINE	targetBased	2	Completed	24/11/2021	https://clinicaltrials.gov/study/NCT05131867	0.2	LoF	protect
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	AVPR1A	Vasopressin V1a receptor	spondylolisthesis	DESMOPRESSIN	targetBased	4	Not yet recruiting	28/03/2024	https://clinicaltrials.gov/study/NCT06255366	1	GoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	myositis	TOFACITINIB	targetBased	2	Recruiting	10/06/2022	https://clinicaltrials.gov/study/NCT05400889	0.2	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	ankylosing spondylitis	TOFACITINIB	targetBased	2	Recruiting	26/04/2023	https://clinicaltrials.gov/study/NCT05814939	0.2	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	ankylosing spondylitis	TOFACITINIB	targetBased	4	Completed	01/01/2022	https://clinicaltrials.gov/study/NCT06310057	1	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	ankylosing spondylitis	TOFACITINIB	targetBased	4	Unknown status	16/01/2018	https://clinicaltrials.gov/study/NCT03504072	1	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	ankylosing spondylitis	TOFACITINIB	targetBased	2	Completed	01/04/2013	https://clinicaltrials.gov/study/NCT01786668	0.2	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	ankylosing spondylitis	TOFACITINIB	targetBased	3	Completed	07/06/2018	https://clinicaltrials.gov/study/NCT03502616	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	ankylosing spondylitis	TOFACITINIB	targetBased	2	Unknown status	01/09/2017	https://clinicaltrials.gov/study/NCT03738956	0.2	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	ankylosing spondylitis	TOFACITINIB	targetBased	4	Not yet recruiting	10/11/2023	https://clinicaltrials.gov/study/NCT06112665	1	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	systemic scleroderma	TOFACITINIB	targetBased	2	Recruiting	01/11/2023	https://clinicaltrials.gov/study/NCT06044844	0.2	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	dermatomyositis	TOFACITINIB	targetBased	4	Enrolling by invitation	19/03/2024	https://clinicaltrials.gov/study/NCT06438679	1	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	polymyalgia rheumatica	TOFACITINIB	targetBased	2	Completed	01/01/2021	https://clinicaltrials.gov/study/NCT04799262	0.2	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	polymyalgia rheumatica	TOFACITINIB	targetBased	3	Not yet recruiting	15/01/2024	https://clinicaltrials.gov/study/NCT06172361	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	psoriatic arthritis	TOFACITINIB	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=68e3d6b2-7838-4d2d-a417-09d919b43e13	1	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	psoriatic arthritis	TOFACITINIB	targetBased	3	Completed	15/09/2017	https://clinicaltrials.gov/study/NCT03736161	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	psoriatic arthritis	TOFACITINIB	targetBased	2	Not yet recruiting	05/02/2024	https://clinicaltrials.gov/study/NCT06176508	0.2	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	psoriatic arthritis	TOFACITINIB	targetBased	4	Recruiting	15/11/2021	https://clinicaltrials.gov/study/NCT05080218	1	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	psoriatic arthritis	TOFACITINIB	targetBased	3	Completed	20/01/2014	https://clinicaltrials.gov/study/NCT01877668	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	psoriatic arthritis	TOFACITINIB	targetBased	3	Completed	10/08/2018	https://clinicaltrials.gov/study/NCT03486457	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	psoriatic arthritis	TOFACITINIB	targetBased	3	Recruiting	19/10/2020	https://clinicaltrials.gov/study/NCT04610476	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	psoriatic arthritis	TOFACITINIB	targetBased	3	Completed	17/02/2014	https://clinicaltrials.gov/study/NCT01976364	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	psoriatic arthritis	TOFACITINIB	targetBased	3	Completed	01/08/2013	https://clinicaltrials.gov/study/NCT01882439	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	juvenile idiopathic arthritis	TOFACITINIB	targetBased	2	Active, not recruiting	18/03/2013	https://clinicaltrials.gov/study/NCT01500551	0.2	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	juvenile idiopathic arthritis	TOFACITINIB	targetBased	3	Completed	10/05/2018	https://clinicaltrials.gov/study/NCT03000439	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	juvenile idiopathic arthritis	TOFACITINIB	targetBased	3	Completed	10/06/2016	https://clinicaltrials.gov/study/NCT02592434	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	myocarditis	TOFACITINIB	targetBased	2	Not yet recruiting	01/07/2024	https://clinicaltrials.gov/study/NCT06393972	0.2	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	postmenopausal osteoporosis	ARZOXIFENE	targetBased	3	Completed	01/04/2004	https://clinicaltrials.gov/study/NCT00085956	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	postmenopausal osteoporosis	ARZOXIFENE	targetBased	3	Completed	01/04/2004	https://clinicaltrials.gov/study/NCT00085956	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	postmenopausal osteoporosis	ARZOXIFENE	targetBased	3	Completed	01/06/2004	https://clinicaltrials.gov/study/NCT00088010	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	postmenopausal osteoporosis	ARZOXIFENE	targetBased	3	Completed	01/06/2004	https://clinicaltrials.gov/study/NCT00088010	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	postmenopausal osteoporosis	ARZOXIFENE	targetBased	3	Completed	01/10/2006	https://clinicaltrials.gov/study/NCT00383422	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	postmenopausal osteoporosis	ARZOXIFENE	targetBased	3	Completed	01/10/2006	https://clinicaltrials.gov/study/NCT00383422	0.7		protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	postmenopausal osteoporosis	ARZOXIFENE	targetBased	3	Completed	01/10/2006	https://clinicaltrials.gov/study/NCT00383422	0.7		protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	postmenopausal osteoporosis	ARZOXIFENE	targetBased	3	Completed	01/04/2004	https://clinicaltrials.gov/study/NCT00085956	0.7		protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	postmenopausal osteoporosis	ARZOXIFENE	targetBased	3	Completed	01/06/2004	https://clinicaltrials.gov/study/NCT00088010	0.7		protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	osteoporosis	ARZOXIFENE	targetBased	2	Completed	01/12/2008	https://clinicaltrials.gov/study/NCT00767299	0.2		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	osteoporosis	ARZOXIFENE	targetBased	2	Completed	01/12/2008	https://clinicaltrials.gov/study/NCT00767299	0.2		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	osteoporosis	ARZOXIFENE	targetBased	2	Completed	01/12/2008	https://clinicaltrials.gov/study/NCT00767299	0.2		protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	rotator cuff tear	HYDROCODONE	targetBased	4	Withdrawn	01/01/2015	https://clinicaltrials.gov/study/NCT02153177	1	GoF	protect	The study was withdrawn prior to any participants being enrolled.
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	rotator cuff tear	HYDROCODONE	targetBased	2	Completed	22/01/2019	https://clinicaltrials.gov/study/NCT03818919	0.2	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	rib fracture	HYDROCODONE	targetBased	4	Unknown status	06/11/2018	https://clinicaltrials.gov/study/NCT03619785	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	humerus fracture	HYDROCODONE	targetBased	4	Terminated	07/06/2021	https://clinicaltrials.gov/study/NCT04905563	1	GoF	protect	Clinical evidence supporting the hypothesis of this study has been published
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	humerus fracture	HYDROCODONE	targetBased	4	Terminated	07/06/2021	https://clinicaltrials.gov/study/NCT04905563	1	GoF	protect	Clinical evidence supporting the hypothesis of this study has been published
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	humerus fracture	HYDROCODONE	targetBased	4	Enrolling by invitation	15/04/2019	https://clinicaltrials.gov/study/NCT06187584	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	humerus fracture	HYDROCODONE	targetBased	4	Enrolling by invitation	15/04/2019	https://clinicaltrials.gov/study/NCT06187584	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	humerus fracture	HYDROCODONE	targetBased	4	Enrolling by invitation	12/09/2023	https://clinicaltrials.gov/study/NCT05640674	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	humerus fracture	HYDROCODONE	targetBased	4	Enrolling by invitation	12/09/2023	https://clinicaltrials.gov/study/NCT05640674	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	osteoarthritis	HYDROCODONE	targetBased	2	Completed	01/09/2002	https://clinicaltrials.gov/study/NCT02222740	0.2	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	osteoarthritis	HYDROCODONE	targetBased	3	Completed	01/02/2006	https://clinicaltrials.gov/study/NCT00298974	0.7	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	humerus fracture	HYDROCODONE	targetBased	4	Terminated	07/06/2021	https://clinicaltrials.gov/study/NCT04905563	1	GoF	protect	Clinical evidence supporting the hypothesis of this study has been published
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	humerus fracture	HYDROCODONE	targetBased	4	Enrolling by invitation	15/04/2019	https://clinicaltrials.gov/study/NCT06187584	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	humerus fracture	HYDROCODONE	targetBased	4	Enrolling by invitation	12/09/2023	https://clinicaltrials.gov/study/NCT05640674	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	toothache	HYDROCODONE	targetBased	4	Completed	01/12/2007	https://clinicaltrials.gov/study/NCT00574015	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	rib fracture	HYDROCODONE	targetBased	4	Unknown status	06/11/2018	https://clinicaltrials.gov/study/NCT03619785	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	rib fracture	HYDROCODONE	targetBased	4	Unknown status	06/11/2018	https://clinicaltrials.gov/study/NCT03619785	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	rotator cuff tear	HYDROCODONE	targetBased	2	Completed	22/01/2019	https://clinicaltrials.gov/study/NCT03818919	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	rotator cuff tear	HYDROCODONE	targetBased	2	Completed	22/01/2019	https://clinicaltrials.gov/study/NCT03818919	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	rotator cuff tear	HYDROCODONE	targetBased	4	Withdrawn	01/01/2015	https://clinicaltrials.gov/study/NCT02153177	1	GoF	protect	The study was withdrawn prior to any participants being enrolled.
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	rotator cuff tear	HYDROCODONE	targetBased	4	Withdrawn	01/01/2015	https://clinicaltrials.gov/study/NCT02153177	1	GoF	protect	The study was withdrawn prior to any participants being enrolled.
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis	HYDROCODONE	targetBased	2	Completed	01/09/2002	https://clinicaltrials.gov/study/NCT02222740	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis	HYDROCODONE	targetBased	2	Completed	01/09/2002	https://clinicaltrials.gov/study/NCT02222740	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis	HYDROCODONE	targetBased	3	Completed	01/02/2006	https://clinicaltrials.gov/study/NCT00298974	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis	HYDROCODONE	targetBased	3	Completed	01/02/2006	https://clinicaltrials.gov/study/NCT00298974	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	toothache	HYDROCODONE	targetBased	4	Completed	01/12/2007	https://clinicaltrials.gov/study/NCT00574015	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	toothache	HYDROCODONE	targetBased	4	Completed	01/12/2007	https://clinicaltrials.gov/study/NCT00574015	1	GoF	protect
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	Oxytocin receptor	osteoarthritis, knee	OXYTOCIN	targetBased	2	Withdrawn	01/12/2021	https://clinicaltrials.gov/study/NCT04427540	0.2	GoF	protect	Study was not initiated; no subjects were consented or enrolled
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	Oxytocin receptor	osteoarthritis, knee	OXYTOCIN	targetBased	2	Withdrawn	01/01/2024	https://clinicaltrials.gov/study/NCT04493229	0.2	GoF	protect	study team decided not to proceed with project
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	Oxytocin receptor	osteoarthritis, knee	OXYTOCIN	targetBased	2	Not yet recruiting	01/06/2025	https://clinicaltrials.gov/study/NCT04435704	0.2	GoF	protect
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	Oxytocin receptor	osteoarthritis, knee	OXYTOCIN	targetBased	2	Withdrawn	01/12/2023	https://clinicaltrials.gov/study/NCT04431193	0.2	GoF	protect	Study will be replaced by a revised study protocol
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	Oxytocin receptor	osteoarthritis, knee	OXYTOCIN	targetBased	2	Recruiting	04/11/2020	https://clinicaltrials.gov/study/NCT04431206	0.2	GoF	protect
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	Oxytocin receptor	osteoarthritis, knee	OXYTOCIN	targetBased	2	Recruiting	06/08/2019	https://clinicaltrials.gov/study/NCT03878589	0.2	GoF	protect
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	Oxytocin receptor	osteoarthritis, knee	OXYTOCIN	targetBased	2	Withdrawn	01/01/2023	https://clinicaltrials.gov/study/NCT04429880	0.2	GoF	protect	Study was not initiated; no subjects enrolled. A replacement study will be submitted
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	Oxytocin receptor	osteoarthritis	OXYTOCIN	targetBased	2	Recruiting	06/08/2019	https://clinicaltrials.gov/study/NCT03878589	0.2	GoF	protect
Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).	OXTR	OXTR	Oxytocin receptor	interstitial cystitis	OXYTOCIN	targetBased	4	Completed	01/06/2010	https://clinicaltrials.gov/study/NCT00919802	1	GoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	muscle cramp	NICARDIPINE	targetBased	3	Completed	01/11/2020	https://clinicaltrials.gov/study/NCT04538534	0.7	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	spinal stenosis	NICARDIPINE	targetBased	4	Completed	01/05/2012	https://clinicaltrials.gov/study/NCT02271191	1	LoF	protect
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	DNA methyltransferase-1	myelofibrosis	AZACITIDINE	targetBased	2	Completed	01/06/2005	https://clinicaltrials.gov/study/NCT00569660	0.2	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	hypertrophic cardiomyopathy	AMLODIPINE	targetBased	2	Completed	08/01/2020	https://clinicaltrials.gov/study/NCT04164732	0.2	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	osteoarthritis	AMLODIPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=322f926c-99ac-49f8-9cc5-584594f2891f	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis, hip	HYDROMORPHONE	targetBased	3	Completed	01/11/2003	https://clinicaltrials.gov/study/NCT00411164	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis, hip	HYDROMORPHONE	targetBased	3	Completed	01/11/2003	https://clinicaltrials.gov/study/NCT00411164	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis, hip	HYDROMORPHONE	targetBased	3	Completed		https://clinicaltrials.gov/study/NCT00399048	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis, hip	HYDROMORPHONE	targetBased	3	Completed		https://clinicaltrials.gov/study/NCT00399048	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	rib fracture	HYDROMORPHONE	targetBased	4	Unknown status	06/11/2018	https://clinicaltrials.gov/study/NCT03619785	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	rib fracture	HYDROMORPHONE	targetBased	4	Unknown status	06/11/2018	https://clinicaltrials.gov/study/NCT03619785	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis, knee	HYDROMORPHONE	targetBased	3	Completed	01/11/2003	https://clinicaltrials.gov/study/NCT00411164	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis, knee	HYDROMORPHONE	targetBased	3	Completed	01/11/2003	https://clinicaltrials.gov/study/NCT00411164	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis, knee	HYDROMORPHONE	targetBased	3	Completed		https://clinicaltrials.gov/study/NCT00399048	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis, knee	HYDROMORPHONE	targetBased	3	Completed		https://clinicaltrials.gov/study/NCT00399048	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	sickle cell anemia	HYDROMORPHONE	targetBased	3	Terminated	13/08/2019	https://clinicaltrials.gov/study/NCT03933397	0.7	GoF	protect	Due to COVID enrollment numbers needed to meet the primary endpoint will not be met.
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	sickle cell anemia	HYDROMORPHONE	targetBased	3	Terminated	13/08/2019	https://clinicaltrials.gov/study/NCT03933397	0.7	GoF	protect	Due to COVID enrollment numbers needed to meet the primary endpoint will not be met.
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	sickle cell anemia	HYDROMORPHONE	targetBased	4	Completed	15/03/2015	https://clinicaltrials.gov/study/NCT02222246	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	sickle cell anemia	HYDROMORPHONE	targetBased	4	Completed	15/03/2015	https://clinicaltrials.gov/study/NCT02222246	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	osteoporosis	ESTRADIOL VALERATE	targetBased	4	Completed	01/02/1998	https://clinicaltrials.gov/study/NCT00860964	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	osteoporosis	ESTRADIOL VALERATE	targetBased	4	Completed	01/02/1998	https://clinicaltrials.gov/study/NCT00860964	1	GoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	systemic scleroderma	NILOTINIB	targetBased	2	Completed	01/07/2010	https://clinicaltrials.gov/study/NCT01166139	0.2	LoF	protect
Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of myeloid cell leukemia sequence 1 (MCL1) interactions with BIM-BH3 peptide.	MCL1	MCL1	Induced myeloid leukemia cell differentiation protein Mcl-1 , MCL1 apoptosis regulator, BCL2 family member, Myeloid cell leukemia ES variant	myelofibrosis	OBATOCLAX	targetBased	2	Completed	01/07/2006	https://clinicaltrials.gov/study/NCT00360035	0.2	LoF	protect
uHTS of Mcl-1/Bid interaction inhibitors	MCL1	MCL1	Induced myeloid leukemia cell differentiation protein Mcl-1 , MCL1 apoptosis regulator, BCL2 family member, Myeloid cell leukemia ES variant	myelofibrosis	OBATOCLAX	targetBased	2	Completed	01/07/2006	https://clinicaltrials.gov/study/NCT00360035	0.2	LoF	protect
uHTS of Mcl-1/Noxa interaction inhibitors	MCL1	MCL1	Induced myeloid leukemia cell differentiation protein Mcl-1 , MCL1 apoptosis regulator, BCL2 family member, Myeloid cell leukemia ES variant	myelofibrosis	OBATOCLAX	targetBased	2	Completed	01/07/2006	https://clinicaltrials.gov/study/NCT00360035	0.2	LoF	protect
Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Bfl-1	BCL2A1_modulators	BCL2A1	Bcl-2-related protein A1	myelofibrosis	OBATOCLAX	targetBased	2	Completed	01/07/2006	https://clinicaltrials.gov/study/NCT00360035	0.2	LoF	protect
Primary biochemical high throughput screening assay to identify inhibitors of BCL2-related protein, long isoform (BCLXL).	BCL2L1_modulators	BCL2L1	Bcl-2-like protein 1	myelofibrosis	OBATOCLAX	targetBased	2	Completed	01/07/2006	https://clinicaltrials.gov/study/NCT00360035	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	systemic lupus erythematosus	HYDROXYCHLOROQUINE	targetBased	4	Recruiting	31/12/2022	https://clinicaltrials.gov/study/NCT05666336	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	systemic lupus erythematosus	HYDROXYCHLOROQUINE	targetBased	2	Active, not recruiting	28/12/2017	https://clinicaltrials.gov/study/NCT03030118	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	systemic lupus erythematosus	HYDROXYCHLOROQUINE	targetBased	4	Completed	05/06/2017	https://clinicaltrials.gov/study/NCT03122431	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	systemic lupus erythematosus	HYDROXYCHLOROQUINE	targetBased	4	Completed	01/06/2007	https://clinicaltrials.gov/study/NCT00413361	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	systemic lupus erythematosus	HYDROXYCHLOROQUINE	targetBased	2	Terminated	20/11/2013	https://clinicaltrials.gov/study/NCT01946880	0.2	LoF	protect	Slow enrollment.
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	systemic lupus erythematosus	HYDROXYCHLOROQUINE	targetBased	3	Completed	01/03/2012	https://clinicaltrials.gov/study/NCT01551069	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	cutaneous lupus erythematosus	HYDROXYCHLOROQUINE	targetBased	3	Completed	01/03/2012	https://clinicaltrials.gov/study/NCT01551069	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	cutaneous lupus erythematosus	HYDROXYCHLOROQUINE	targetBased	4	Completed	05/06/2017	https://clinicaltrials.gov/study/NCT03122431	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	ankylosing spondylitis	HYDROXYCHLOROQUINE	targetBased	4	Not yet recruiting	07/10/2019	https://clinicaltrials.gov/study/NCT04077957	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	osteoarthritis	HYDROXYCHLOROQUINE	targetBased	3	Completed	01/07/2010	https://clinicaltrials.gov/study/NCT01148043	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	sarcoidosis	HYDROXYCHLOROQUINE	targetBased	4	Not yet recruiting	01/04/2024	https://clinicaltrials.gov/study/NCT05841758	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	osteoarthritis, knee	HYDROXYCHLOROQUINE	targetBased	2	Completed	01/05/2012	https://clinicaltrials.gov/study/NCT01645176	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	pulmonary sarcoidosis	HYDROXYCHLOROQUINE	targetBased	3	Not yet recruiting	01/03/2022	https://clinicaltrials.gov/study/NCT05247554	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	pulmonary sarcoidosis	HYDROXYCHLOROQUINE	targetBased	3	Completed	01/03/2009	https://clinicaltrials.gov/study/NCT02200146	0.7	LoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	Osteopenia	ERGOCALCIFEROL	targetBased	2	Completed	10/08/2020	https://clinicaltrials.gov/study/NCT04768439	0.2	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	rickets	ERGOCALCIFEROL	targetBased	4	Completed	01/01/2004	https://clinicaltrials.gov/study/NCT00949832	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	rickets	ERGOCALCIFEROL	targetBased	4	Completed	01/11/2007	https://clinicaltrials.gov/study/NCT01578434	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	Osteopenia	ERGOCALCIFEROL	targetBased	3	Completed	01/09/2007	https://clinicaltrials.gov/study/NCT00463268	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	chronic rhinosinusitis with nasal polyps	ERGOCALCIFEROL	targetBased	3	Unknown status	01/05/2016	https://clinicaltrials.gov/study/NCT02668861	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	sickle cell anemia	ERGOCALCIFEROL	targetBased	2	Completed	01/02/2009	https://clinicaltrials.gov/study/NCT01331148	0.2	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	sickle cell anemia	ERGOCALCIFEROL	targetBased	3	Completed	30/11/2018	https://clinicaltrials.gov/study/NCT03417947	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	bone fracture	ERGOCALCIFEROL	targetBased	4	Completed	01/06/2016	https://clinicaltrials.gov/study/NCT02753283	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	hip fracture	ERGOCALCIFEROL	targetBased	4	Completed	01/10/2007	https://clinicaltrials.gov/study/NCT00424619	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	hip fracture	ERGOCALCIFEROL	targetBased	3	Unknown status	17/05/2017	https://clinicaltrials.gov/study/NCT03133195	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	hypophosphatemic rickets	ERGOCALCIFEROL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=00c063ce-5a2c-4ccb-87df-6ec3df0c9fa6	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	osteitis deformans	ERGOCALCIFEROL	targetBased	3	Completed	01/01/2001	https://clinicaltrials.gov/study/NCT00051636	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	osteitis deformans	ERGOCALCIFEROL	targetBased	3	Completed	01/04/2002	https://clinicaltrials.gov/study/NCT00103740	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	cutaneous lupus erythematosus	ERGOCALCIFEROL	targetBased	2	Terminated	01/12/2011	https://clinicaltrials.gov/study/NCT01498406	0.2	GoF	protect	secondary to funding issues and low enrollment
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	osteogenesis imperfecta type 3	ERGOCALCIFEROL	targetBased	2	Completed	11/09/2017	https://clinicaltrials.gov/study/NCT03118570	0.2	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	X-linked hypophosphatemia	ERGOCALCIFEROL	targetBased	3	Completed	08/09/2016	https://clinicaltrials.gov/study/NCT02915705	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	enamel caries	ERGOCALCIFEROL	targetBased	4	Recruiting	12/12/2023	https://clinicaltrials.gov/study/NCT06172764	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	osteoporosis	ERGOCALCIFEROL	targetBased	3	Completed	01/04/2002	https://clinicaltrials.gov/study/NCT00048061	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	osteoporosis	ERGOCALCIFEROL	targetBased	4	Unknown status	01/01/2007	https://clinicaltrials.gov/study/NCT00634686	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	osteoporosis	ERGOCALCIFEROL	targetBased	3	Completed		https://clinicaltrials.gov/study/NCT00000611	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	osteoporosis	ERGOCALCIFEROL	targetBased	4	Completed	01/04/2009	https://clinicaltrials.gov/study/NCT00887354	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	osteoporosis	ERGOCALCIFEROL	targetBased	2	Completed	01/03/2008	https://clinicaltrials.gov/study/NCT00663221	0.2	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	osteoporosis	ERGOCALCIFEROL	targetBased	3	Completed	01/03/2006	https://clinicaltrials.gov/study/NCT00329797	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	osteoporosis	ERGOCALCIFEROL	targetBased	3	Completed	01/10/2006	https://clinicaltrials.gov/study/NCT00404820	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	osteoporosis	ERGOCALCIFEROL	targetBased	3	Active, not recruiting	29/04/2017	https://clinicaltrials.gov/study/NCT03293108	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	osteoporosis	ERGOCALCIFEROL	targetBased	4	Completed	01/06/2016	https://clinicaltrials.gov/study/NCT02753283	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	osteoporosis	ERGOCALCIFEROL	targetBased	2	Completed	03/12/2008	https://clinicaltrials.gov/study/NCT00752557	0.2	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	osteoporosis	ERGOCALCIFEROL	targetBased	4	Completed	01/01/2013	https://clinicaltrials.gov/study/NCT01753856	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	osteoporosis	ERGOCALCIFEROL	targetBased	3	Completed	01/10/2011	https://clinicaltrials.gov/study/NCT01656512	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	osteoporosis	ERGOCALCIFEROL	targetBased	2	Recruiting	12/10/2017	https://clinicaltrials.gov/study/NCT03186131	0.2	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	osteoporosis	ERGOCALCIFEROL	targetBased	4	Completed	01/04/2001	https://clinicaltrials.gov/study/NCT02416271	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	osteoporosis	ERGOCALCIFEROL	targetBased	3	Completed	01/03/2003	https://clinicaltrials.gov/study/NCT00054418	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	osteoporosis	ERGOCALCIFEROL	targetBased	4	Recruiting	09/10/2021	https://clinicaltrials.gov/study/NCT05203588	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	osteogenesis imperfecta	ERGOCALCIFEROL	targetBased	2	Completed	11/09/2017	https://clinicaltrials.gov/study/NCT03118570	0.2	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	osteogenesis imperfecta type 4	ERGOCALCIFEROL	targetBased	2	Completed	11/09/2017	https://clinicaltrials.gov/study/NCT03118570	0.2	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	postmenopausal osteoporosis	ERGOCALCIFEROL	targetBased	3	Completed	01/09/2002	https://clinicaltrials.gov/study/NCT00092014	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	postmenopausal osteoporosis	ERGOCALCIFEROL	targetBased	3	Active, not recruiting	31/03/2022	https://clinicaltrials.gov/study/NCT05338086	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	postmenopausal osteoporosis	ERGOCALCIFEROL	targetBased	4	Completed	01/06/2016	https://clinicaltrials.gov/study/NCT02753283	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	postmenopausal osteoporosis	ERGOCALCIFEROL	targetBased	3	Completed	01/01/2014	https://clinicaltrials.gov/study/NCT02014467	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	postmenopausal osteoporosis	ERGOCALCIFEROL	targetBased	4	Unknown status	01/06/2017	https://clinicaltrials.gov/study/NCT03158246	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	postmenopausal osteoporosis	ERGOCALCIFEROL	targetBased	3	Completed	01/08/1996	https://clinicaltrials.gov/study/NCT00670501	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	postmenopausal osteoporosis	ERGOCALCIFEROL	targetBased	4	Recruiting	03/01/2023	https://clinicaltrials.gov/study/NCT05630768	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	postmenopausal osteoporosis	ERGOCALCIFEROL	targetBased	4	Completed	01/03/2006	https://clinicaltrials.gov/study/NCT00271713	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	postmenopausal osteoporosis	ERGOCALCIFEROL	targetBased	4	Completed	01/10/2012	https://clinicaltrials.gov/study/NCT01709110	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	spinal cord injury	ERGOCALCIFEROL	targetBased	2	Active, not recruiting	01/10/2021	https://clinicaltrials.gov/study/NCT05008484	0.2	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	femoral neck fracture	ERGOCALCIFEROL	targetBased	3	Terminated	01/09/2014	https://clinicaltrials.gov/study/NCT01908751	0.7	GoF	protect	Continuing beyond the pilot phase of the trial was deemed unfeasible
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	osteoarthritis, knee	ERGOCALCIFEROL	targetBased	4	Completed	01/02/2020	https://clinicaltrials.gov/study/NCT04177758	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	osteoarthritis, knee	ERGOCALCIFEROL	targetBased	3	Completed	01/08/2010	https://clinicaltrials.gov/study/NCT01176344	0.7	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	lower extremity fracture	ATROPINE	targetBased	4	Unknown status	15/09/2017	https://clinicaltrials.gov/study/NCT03580889	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	lower extremity fracture	ATROPINE	targetBased	4	Unknown status	15/09/2017	https://clinicaltrials.gov/study/NCT03580889	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	lower extremity fracture	ATROPINE	targetBased	4	Unknown status	15/09/2017	https://clinicaltrials.gov/study/NCT03580889	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	lower extremity fracture	ATROPINE	targetBased	4	Unknown status	15/09/2017	https://clinicaltrials.gov/study/NCT03580889	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	lower extremity fracture	ATROPINE	targetBased	4	Unknown status	15/09/2017	https://clinicaltrials.gov/study/NCT03580889	1	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	rotator cuff tear	BUPRENORPHINE	targetBased	2	Completed	22/09/2016	https://clinicaltrials.gov/study/NCT03380533	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Intervertebral disk degeneration	BUPRENORPHINE	targetBased	3	Completed	01/08/2009	https://clinicaltrials.gov/study/NCT01476774	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Intervertebral disk degeneration	BUPRENORPHINE	targetBased	3	Completed	01/08/2009	https://clinicaltrials.gov/study/NCT01476774	0.7	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	osteoarthritis	BUPRENORPHINE	targetBased	4	Completed	01/03/2006	https://clinicaltrials.gov/study/NCT00324038	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	osteoarthritis	BUPRENORPHINE	targetBased	3	Completed	01/04/2003	https://clinicaltrials.gov/study/NCT00313846	0.7	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	osteoarthritis	BUPRENORPHINE	targetBased	3	Completed	01/11/1996	https://clinicaltrials.gov/study/NCT00315848	0.7	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	osteoarthritis	BUPRENORPHINE	targetBased	3	Terminated	01/12/2003	https://clinicaltrials.gov/study/NCT00315458	0.7	GoF	protect	Administrative reasons.
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	osteoarthritis	BUPRENORPHINE	targetBased	3	Completed	01/06/1999	https://clinicaltrials.gov/study/NCT00314652	0.7	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	osteoarthritis	BUPRENORPHINE	targetBased	3	Completed	01/04/2003	https://clinicaltrials.gov/study/NCT01141283	0.7	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	osteoarthritis	BUPRENORPHINE	targetBased	3	Completed	01/03/2011	https://clinicaltrials.gov/study/NCT01298765	0.7	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	osteoarthritis	BUPRENORPHINE	targetBased	3	Terminated	01/04/2004	https://clinicaltrials.gov/study/NCT01135524	0.7	GoF	protect	This study was terminated early for administrative reasons.
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	osteoarthritis	BUPRENORPHINE	targetBased	3	Terminated	01/01/2004	https://clinicaltrials.gov/study/NCT00320801	0.7	GoF	protect	This study was terminated early due to administrative reasons.
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	osteoarthritis	BUPRENORPHINE	targetBased	3	Completed	01/06/2003	https://clinicaltrials.gov/study/NCT00312572	0.7	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	osteoarthritis	BUPRENORPHINE	targetBased	3	Terminated	01/04/2004	https://clinicaltrials.gov/study/NCT00312221	0.7	GoF	protect	terminated early for administrative reasons unrelated to safety or efficacy
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	osteoarthritis	BUPRENORPHINE	targetBased	4	Completed	01/03/2008	https://clinicaltrials.gov/study/NCT01019265	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	toothache	BUPRENORPHINE	targetBased	2	Completed	01/08/2009	https://clinicaltrials.gov/study/NCT00941304	0.2	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	Intervertebral disk degeneration	BUPRENORPHINE	targetBased	3	Completed	01/08/2009	https://clinicaltrials.gov/study/NCT01476774	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	rotator cuff tear	BUPRENORPHINE	targetBased	2	Completed	22/09/2016	https://clinicaltrials.gov/study/NCT03380533	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	rotator cuff tear	BUPRENORPHINE	targetBased	2	Completed	22/09/2016	https://clinicaltrials.gov/study/NCT03380533	0.2	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	sickle cell anemia	BUPRENORPHINE	targetBased	2	Completed	01/08/2018	https://clinicaltrials.gov/study/NCT03492099	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis	BUPRENORPHINE	targetBased	3	Completed	01/04/2003	https://clinicaltrials.gov/study/NCT00313846	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis	BUPRENORPHINE	targetBased	3	Completed	01/04/2003	https://clinicaltrials.gov/study/NCT00313846	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis	BUPRENORPHINE	targetBased	3	Terminated	01/04/2004	https://clinicaltrials.gov/study/NCT01135524	0.7	GoF	protect	This study was terminated early for administrative reasons.
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis	BUPRENORPHINE	targetBased	3	Terminated	01/04/2004	https://clinicaltrials.gov/study/NCT01135524	0.7	GoF	protect	This study was terminated early for administrative reasons.
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis	BUPRENORPHINE	targetBased	3	Completed	01/04/2003	https://clinicaltrials.gov/study/NCT01141283	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis	BUPRENORPHINE	targetBased	3	Completed	01/04/2003	https://clinicaltrials.gov/study/NCT01141283	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis	BUPRENORPHINE	targetBased	3	Terminated	01/12/2003	https://clinicaltrials.gov/study/NCT00315458	0.7	GoF	protect	Administrative reasons.
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis	BUPRENORPHINE	targetBased	3	Terminated	01/12/2003	https://clinicaltrials.gov/study/NCT00315458	0.7	GoF	protect	Administrative reasons.
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis	BUPRENORPHINE	targetBased	3	Completed	01/06/2003	https://clinicaltrials.gov/study/NCT00312572	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis	BUPRENORPHINE	targetBased	3	Completed	01/06/2003	https://clinicaltrials.gov/study/NCT00312572	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis	BUPRENORPHINE	targetBased	3	Completed	01/03/2011	https://clinicaltrials.gov/study/NCT01298765	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis	BUPRENORPHINE	targetBased	3	Completed	01/03/2011	https://clinicaltrials.gov/study/NCT01298765	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis	BUPRENORPHINE	targetBased	4	Completed	01/03/2008	https://clinicaltrials.gov/study/NCT01019265	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis	BUPRENORPHINE	targetBased	4	Completed	01/03/2008	https://clinicaltrials.gov/study/NCT01019265	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis	BUPRENORPHINE	targetBased	3	Terminated	01/04/2004	https://clinicaltrials.gov/study/NCT00312221	0.7	GoF	protect	terminated early for administrative reasons unrelated to safety or efficacy
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis	BUPRENORPHINE	targetBased	3	Terminated	01/04/2004	https://clinicaltrials.gov/study/NCT00312221	0.7	GoF	protect	terminated early for administrative reasons unrelated to safety or efficacy
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis	BUPRENORPHINE	targetBased	4	Completed	01/03/2006	https://clinicaltrials.gov/study/NCT00324038	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis	BUPRENORPHINE	targetBased	4	Completed	01/03/2006	https://clinicaltrials.gov/study/NCT00324038	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis	BUPRENORPHINE	targetBased	3	Completed	01/11/1996	https://clinicaltrials.gov/study/NCT00315848	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis	BUPRENORPHINE	targetBased	3	Completed	01/11/1996	https://clinicaltrials.gov/study/NCT00315848	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis	BUPRENORPHINE	targetBased	3	Terminated	01/01/2004	https://clinicaltrials.gov/study/NCT00320801	0.7	GoF	protect	This study was terminated early due to administrative reasons.
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis	BUPRENORPHINE	targetBased	3	Terminated	01/01/2004	https://clinicaltrials.gov/study/NCT00320801	0.7	GoF	protect	This study was terminated early due to administrative reasons.
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis	BUPRENORPHINE	targetBased	3	Completed	01/06/1999	https://clinicaltrials.gov/study/NCT00314652	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis	BUPRENORPHINE	targetBased	3	Completed	01/06/1999	https://clinicaltrials.gov/study/NCT00314652	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	sickle cell anemia	BUPRENORPHINE	targetBased	2	Completed	01/08/2018	https://clinicaltrials.gov/study/NCT03492099	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	sickle cell anemia	BUPRENORPHINE	targetBased	2	Completed	01/08/2018	https://clinicaltrials.gov/study/NCT03492099	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	toothache	BUPRENORPHINE	targetBased	2	Completed	01/08/2009	https://clinicaltrials.gov/study/NCT00941304	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	toothache	BUPRENORPHINE	targetBased	2	Completed	01/08/2009	https://clinicaltrials.gov/study/NCT00941304	0.2	GoF	protect
Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2	THRB	THRB	Thyroid hormone receptor beta	systemic lupus erythematosus	LEVOTHYROXINE	targetBased	4	Withdrawn	01/01/2011	https://clinicaltrials.gov/study/NCT01276782	1	GoF	protect	Withdraw the study because further analysis showed that it would be futile.
qHTS Assay for Activators of Human alpha-Glucosidase as a Potential Chaperone Treatment of Pompe Disease	GAA	GAA	Lysosomal alpha-glucosidase	Glycogen storage disease due to acid maltase deficiency	DUVOGLUSTAT HYDROCHLORIDE	targetBased	2	Completed	31/10/2011	https://clinicaltrials.gov/study/NCT01380743	0.2	GoF	protect
qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase Cleavage of Glycogen	GAA_inhibitors	GAA	Lysosomal alpha-glucosidase	Glycogen storage disease due to acid maltase deficiency	DUVOGLUSTAT HYDROCHLORIDE	targetBased	2	Completed	31/10/2011	https://clinicaltrials.gov/study/NCT01380743	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	sickle cell anemia	DIACETYLMORPHINE	targetBased	4	Terminated	01/03/2011	https://clinicaltrials.gov/study/NCT00880373	1	GoF	protect	The funding withdrawal and early termination of the trial is based upon lack of suitable recruitment figures in order to reach the required trial endpoints.
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	sickle cell anemia	DIACETYLMORPHINE	targetBased	4	Terminated	01/03/2011	https://clinicaltrials.gov/study/NCT00880373	1	GoF	protect	The funding withdrawal and early termination of the trial is based upon lack of suitable recruitment figures in order to reach the required trial endpoints.
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	Hypereosinophilic syndrome	IMATINIB MESYLATE	targetBased	2	Terminated	12/06/2003	https://clinicaltrials.gov/study/NCT00230334	0.2	LoF	protect	terminated by PI due to insufficient accrual
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	Hypereosinophilic syndrome	IMATINIB MESYLATE	targetBased	2	Terminated	01/09/2002	https://clinicaltrials.gov/study/NCT00171860	0.2	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	systemic scleroderma	IMATINIB MESYLATE	targetBased	2	Completed	02/01/2008	https://clinicaltrials.gov/study/NCT00613171	0.2	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	systemic scleroderma	IMATINIB MESYLATE	targetBased	2	Completed	01/08/2007	https://clinicaltrials.gov/study/NCT00555581	0.2	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	systemic scleroderma	IMATINIB MESYLATE	targetBased	2	Completed	01/12/2007	https://clinicaltrials.gov/study/NCT00479934	0.2	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	adult fibrosarcoma	IMATINIB MESYLATE	targetBased	2	Completed	01/05/2004	https://clinicaltrials.gov/study/NCT00084630	0.2	LoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	localised scleroderma	IMATINIB MESYLATE	targetBased	2	Completed	01/12/2007	https://clinicaltrials.gov/study/NCT00479934	0.2	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	osteoporosis	ESTRONE SULFURIC ACID	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=03cdbf5b-b572-448f-80e9-b3e812959901	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	osteoporosis	ESTRONE SULFURIC ACID	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=03cdbf5b-b572-448f-80e9-b3e812959901	1	GoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	peripheral primitive neuroectodermal tumor of bone	VINCRISTINE SULFATE	targetBased	3	Active, not recruiting	22/11/2010	https://clinicaltrials.gov/study/NCT01231906	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	Ewing sarcoma of bone	VINCRISTINE SULFATE	targetBased	2	Completed	01/02/2008	https://clinicaltrials.gov/study/NCT00516295	0.2	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	spindle cell rhabdomyosarcoma	VINCRISTINE SULFATE	targetBased	3	Recruiting	14/09/2021	https://clinicaltrials.gov/study/NCT04994132	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	spindle cell rhabdomyosarcoma	VINCRISTINE SULFATE	targetBased	3	Active, not recruiting	01/06/2016	https://clinicaltrials.gov/study/NCT02567435	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	bone fracture	TOREMIFENE	targetBased	3	Withdrawn	01/03/2011	https://clinicaltrials.gov/study/NCT01214291	0.7		protect	cost of conducting the study and increased burden on the clinical trial professionals make it impossible for us to proceed with the development of the drug.
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	bone fracture	TOREMIFENE	targetBased	3	Withdrawn	01/03/2011	https://clinicaltrials.gov/study/NCT01214291	0.7		protect	cost of conducting the study and increased burden on the clinical trial professionals make it impossible for us to proceed with the development of the drug.
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	bone fracture	TOREMIFENE	targetBased	3	Completed	01/10/2003	https://clinicaltrials.gov/study/NCT00129142	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	bone fracture	TOREMIFENE	targetBased	3	Completed	01/10/2003	https://clinicaltrials.gov/study/NCT00129142	0.7		protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	osteoporosis	TOREMIFENE	targetBased	3	Completed	01/10/2003	https://clinicaltrials.gov/study/NCT00129142	0.7		protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	bone fracture	TOREMIFENE	targetBased	3	Withdrawn	01/03/2011	https://clinicaltrials.gov/study/NCT01214291	0.7		protect	cost of conducting the study and increased burden on the clinical trial professionals make it impossible for us to proceed with the development of the drug.
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	bone fracture	TOREMIFENE	targetBased	3	Completed	01/10/2003	https://clinicaltrials.gov/study/NCT00129142	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	osteoporosis	TOREMIFENE	targetBased	3	Completed	01/10/2003	https://clinicaltrials.gov/study/NCT00129142	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	osteoporosis	TOREMIFENE	targetBased	3	Completed	01/10/2003	https://clinicaltrials.gov/study/NCT00129142	0.7		protect
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	PTH1R	Parathyroid hormone/parathyroid hormone-related peptide receptor	radius fracture	TERIPARATIDE	targetBased	2	Completed	01/12/2004	https://clinicaltrials.gov/study/NCT00190944	0.2	GoF	protect
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	PTH1R	Parathyroid hormone/parathyroid hormone-related peptide receptor	postmenopausal osteoporosis	TERIPARATIDE	targetBased	3	Completed	01/11/2003	https://clinicaltrials.gov/study/NCT00532207	0.7	GoF	protect
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	PTH1R	Parathyroid hormone/parathyroid hormone-related peptide receptor	postmenopausal osteoporosis	TERIPARATIDE	targetBased	4	Completed	01/01/2013	https://clinicaltrials.gov/study/NCT01750086	1	GoF	protect
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	PTH1R	Parathyroid hormone/parathyroid hormone-related peptide receptor	postmenopausal osteoporosis	TERIPARATIDE	targetBased	4	Unknown status	01/06/2013	https://clinicaltrials.gov/study/NCT01945788	1	GoF	protect
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	PTH1R	Parathyroid hormone/parathyroid hormone-related peptide receptor	postmenopausal osteoporosis	TERIPARATIDE	targetBased	3	Completed	01/08/2003	https://clinicaltrials.gov/study/NCT00542984	0.7	GoF	protect
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	PTH1R	Parathyroid hormone/parathyroid hormone-related peptide receptor	postmenopausal osteoporosis	TERIPARATIDE	targetBased	4	Completed	01/11/2004	https://clinicaltrials.gov/study/NCT00079924	1	GoF	protect
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	PTH1R	Parathyroid hormone/parathyroid hormone-related peptide receptor	postmenopausal osteoporosis	TERIPARATIDE	targetBased	4	Completed	01/09/2005	https://clinicaltrials.gov/study/NCT00239629	1	GoF	protect
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	PTH1R	Parathyroid hormone/parathyroid hormone-related peptide receptor	postmenopausal osteoporosis	TERIPARATIDE	targetBased	4	Completed	01/08/2014	https://clinicaltrials.gov/study/NCT02176382	1	GoF	protect
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	PTH1R	Parathyroid hormone/parathyroid hormone-related peptide receptor	postmenopausal osteoporosis	TERIPARATIDE	targetBased	4	Completed	02/09/2019	https://clinicaltrials.gov/study/NCT04026256	1	GoF	protect
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	PTH1R	Parathyroid hormone/parathyroid hormone-related peptide receptor	postmenopausal osteoporosis	TERIPARATIDE	targetBased	4	Completed	01/04/2003	https://clinicaltrials.gov/study/NCT00532545	1	GoF	protect
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	PTH1R	Parathyroid hormone/parathyroid hormone-related peptide receptor	postmenopausal osteoporosis	TERIPARATIDE	targetBased	2	Completed	01/02/2011	https://clinicaltrials.gov/study/NCT01321723	0.2	GoF	protect
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	PTH1R	Parathyroid hormone/parathyroid hormone-related peptide receptor	postmenopausal osteoporosis	TERIPARATIDE	targetBased	4	Completed	01/10/2001	https://clinicaltrials.gov/study/NCT00035256	1	GoF	protect
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	PTH1R	Parathyroid hormone/parathyroid hormone-related peptide receptor	postmenopausal osteoporosis	TERIPARATIDE	targetBased	4	Completed	01/11/2007	https://clinicaltrials.gov/study/NCT00557310	1	GoF	protect
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	PTH1R	Parathyroid hormone/parathyroid hormone-related peptide receptor	postmenopausal osteoporosis	TERIPARATIDE	targetBased	4	Completed	01/07/2009	https://clinicaltrials.gov/study/NCT00927186	1	GoF	protect
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	PTH1R	Parathyroid hormone/parathyroid hormone-related peptide receptor	postmenopausal osteoporosis	TERIPARATIDE	targetBased	3	Completed	01/12/2002	https://clinicaltrials.gov/study/NCT00543218	0.7	GoF	protect
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	PTH1R	Parathyroid hormone/parathyroid hormone-related peptide receptor	postmenopausal osteoporosis	TERIPARATIDE	targetBased	3	Completed	31/01/2013	https://clinicaltrials.gov/study/NCT01796301	0.7	GoF	protect
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	PTH1R	Parathyroid hormone/parathyroid hormone-related peptide receptor	postmenopausal osteoporosis	TERIPARATIDE	targetBased	3	Completed	01/04/2011	https://clinicaltrials.gov/study/NCT01343004	0.7	GoF	protect
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	PTH1R	Parathyroid hormone/parathyroid hormone-related peptide receptor	postmenopausal osteoporosis	TERIPARATIDE	targetBased	4	Completed	01/10/2012	https://clinicaltrials.gov/study/NCT01709110	1	GoF	protect
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	PTH1R	Parathyroid hormone/parathyroid hormone-related peptide receptor	postmenopausal osteoporosis	TERIPARATIDE	targetBased	3	Completed		https://clinicaltrials.gov/study/NCT00046137	0.7	GoF	protect
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	PTH1R	Parathyroid hormone/parathyroid hormone-related peptide receptor	postmenopausal osteoporosis	TERIPARATIDE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/teriparatide-sun	1	GoF	protect
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	PTH1R	Parathyroid hormone/parathyroid hormone-related peptide receptor	postmenopausal osteoporosis	TERIPARATIDE	targetBased	3	Completed	01/06/2003	https://clinicaltrials.gov/study/NCT00543023	0.7	GoF	protect
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	PTH1R	Parathyroid hormone/parathyroid hormone-related peptide receptor	postmenopausal osteoporosis	TERIPARATIDE	targetBased	3	Completed	01/08/1996	https://clinicaltrials.gov/study/NCT00670501	0.7	GoF	protect
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	PTH1R	Parathyroid hormone/parathyroid hormone-related peptide receptor	postmenopausal osteoporosis	TERIPARATIDE	targetBased	4	Completed	01/08/2002	https://clinicaltrials.gov/study/NCT00191425	1	GoF	protect
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	PTH1R	Parathyroid hormone/parathyroid hormone-related peptide receptor	hip fracture	TERIPARATIDE	targetBased	3	Unknown status	17/05/2017	https://clinicaltrials.gov/study/NCT03133195	0.7	GoF	protect
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	PTH1R	Parathyroid hormone/parathyroid hormone-related peptide receptor	osteoporosis	TERIPARATIDE	targetBased	4	Completed	01/05/2011	https://clinicaltrials.gov/study/NCT01360424	1	GoF	protect
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	PTH1R	Parathyroid hormone/parathyroid hormone-related peptide receptor	osteoporosis	TERIPARATIDE	targetBased	3	Completed	01/04/2011	https://clinicaltrials.gov/study/NCT01343004	0.7	GoF	protect
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	PTH1R	Parathyroid hormone/parathyroid hormone-related peptide receptor	osteoporosis	TERIPARATIDE	targetBased	3	Completed	01/12/2006	https://clinicaltrials.gov/study/NCT00439244	0.7	GoF	protect
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	PTH1R	Parathyroid hormone/parathyroid hormone-related peptide receptor	osteoporosis	TERIPARATIDE	targetBased	4	Completed	01/11/2005	https://clinicaltrials.gov/study/NCT00259298	1	GoF	protect
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	PTH1R	Parathyroid hormone/parathyroid hormone-related peptide receptor	osteoporosis	TERIPARATIDE	targetBased	3	Completed	01/11/2002	https://clinicaltrials.gov/study/NCT00051558	0.7	GoF	protect
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	PTH1R	Parathyroid hormone/parathyroid hormone-related peptide receptor	osteoporosis	TERIPARATIDE	targetBased	3	Completed	01/12/2003	https://clinicaltrials.gov/study/NCT00065637	0.7	GoF	protect
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	PTH1R	Parathyroid hormone/parathyroid hormone-related peptide receptor	osteoporosis	TERIPARATIDE	targetBased	3	Completed	01/01/2008	https://clinicaltrials.gov/study/NCT00577863	0.7	GoF	protect
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	PTH1R	Parathyroid hormone/parathyroid hormone-related peptide receptor	osteoporosis	TERIPARATIDE	targetBased	4	Completed	01/04/2009	https://clinicaltrials.gov/study/NCT00887354	1	GoF	protect
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	PTH1R	Parathyroid hormone/parathyroid hormone-related peptide receptor	osteoporosis	TERIPARATIDE	targetBased	2	Completed	01/04/2008	https://clinicaltrials.gov/study/NCT00535860	0.2	GoF	protect
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	PTH1R	Parathyroid hormone/parathyroid hormone-related peptide receptor	osteoporosis	TERIPARATIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1b007339-dd0d-f019-5e0a-9b1b0f75011c	1	GoF	protect
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	PTH1R	Parathyroid hormone/parathyroid hormone-related peptide receptor	osteoporosis	TERIPARATIDE	targetBased	4	Completed	01/07/2008	https://clinicaltrials.gov/study/NCT01153425	1	GoF	protect
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	PTH1R	Parathyroid hormone/parathyroid hormone-related peptide receptor	osteoporosis	TERIPARATIDE	targetBased	3	Completed	01/12/2016	https://clinicaltrials.gov/study/NCT03002428	0.7	GoF	protect
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	PTH1R	Parathyroid hormone/parathyroid hormone-related peptide receptor	osteoporosis	TERIPARATIDE	targetBased	4	Completed	01/03/2006	https://clinicaltrials.gov/study/NCT01535027	1	GoF	protect
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	PTH1R	Parathyroid hormone/parathyroid hormone-related peptide receptor	osteoporosis	TERIPARATIDE	targetBased	3	Completed	01/09/2003	https://clinicaltrials.gov/study/NCT00191893	0.7	GoF	protect
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	PTH1R	Parathyroid hormone/parathyroid hormone-related peptide receptor	osteoporosis	TERIPARATIDE	targetBased	4	Recruiting	01/07/2019	https://clinicaltrials.gov/study/NCT03994172	1	GoF	protect
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	PTH1R	Parathyroid hormone/parathyroid hormone-related peptide receptor	osteoporosis	TERIPARATIDE	targetBased	3	Completed	01/01/2007	https://clinicaltrials.gov/study/NCT00433160	0.7	GoF	protect
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	PTH1R	Parathyroid hormone/parathyroid hormone-related peptide receptor	osteoporosis	TERIPARATIDE	targetBased	2	Completed	01/02/2005	https://clinicaltrials.gov/study/NCT00191867	0.2	GoF	protect
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	PTH1R	Parathyroid hormone/parathyroid hormone-related peptide receptor	osteoporosis	TERIPARATIDE	targetBased	4	Completed	01/08/2011	https://clinicaltrials.gov/study/NCT01430104	1	GoF	protect
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	PTH1R	Parathyroid hormone/parathyroid hormone-related peptide receptor	osteoporosis	TERIPARATIDE	targetBased	4	Completed	01/01/2011	https://clinicaltrials.gov/study/NCT01293292	1	GoF	protect
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	PTH1R	Parathyroid hormone/parathyroid hormone-related peptide receptor	osteoporosis	TERIPARATIDE	targetBased	2	Completed	01/06/2009	https://clinicaltrials.gov/study/NCT00926380	0.2	GoF	protect
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	PTH1R	Parathyroid hormone/parathyroid hormone-related peptide receptor	osteoporosis	TERIPARATIDE	targetBased	3	Completed	01/07/2007	https://clinicaltrials.gov/study/NCT00503399	0.7	GoF	protect
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	PTH1R	Parathyroid hormone/parathyroid hormone-related peptide receptor	osteoporosis	TERIPARATIDE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/teriparatide-sun	1	GoF	protect
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	PTH1R	Parathyroid hormone/parathyroid hormone-related peptide receptor	osteoporosis	TERIPARATIDE	targetBased	2	Completed	02/08/2012	https://clinicaltrials.gov/study/NCT01440803	0.2	GoF	protect
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	PTH1R	Parathyroid hormone/parathyroid hormone-related peptide receptor	osteoporosis	TERIPARATIDE	targetBased	2	Completed	01/11/2009	https://clinicaltrials.gov/study/NCT01011556	0.2	GoF	protect
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	PTH1R	Parathyroid hormone/parathyroid hormone-related peptide receptor	osteoporosis	TERIPARATIDE	targetBased	4	Completed	01/04/2001	https://clinicaltrials.gov/study/NCT02416271	1	GoF	protect
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	PTH1R	Parathyroid hormone/parathyroid hormone-related peptide receptor	osteoporosis	TERIPARATIDE	targetBased	2	Completed	01/09/1987	https://clinicaltrials.gov/study/NCT00005006	0.2	GoF	protect
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	PTH1R	Parathyroid hormone/parathyroid hormone-related peptide receptor	osteoporosis	TERIPARATIDE	targetBased	4	Unknown status	01/05/2014	https://clinicaltrials.gov/study/NCT02156960	1	GoF	protect
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	PTH1R	Parathyroid hormone/parathyroid hormone-related peptide receptor	osteoporosis	TERIPARATIDE	targetBased	4	Recruiting	21/03/2022	https://clinicaltrials.gov/study/NCT05151484	1	GoF	protect
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	PTH1R	Parathyroid hormone/parathyroid hormone-related peptide receptor	osteoporosis	TERIPARATIDE	targetBased	2	Unknown status	01/09/2005	https://clinicaltrials.gov/study/NCT00668941	0.2	GoF	protect
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	PTH1R	Parathyroid hormone/parathyroid hormone-related peptide receptor	osteoporosis	TERIPARATIDE	targetBased	4	Completed	01/01/2013	https://clinicaltrials.gov/study/NCT01753856	1	GoF	protect
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	PTH1R	Parathyroid hormone/parathyroid hormone-related peptide receptor	osteoporosis	TERIPARATIDE	targetBased	2	Completed	01/04/2007	https://clinicaltrials.gov/study/NCT00542425	0.2	GoF	protect
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	PTH1R	Parathyroid hormone/parathyroid hormone-related peptide receptor	osteoporosis	TERIPARATIDE	targetBased	3	Completed	01/12/2006	https://clinicaltrials.gov/study/NCT00414973	0.7	GoF	protect
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	PTH1R	Parathyroid hormone/parathyroid hormone-related peptide receptor	osteoporosis	TERIPARATIDE	targetBased	2	Completed	01/06/2007	https://clinicaltrials.gov/study/NCT00489918	0.2	GoF	protect
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	PTH1R	Parathyroid hormone/parathyroid hormone-related peptide receptor	osteoporosis	TERIPARATIDE	targetBased	4	Enrolling by invitation	01/02/2024	https://clinicaltrials.gov/study/NCT06264609	1	GoF	protect
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	PTH1R	Parathyroid hormone/parathyroid hormone-related peptide receptor	osteoporosis	TERIPARATIDE	targetBased	3	Completed	01/09/2003	https://clinicaltrials.gov/study/NCT00191802	0.7	GoF	protect
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	PTH1R	Parathyroid hormone/parathyroid hormone-related peptide receptor	osteoporosis	TERIPARATIDE	targetBased	4	Terminated	01/07/2006	https://clinicaltrials.gov/study/NCT00446589	1	GoF	protect	due to financial problems
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	PTH1R	Parathyroid hormone/parathyroid hormone-related peptide receptor	osteoporosis	TERIPARATIDE	targetBased	3	Completed	01/07/2004	https://clinicaltrials.gov/study/NCT00191321	0.7	GoF	protect
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	PTH1R	Parathyroid hormone/parathyroid hormone-related peptide receptor	osteoporosis	TERIPARATIDE	targetBased	4	Completed	01/09/2010	https://clinicaltrials.gov/study/NCT01166958	1	GoF	protect
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	PTH1R	Parathyroid hormone/parathyroid hormone-related peptide receptor	osteoporosis	TERIPARATIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aae667c5-381f-4f92-93df-2ed6158d07b0	1	GoF	protect
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	PTH1R	Parathyroid hormone/parathyroid hormone-related peptide receptor	osteoporosis	TERIPARATIDE	targetBased	3	Completed	01/12/2003	https://clinicaltrials.gov/study/NCT01611571	0.7	GoF	protect
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	PTH1R	Parathyroid hormone/parathyroid hormone-related peptide receptor	osteoarthritis, knee	TERIPARATIDE	targetBased	2	Completed	01/02/2010	https://clinicaltrials.gov/study/NCT01063504	0.2	GoF	protect
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	PTH1R	Parathyroid hormone/parathyroid hormone-related peptide receptor	osteoarthritis, knee	TERIPARATIDE	targetBased	2	Completed	01/05/2017	https://clinicaltrials.gov/study/NCT03072147	0.2	GoF	protect
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	PTH1R	Parathyroid hormone/parathyroid hormone-related peptide receptor	bone fracture	TERIPARATIDE	targetBased	3	Completed	01/02/2012	https://clinicaltrials.gov/study/NCT01473589	0.7	GoF	protect
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	PTH1R	Parathyroid hormone/parathyroid hormone-related peptide receptor	bone fracture	TERIPARATIDE	targetBased	3	Recruiting	23/12/2019	https://clinicaltrials.gov/study/NCT04196855	0.7	GoF	protect
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	PTH1R	Parathyroid hormone/parathyroid hormone-related peptide receptor	bone fracture	TERIPARATIDE	targetBased	3	Completed	24/05/2021	https://clinicaltrials.gov/study/NCT04921124	0.7	GoF	protect
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	PTH1R	Parathyroid hormone/parathyroid hormone-related peptide receptor	bone fracture	TERIPARATIDE	targetBased	3	Completed	01/01/2012	https://clinicaltrials.gov/study/NCT01473602	0.7	GoF	protect
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	PTH1R	Parathyroid hormone/parathyroid hormone-related peptide receptor	bone fracture	TERIPARATIDE	targetBased	4	Unknown status	01/10/2016	https://clinicaltrials.gov/study/NCT02955056	1	GoF	protect
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	PTH1R	Parathyroid hormone/parathyroid hormone-related peptide receptor	bone fracture	TERIPARATIDE	targetBased	4	Enrolling by invitation	08/12/2022	https://clinicaltrials.gov/study/NCT04589819	1	GoF	protect
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	PTH1R	Parathyroid hormone/parathyroid hormone-related peptide receptor	bone fracture	TERIPARATIDE	targetBased	3	Completed	01/07/2013	https://clinicaltrials.gov/study/NCT01896011	0.7	GoF	protect
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	PTH1R	Parathyroid hormone/parathyroid hormone-related peptide receptor	bone fracture	TERIPARATIDE	targetBased	4	Not yet recruiting	01/10/2020	https://clinicaltrials.gov/study/NCT04533984	1	GoF	protect
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	PTH1R	Parathyroid hormone/parathyroid hormone-related peptide receptor	bone fracture	TERIPARATIDE	targetBased	4	Unknown status	01/07/2010	https://clinicaltrials.gov/study/NCT01173081	1	GoF	protect
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	PTH1R	Parathyroid hormone/parathyroid hormone-related peptide receptor	humerus fracture	TERIPARATIDE	targetBased	4	Completed	01/04/2010	https://clinicaltrials.gov/study/NCT01105832	1	GoF	protect
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	PTH1R	Parathyroid hormone/parathyroid hormone-related peptide receptor	Osteopenia	TERIPARATIDE	targetBased	3	Completed	01/12/2003	https://clinicaltrials.gov/study/NCT00065637	0.7	GoF	protect
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	PTH1R	Parathyroid hormone/parathyroid hormone-related peptide receptor	spinal stenosis	TERIPARATIDE	targetBased	4	Completed	01/08/2012	https://clinicaltrials.gov/study/NCT02090244	1	GoF	protect
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	PTH1R	Parathyroid hormone/parathyroid hormone-related peptide receptor	neurogenic arthropathy	TERIPARATIDE	targetBased	2	Completed	01/01/2014	https://clinicaltrials.gov/study/NCT02023411	0.2	GoF	protect
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	PTH1R	Parathyroid hormone/parathyroid hormone-related peptide receptor	osteogenesis imperfecta	TERIPARATIDE	targetBased	2	Terminated	01/11/2012	https://clinicaltrials.gov/study/NCT01679080	0.2	GoF	protect	Eli Lilly has withdrawn support to the study of teriparatide and placebo pens. The study was not able to continue as a randomized study without the supply of placebo pens.
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	PTH1R	Parathyroid hormone/parathyroid hormone-related peptide receptor	osteogenesis imperfecta	TERIPARATIDE	targetBased	4	Completed	01/06/2005	https://clinicaltrials.gov/study/NCT00131469	1	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	systemic lupus erythematosus	HYDROXYCHLOROQUINE SULFATE	targetBased	3	Completed	01/03/2012	https://clinicaltrials.gov/study/NCT01551069	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	systemic lupus erythematosus	HYDROXYCHLOROQUINE SULFATE	targetBased	2	Terminated	20/11/2013	https://clinicaltrials.gov/study/NCT01946880	0.2	LoF	protect	Slow enrollment.
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	cutaneous lupus erythematosus	HYDROXYCHLOROQUINE SULFATE	targetBased	3	Completed	01/03/2012	https://clinicaltrials.gov/study/NCT01551069	0.7	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		systemic lupus erythematosus	MEMANTINE HYDROCHLORIDE	targetBased	2	Recruiting	23/08/2018	https://clinicaltrials.gov/study/NCT03527472	0.2	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		sickle cell anemia	MEMANTINE HYDROCHLORIDE	targetBased	2	Recruiting	02/02/2018	https://clinicaltrials.gov/study/NCT03247218	0.2	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		idiopathic scoliosis	KETAMINE HYDROCHLORIDE	targetBased	2	Completed	01/01/2012	https://clinicaltrials.gov/study/NCT02571491	0.2	LoF	protect
uHTS identification of small molecule modulators of NR3A	GRIN3A	GRIN3A		bone fracture	KETAMINE HYDROCHLORIDE	targetBased	3	Completed	05/07/2018	https://clinicaltrials.gov/study/NCT03525821	0.7	LoF	protect
Inhibitors of the EP2 Prostaglandin E2 Receptor - Primary Screen	PTGER2	PTGER2	Prostaglandin E2 receptor EP2 subtype	tibia fracture	EVATANEPAG	targetBased	2	Completed	01/01/2008	https://clinicaltrials.gov/study/NCT00533377	0.2	GoF	protect
Modulators of the EP2 prostaglandin E2 receptor - Primary Screening	PTGER2	PTGER2	Prostaglandin E2 receptor EP2 subtype	tibia fracture	EVATANEPAG	targetBased	2	Completed	01/01/2008	https://clinicaltrials.gov/study/NCT00533377	0.2	GoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	spindle cell rhabdomyosarcoma	VINORELBINE	targetBased	3	Active, not recruiting	01/06/2016	https://clinicaltrials.gov/study/NCT02567435	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	spindle cell rhabdomyosarcoma	VINORELBINE	targetBased	3	Recruiting	14/09/2021	https://clinicaltrials.gov/study/NCT04994132	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	childhood pleomorphic rhabdomyosarcoma	VINORELBINE	targetBased	2	Completed	01/10/2010	https://clinicaltrials.gov/study/NCT01222715	0.2	LoF	protect
Thrombin 1536 HTS	F2_modulation	F2	Prothrombin	total joint arthroplasty	DABIGATRAN ETEXILATE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/pradaxa	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	spindle cell rhabdomyosarcoma	VINORELBINE TARTRATE	targetBased	3	Recruiting	14/09/2021	https://clinicaltrials.gov/study/NCT04994132	0.7	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	childhood pleomorphic rhabdomyosarcoma	VINORELBINE TARTRATE	targetBased	2	Completed	01/10/2010	https://clinicaltrials.gov/study/NCT01222715	0.2	LoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	osteoporosis	DP001	targetBased	2	Completed	01/03/2007	https://clinicaltrials.gov/study/NCT00715676	0.2	GoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	myelofibrosis	MOMELOTINIB	targetBased	3	Completed	06/12/2013	https://clinicaltrials.gov/study/NCT01969838	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	myelofibrosis	MOMELOTINIB	targetBased	2	Completed	30/04/2014	https://clinicaltrials.gov/study/NCT02124746	0.2	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	myelofibrosis	MOMELOTINIB	targetBased	2	Completed	01/11/2010	https://clinicaltrials.gov/study/NCT01236638	0.2	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	myelofibrosis	MOMELOTINIB	targetBased	3	Completed	19/06/2014	https://clinicaltrials.gov/study/NCT02101268	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	Chagas cardiomyopathy	AMIODARONE HYDROCHLORIDE	targetBased	3	Unknown status	12/06/2017	https://clinicaltrials.gov/study/NCT03193749	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	Chagas cardiomyopathy	AMIODARONE HYDROCHLORIDE	targetBased	3	Unknown status	12/06/2017	https://clinicaltrials.gov/study/NCT03193749	0.7	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	Chagas cardiomyopathy	AMIODARONE HYDROCHLORIDE	targetBased	3	Unknown status	12/06/2017	https://clinicaltrials.gov/study/NCT03193749	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	AL amyloidosis	AMIODARONE HYDROCHLORIDE	targetBased	2	Terminated	01/01/2012	https://clinicaltrials.gov/study/NCT01511263	0.2	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	AL amyloidosis	AMIODARONE HYDROCHLORIDE	targetBased	2	Terminated	01/01/2012	https://clinicaltrials.gov/study/NCT01511263	0.2	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	AL amyloidosis	AMIODARONE HYDROCHLORIDE	targetBased	2	Terminated	01/01/2012	https://clinicaltrials.gov/study/NCT01511263	0.2	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	osteoarthritis	AMLODIPINE BESYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=322f926c-99ac-49f8-9cc5-584594f2891f	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Muscle spasm	CYCLOBENZAPRINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ec636fad-9537-4001-a691-c7b4cc2b6a96	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Muscle spasm	CYCLOBENZAPRINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=0038f081-a867-43ed-8415-9f0003871291	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Muscle spasm	CYCLOBENZAPRINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=06da53af-5b46-4e32-a64c-9677e27ae229	1	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	bone fracture	TOREMIFENE CITRATE	targetBased	3	Completed	01/10/2003	https://clinicaltrials.gov/study/NCT00129142	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	bone fracture	TOREMIFENE CITRATE	targetBased	3	Completed	01/10/2003	https://clinicaltrials.gov/study/NCT00129142	0.7		protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	osteoporosis	TOREMIFENE CITRATE	targetBased	3	Completed	01/10/2003	https://clinicaltrials.gov/study/NCT00129142	0.7		protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	bone fracture	TOREMIFENE CITRATE	targetBased	3	Completed	01/10/2003	https://clinicaltrials.gov/study/NCT00129142	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	osteoporosis	TOREMIFENE CITRATE	targetBased	3	Completed	01/10/2003	https://clinicaltrials.gov/study/NCT00129142	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	osteoporosis	TOREMIFENE CITRATE	targetBased	3	Completed	01/10/2003	https://clinicaltrials.gov/study/NCT00129142	0.7		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	Potassium channel subfamily K member 3	osteoarthritis	SEVOFLURANE	targetBased	4	Completed	01/09/2016	https://clinicaltrials.gov/study/NCT03540030	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	two-pore domain potassium channel	osteoarthritis	SEVOFLURANE	targetBased	4	Completed	01/09/2016	https://clinicaltrials.gov/study/NCT03540030	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	two-pore domain potassium channel	sinusitis	SEVOFLURANE	targetBased	4	Completed	01/07/2015	https://clinicaltrials.gov/study/NCT02578862	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	Potassium channel subfamily K member 3	bone fracture	SEVOFLURANE	targetBased	4	Completed	01/11/2015	https://clinicaltrials.gov/study/NCT02621255	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	Potassium channel subfamily K member 3	avascular necrosis	SEVOFLURANE	targetBased	4	Completed	01/09/2016	https://clinicaltrials.gov/study/NCT03540030	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	two-pore domain potassium channel	rotator cuff tear	SEVOFLURANE	targetBased	4	Completed	01/09/2016	https://clinicaltrials.gov/study/NCT03540030	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	two-pore domain potassium channel	bone fracture	SEVOFLURANE	targetBased	4	Completed	01/11/2015	https://clinicaltrials.gov/study/NCT02621255	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	Potassium channel subfamily K member 3	rotator cuff tear	SEVOFLURANE	targetBased	4	Completed	01/09/2016	https://clinicaltrials.gov/study/NCT03540030	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	two-pore domain potassium channel	avascular necrosis	SEVOFLURANE	targetBased	4	Completed	01/09/2016	https://clinicaltrials.gov/study/NCT03540030	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	Potassium channel subfamily K member 3	sinusitis	SEVOFLURANE	targetBased	4	Completed	01/07/2015	https://clinicaltrials.gov/study/NCT02578862	1		protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	Muscle weakness	GUANIDINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=903fbd33-e5d9-41fb-9414-7bd6f42a8593	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	Muscle weakness	GUANIDINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=903fbd33-e5d9-41fb-9414-7bd6f42a8593	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	Muscle weakness	GUANIDINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=903fbd33-e5d9-41fb-9414-7bd6f42a8593	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	Muscle weakness	GUANIDINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=903fbd33-e5d9-41fb-9414-7bd6f42a8593	1	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	Muscle weakness	GUANIDINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=903fbd33-e5d9-41fb-9414-7bd6f42a8593	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	Muscle weakness	GUANIDINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=903fbd33-e5d9-41fb-9414-7bd6f42a8593	1	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	Muscle weakness	GUANIDINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=903fbd33-e5d9-41fb-9414-7bd6f42a8593	1	LoF	protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	Potassium channel subfamily K member 3	osteoarthritis	DESFLURANE	targetBased	4	Completed	01/09/2016	https://clinicaltrials.gov/study/NCT03540030	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	two-pore domain potassium channel	osteoarthritis	DESFLURANE	targetBased	4	Completed	01/09/2016	https://clinicaltrials.gov/study/NCT03540030	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	Potassium channel subfamily K member 3	avascular necrosis	DESFLURANE	targetBased	4	Completed	01/09/2016	https://clinicaltrials.gov/study/NCT03540030	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	two-pore domain potassium channel	rotator cuff tear	DESFLURANE	targetBased	4	Completed	01/09/2016	https://clinicaltrials.gov/study/NCT03540030	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	KCNK3	Potassium channel subfamily K member 3	rotator cuff tear	DESFLURANE	targetBased	4	Completed	01/09/2016	https://clinicaltrials.gov/study/NCT03540030	1		protect
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	KCNK9	two-pore domain potassium channel	avascular necrosis	DESFLURANE	targetBased	4	Completed	01/09/2016	https://clinicaltrials.gov/study/NCT03540030	1		protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	spinal stenosis	OXYMORPHONE HYDROCHLORIDE	targetBased	4	Terminated	01/03/2008	https://clinicaltrials.gov/study/NCT00652093	1	GoF	protect	Removal of Darvocet from US market
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	spinal stenosis	OXYMORPHONE HYDROCHLORIDE	targetBased	4	Terminated	01/03/2008	https://clinicaltrials.gov/study/NCT00652093	1	GoF	protect	Removal of Darvocet from US market
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	spinal stenosis	OXYMORPHONE HYDROCHLORIDE	targetBased	4	Terminated	01/03/2008	https://clinicaltrials.gov/study/NCT00652093	1	GoF	protect	Removal of Darvocet from US market
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	idiopathic scoliosis	METHADONE HYDROCHLORIDE	targetBased	2	Completed	01/09/2013	https://clinicaltrials.gov/study/NCT01795495	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	idiopathic scoliosis	METHADONE HYDROCHLORIDE	targetBased	2	Completed	01/09/2013	https://clinicaltrials.gov/study/NCT01795495	0.2	GoF	protect
qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium	IMPA1	IMPA1	Inositol monophosphatase 1	spinal cord injury	LITHIUM CARBONATE	targetBased	2	Completed	01/08/2008	https://clinicaltrials.gov/study/NCT00750061	0.2	LoF	protect
qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium	IMPA1	IMPA1	Inositol monophosphatase 1	bone fracture	LITHIUM CARBONATE	targetBased	2	Recruiting	21/07/2017	https://clinicaltrials.gov/study/NCT02999022	0.2	LoF	protect
Luminescence Cell-Free Homogenous Primary HTS to Identify Inhibitors of GSK-3 alpha	GSK3A	GSK3A	Glycogen synthase kinase-3 alpha	spinal cord injury	LITHIUM CARBONATE	targetBased	2	Completed	01/08/2008	https://clinicaltrials.gov/study/NCT00750061	0.2	LoF	protect
Luminescence Cell-Free Homogenous Primary HTS to Identify Inhibitors of GSK-3 alpha	GSK3A	GSK3A	Glycogen synthase kinase-3 alpha	bone fracture	LITHIUM CARBONATE	targetBased	2	Recruiting	21/07/2017	https://clinicaltrials.gov/study/NCT02999022	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis, hip	OXYCODONE HYDROCHLORIDE	targetBased	3	Completed		https://clinicaltrials.gov/study/NCT00399048	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis, hip	OXYCODONE HYDROCHLORIDE	targetBased	3	Completed		https://clinicaltrials.gov/study/NCT00399048	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	bone fracture	OXYCODONE HYDROCHLORIDE	targetBased	4	Completed	01/04/2007	https://clinicaltrials.gov/study/NCT00254631	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	bone fracture	OXYCODONE HYDROCHLORIDE	targetBased	4	Completed	01/04/2007	https://clinicaltrials.gov/study/NCT00254631	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis, knee	OXYCODONE HYDROCHLORIDE	targetBased	3	Completed		https://clinicaltrials.gov/study/NCT00399048	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis, knee	OXYCODONE HYDROCHLORIDE	targetBased	3	Completed		https://clinicaltrials.gov/study/NCT00399048	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis, knee	OXYCODONE HYDROCHLORIDE	targetBased	2	Completed	01/06/2011	https://clinicaltrials.gov/study/NCT01366014	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis, knee	OXYCODONE HYDROCHLORIDE	targetBased	2	Completed	01/06/2011	https://clinicaltrials.gov/study/NCT01366014	0.2	GoF	protect
qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS	TXNRD1	TXNRD1	Thioredoxin reductase 1, cytoplasmic	systemic lupus erythematosus	ARSENIC TRIOXIDE	targetBased	2	Terminated	01/07/2013	https://clinicaltrials.gov/study/NCT01738360	0.2	LoF	protect	Difficulty of inclusions and a sufficient number of relevant clinical information
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	osteoporosis	ESTROPIPATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=03cdbf5b-b572-448f-80e9-b3e812959901	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	osteoporosis	ESTROPIPATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=03cdbf5b-b572-448f-80e9-b3e812959901	1	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	lower extremity fracture	GLYCOPYRROLATE	targetBased	4	Unknown status	15/09/2017	https://clinicaltrials.gov/study/NCT03580889	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	lower extremity fracture	GLYCOPYRROLATE	targetBased	4	Unknown status	15/09/2017	https://clinicaltrials.gov/study/NCT03580889	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	lower extremity fracture	GLYCOPYRROLATE	targetBased	4	Unknown status	15/09/2017	https://clinicaltrials.gov/study/NCT03580889	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	lower extremity fracture	GLYCOPYRROLATE	targetBased	4	Unknown status	15/09/2017	https://clinicaltrials.gov/study/NCT03580889	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	lower extremity fracture	GLYCOPYRROLATE	targetBased	4	Unknown status	15/09/2017	https://clinicaltrials.gov/study/NCT03580889	1	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	Sciatica	CODEINE PHOSPHATE	targetBased	3	Completed	28/09/2021	https://clinicaltrials.gov/study/NCT05626140	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Sciatica	CODEINE PHOSPHATE	targetBased	3	Completed	28/09/2021	https://clinicaltrials.gov/study/NCT05626140	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Sciatica	CODEINE PHOSPHATE	targetBased	3	Completed	28/09/2021	https://clinicaltrials.gov/study/NCT05626140	0.7	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	Muscle spasm	CODEINE PHOSPHATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=03cdc2f8-78d1-11dc-8314-0800200c9a66	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Muscle spasm	CODEINE PHOSPHATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=03cdc2f8-78d1-11dc-8314-0800200c9a66	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Muscle spasm	CODEINE PHOSPHATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=03cdc2f8-78d1-11dc-8314-0800200c9a66	1	GoF	protect
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	DNA methyltransferase-1	myelofibrosis	DECITABINE	targetBased	2	Terminated	01/03/2008	https://clinicaltrials.gov/study/NCT00630994	0.2	LoF	protect	Stopped due to slow accrual
uHTS identification of DNMT1 inhibitors in a Fluorescent Molecular Beacon assay	DNMT1	DNMT1	DNA methyltransferase-1	sickle cell anemia	DECITABINE	targetBased	2	Recruiting	07/07/2022	https://clinicaltrials.gov/study/NCT05405114	0.2	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	rotator cuff tear	NALBUPHINE HYDROCHLORIDE	targetBased	2	Unknown status	01/01/2016	https://clinicaltrials.gov/study/NCT03034382	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	rotator cuff tear	NALBUPHINE HYDROCHLORIDE	targetBased	2	Unknown status	01/01/2016	https://clinicaltrials.gov/study/NCT03034382	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	rotator cuff tear	NALBUPHINE HYDROCHLORIDE	targetBased	2	Unknown status	01/01/2016	https://clinicaltrials.gov/study/NCT03034382	0.2	GoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	fibromyalgia	ARMODAFINIL	targetBased	4	Completed	01/08/2007	https://clinicaltrials.gov/study/NCT00678691	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	temporomandibular joint disorder	BENZTROPINE	targetBased	2	Completed	01/11/2002	https://clinicaltrials.gov/study/NCT00066937	0.2	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	temporomandibular joint disorder	BENZTROPINE	targetBased	2	Completed	01/11/2002	https://clinicaltrials.gov/study/NCT00066937	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	temporomandibular joint disorder	BENZTROPINE	targetBased	2	Completed	01/11/2002	https://clinicaltrials.gov/study/NCT00066937	0.2	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	temporomandibular joint disorder	BENZTROPINE	targetBased	2	Completed	01/11/2002	https://clinicaltrials.gov/study/NCT00066937	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	temporomandibular joint disorder	BENZTROPINE	targetBased	2	Completed	01/11/2002	https://clinicaltrials.gov/study/NCT00066937	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	Sciatica	BENZTROPINE	targetBased	2	Completed	01/04/1999	https://clinicaltrials.gov/study/NCT00018200	0.2	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	Sciatica	BENZTROPINE	targetBased	2	Completed	01/04/1999	https://clinicaltrials.gov/study/NCT00018200	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	Sciatica	BENZTROPINE	targetBased	2	Completed	01/04/1999	https://clinicaltrials.gov/study/NCT00018200	0.2	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	Sciatica	BENZTROPINE	targetBased	2	Completed	01/04/1999	https://clinicaltrials.gov/study/NCT00018200	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	Sciatica	BENZTROPINE	targetBased	2	Completed	01/04/1999	https://clinicaltrials.gov/study/NCT00018200	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	lower extremity fracture	GLYCOPYRRONIUM	targetBased	4	Unknown status	15/09/2017	https://clinicaltrials.gov/study/NCT03580889	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	lower extremity fracture	GLYCOPYRRONIUM	targetBased	4	Unknown status	15/09/2017	https://clinicaltrials.gov/study/NCT03580889	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	lower extremity fracture	GLYCOPYRRONIUM	targetBased	4	Unknown status	15/09/2017	https://clinicaltrials.gov/study/NCT03580889	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	CHRM4	Muscarinic acetylcholine receptor M4	lower extremity fracture	GLYCOPYRRONIUM	targetBased	4	Unknown status	15/09/2017	https://clinicaltrials.gov/study/NCT03580889	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	CHRM4	Muscarinic acetylcholine receptor M4	lower extremity fracture	GLYCOPYRRONIUM	targetBased	4	Unknown status	15/09/2017	https://clinicaltrials.gov/study/NCT03580889	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	CHRM4	Muscarinic acetylcholine receptor M4	lower extremity fracture	GLYCOPYRRONIUM	targetBased	4	Unknown status	15/09/2017	https://clinicaltrials.gov/study/NCT03580889	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	lower extremity fracture	GLYCOPYRRONIUM	targetBased	4	Unknown status	15/09/2017	https://clinicaltrials.gov/study/NCT03580889	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	lower extremity fracture	GLYCOPYRRONIUM	targetBased	4	Unknown status	15/09/2017	https://clinicaltrials.gov/study/NCT03580889	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	lower extremity fracture	GLYCOPYRRONIUM	targetBased	4	Unknown status	15/09/2017	https://clinicaltrials.gov/study/NCT03580889	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	lower extremity fracture	GLYCOPYRRONIUM	targetBased	4	Unknown status	15/09/2017	https://clinicaltrials.gov/study/NCT03580889	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	lower extremity fracture	GLYCOPYRRONIUM	targetBased	4	Unknown status	15/09/2017	https://clinicaltrials.gov/study/NCT03580889	1	LoF	protect
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	PTH1R	Parathyroid hormone/parathyroid hormone-related peptide receptor	postmenopausal osteoporosis	TERIPARATIDE ACETATE	targetBased	2	Completed	01/11/1998	https://clinicaltrials.gov/study/NCT00018447	0.2	GoF	protect
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	PTH1R	Parathyroid hormone/parathyroid hormone-related peptide receptor	postmenopausal osteoporosis	TERIPARATIDE ACETATE	targetBased	2	Completed	01/05/2004	https://clinicaltrials.gov/study/NCT00086619	0.2	GoF	protect
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	PTH1R	Parathyroid hormone/parathyroid hormone-related peptide receptor	osteoporosis	TERIPARATIDE ACETATE	targetBased	2	Completed	01/05/2004	https://clinicaltrials.gov/study/NCT00086619	0.2	GoF	protect
Natriuretic polypeptide receptor (hNpr1) antagonism - Primary qHTS	NPR1	NPR1	Atrial natriuretic peptide receptor 1	cardiomyopathy	NESIRITIDE	targetBased	3	Completed	01/01/2001	https://clinicaltrials.gov/study/NCT00270387	0.7	GoF	protect
HTS for developing T Cell Immune Modulators	ITGAL	ITGAL	Integrin alpha L, Integrin alpha-L , VWFA domain-containing protein	lupus erythematosus	EFALIZUMAB	targetBased	2	Withdrawn	01/03/2006	https://clinicaltrials.gov/study/NCT00308204	0.2	LoF	protect	inadequate number of enrolled study subjects
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	interstitial cystitis	ESTROGENS, CONJUGATED	targetBased	3	Recruiting	01/12/2022	https://clinicaltrials.gov/study/NCT05658874	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	interstitial cystitis	ESTROGENS, CONJUGATED	targetBased	3	Recruiting	01/12/2022	https://clinicaltrials.gov/study/NCT05658874	0.7	GoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	Osteopenia	ESTROGENS, CONJUGATED	targetBased	3	Terminated	01/10/1999	https://clinicaltrials.gov/study/NCT00000430	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	postmenopausal osteoporosis	ESTROGENS, CONJUGATED	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bfdd5d5b-7569-4848-afa2-e820fbe3c8fb	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	postmenopausal osteoporosis	ESTROGENS, CONJUGATED	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bfdd5d5b-7569-4848-afa2-e820fbe3c8fb	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	postmenopausal osteoporosis	ESTROGENS, CONJUGATED	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e1b75458-2e5b-46b9-92c6-fa6daba3770f	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	postmenopausal osteoporosis	ESTROGENS, CONJUGATED	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e1b75458-2e5b-46b9-92c6-fa6daba3770f	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	postmenopausal osteoporosis	ESTROGENS, CONJUGATED	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e16705d8-4472-4f83-96ac-69fa2be066cb	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	postmenopausal osteoporosis	ESTROGENS, CONJUGATED	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e16705d8-4472-4f83-96ac-69fa2be066cb	1	GoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	systemic lupus erythematosus	ESTROGENS, CONJUGATED	targetBased	4	Completed	01/11/1997	https://clinicaltrials.gov/study/NCT00392093	1	GoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	systemic lupus erythematosus	ESTROGENS, CONJUGATED	targetBased	3	Terminated	01/04/1996	https://clinicaltrials.gov/study/NCT00000419	0.7	GoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	postmenopausal osteoporosis	ESTROGENS, CONJUGATED	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e1b75458-2e5b-46b9-92c6-fa6daba3770f	1	GoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	postmenopausal osteoporosis	ESTROGENS, CONJUGATED	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bfdd5d5b-7569-4848-afa2-e820fbe3c8fb	1	GoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	postmenopausal osteoporosis	ESTROGENS, CONJUGATED	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e16705d8-4472-4f83-96ac-69fa2be066cb	1	GoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	interstitial cystitis	ESTROGENS, CONJUGATED	targetBased	3	Recruiting	01/12/2022	https://clinicaltrials.gov/study/NCT05658874	0.7	GoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	bone disease	ESTROGENS, CONJUGATED	targetBased	3	Completed	01/09/1987	https://clinicaltrials.gov/study/NCT00000466	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	bone disease	ESTROGENS, CONJUGATED	targetBased	3	Completed	01/09/1987	https://clinicaltrials.gov/study/NCT00000466	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	bone disease	ESTROGENS, CONJUGATED	targetBased	3	Completed	01/09/1987	https://clinicaltrials.gov/study/NCT00000466	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	systemic lupus erythematosus	ESTROGENS, CONJUGATED	targetBased	4	Completed	01/11/1997	https://clinicaltrials.gov/study/NCT00392093	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	systemic lupus erythematosus	ESTROGENS, CONJUGATED	targetBased	4	Completed	01/11/1997	https://clinicaltrials.gov/study/NCT00392093	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	systemic lupus erythematosus	ESTROGENS, CONJUGATED	targetBased	3	Terminated	01/04/1996	https://clinicaltrials.gov/study/NCT00000419	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	systemic lupus erythematosus	ESTROGENS, CONJUGATED	targetBased	3	Terminated	01/04/1996	https://clinicaltrials.gov/study/NCT00000419	0.7	GoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	osteoporosis	ESTROGENS, CONJUGATED	targetBased	3	Completed	01/09/2005	https://clinicaltrials.gov/study/NCT00242710	0.7	GoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	osteoporosis	ESTROGENS, CONJUGATED	targetBased	3	Completed	01/09/1987	https://clinicaltrials.gov/study/NCT00000466	0.7	GoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	osteoporosis	ESTROGENS, CONJUGATED	targetBased	3	Completed		https://clinicaltrials.gov/study/NCT00000611	0.7	GoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	osteoporosis	ESTROGENS, CONJUGATED	targetBased	3	Completed	01/08/1993	https://clinicaltrials.gov/study/NCT00004650	0.7	GoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	osteoporosis	ESTROGENS, CONJUGATED	targetBased	3	Terminated	01/10/1999	https://clinicaltrials.gov/study/NCT00000430	0.7	GoF	protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	osteoporosis	ESTROGENS, CONJUGATED	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=751b6213-92d8-40f8-a2d5-83e8dad086dd	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	Osteopenia	ESTROGENS, CONJUGATED	targetBased	3	Terminated	01/10/1999	https://clinicaltrials.gov/study/NCT00000430	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	Osteopenia	ESTROGENS, CONJUGATED	targetBased	3	Terminated	01/10/1999	https://clinicaltrials.gov/study/NCT00000430	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	osteoporosis	ESTROGENS, CONJUGATED	targetBased	3	Completed	01/09/1987	https://clinicaltrials.gov/study/NCT00000466	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	osteoporosis	ESTROGENS, CONJUGATED	targetBased	3	Completed	01/09/1987	https://clinicaltrials.gov/study/NCT00000466	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	osteoporosis	ESTROGENS, CONJUGATED	targetBased	3	Completed		https://clinicaltrials.gov/study/NCT00000611	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	osteoporosis	ESTROGENS, CONJUGATED	targetBased	3	Completed		https://clinicaltrials.gov/study/NCT00000611	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	osteoporosis	ESTROGENS, CONJUGATED	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=751b6213-92d8-40f8-a2d5-83e8dad086dd	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	osteoporosis	ESTROGENS, CONJUGATED	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=751b6213-92d8-40f8-a2d5-83e8dad086dd	1	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	osteoporosis	ESTROGENS, CONJUGATED	targetBased	3	Completed	01/08/1993	https://clinicaltrials.gov/study/NCT00004650	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	osteoporosis	ESTROGENS, CONJUGATED	targetBased	3	Completed	01/08/1993	https://clinicaltrials.gov/study/NCT00004650	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	osteoporosis	ESTROGENS, CONJUGATED	targetBased	3	Completed	01/09/2005	https://clinicaltrials.gov/study/NCT00242710	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	osteoporosis	ESTROGENS, CONJUGATED	targetBased	3	Completed	01/09/2005	https://clinicaltrials.gov/study/NCT00242710	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	osteoporosis	ESTROGENS, CONJUGATED	targetBased	3	Terminated	01/10/1999	https://clinicaltrials.gov/study/NCT00000430	0.7	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	osteoporosis	ESTROGENS, CONJUGATED	targetBased	3	Terminated	01/10/1999	https://clinicaltrials.gov/study/NCT00000430	0.7	GoF	protect
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	ABL1	Tyrosine-protein kinase ABL1	systemic scleroderma	NILOTINIB HYDROCHLORIDE MONOHYDRATE	targetBased	2	Completed	01/07/2010	https://clinicaltrials.gov/study/NCT01166139	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis, hip	TAPENTADOL	targetBased	3	Completed	01/11/2006	https://clinicaltrials.gov/study/NCT00361504	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis, hip	TAPENTADOL	targetBased	3	Completed	01/11/2006	https://clinicaltrials.gov/study/NCT00361504	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis, hip	TAPENTADOL	targetBased	4	Withdrawn	01/08/2012	https://clinicaltrials.gov/study/NCT01631513	1	GoF	protect	It was a business decision to cancel this study in Aug. 2012.
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis, hip	TAPENTADOL	targetBased	4	Withdrawn	01/08/2012	https://clinicaltrials.gov/study/NCT01631513	1	GoF	protect	It was a business decision to cancel this study in Aug. 2012.
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	joint disease	TAPENTADOL	targetBased	3	Completed	01/09/2015	https://clinicaltrials.gov/study/NCT02604446	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	joint disease	TAPENTADOL	targetBased	3	Completed	01/09/2015	https://clinicaltrials.gov/study/NCT02604446	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	bone fracture	TAPENTADOL	targetBased	4	Completed	05/07/2021	https://clinicaltrials.gov/study/NCT05999890	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	bone fracture	TAPENTADOL	targetBased	4	Completed	05/07/2021	https://clinicaltrials.gov/study/NCT05999890	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis, knee	TAPENTADOL	targetBased	4	Withdrawn	01/08/2012	https://clinicaltrials.gov/study/NCT01631513	1	GoF	protect	It was a business decision to cancel this study in Aug. 2012.
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis, knee	TAPENTADOL	targetBased	4	Withdrawn	01/08/2012	https://clinicaltrials.gov/study/NCT01631513	1	GoF	protect	It was a business decision to cancel this study in Aug. 2012.
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis, knee	TAPENTADOL	targetBased	3	Completed	01/11/2006	https://clinicaltrials.gov/study/NCT00361504	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis, knee	TAPENTADOL	targetBased	3	Completed	01/11/2006	https://clinicaltrials.gov/study/NCT00361504	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis	TAPENTADOL	targetBased	3	Completed	01/10/2008	https://clinicaltrials.gov/study/NCT00784277	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis	TAPENTADOL	targetBased	3	Completed	01/10/2008	https://clinicaltrials.gov/study/NCT00784277	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis, hip	TAPENTADOL HYDROCHLORIDE	targetBased	4	Withdrawn	01/08/2012	https://clinicaltrials.gov/study/NCT01631513	1	GoF	protect	It was a business decision to cancel this study in Aug. 2012.
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis, hip	TAPENTADOL HYDROCHLORIDE	targetBased	4	Withdrawn	01/08/2012	https://clinicaltrials.gov/study/NCT01631513	1	GoF	protect	It was a business decision to cancel this study in Aug. 2012.
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	bone fracture	TAPENTADOL HYDROCHLORIDE	targetBased	4	Completed	05/07/2021	https://clinicaltrials.gov/study/NCT05999890	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	bone fracture	TAPENTADOL HYDROCHLORIDE	targetBased	4	Completed	05/07/2021	https://clinicaltrials.gov/study/NCT05999890	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis, knee	TAPENTADOL HYDROCHLORIDE	targetBased	4	Withdrawn	01/08/2012	https://clinicaltrials.gov/study/NCT01631513	1	GoF	protect	It was a business decision to cancel this study in Aug. 2012.
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis, knee	TAPENTADOL HYDROCHLORIDE	targetBased	4	Withdrawn	01/08/2012	https://clinicaltrials.gov/study/NCT01631513	1	GoF	protect	It was a business decision to cancel this study in Aug. 2012.
qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen	IL-1b Inflammasome	IL1B	Interleukin-1 beta	sterile multifocal osteomyelitis with periostitis and pustulosis	RILONACEPT	pathwayBased	2	Completed	12/02/2013	https://clinicaltrials.gov/study/NCT01801449	0.2	LoF	protect
qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen	IL-1b Inflammasome	IL1B	Interleukin-1 beta	familial Mediterranean fever	RILONACEPT	pathwayBased	2	Completed	01/08/2008	https://clinicaltrials.gov/study/NCT00582907	0.2	LoF	protect
qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen	IL-1b Inflammasome	IL1B	Interleukin-1 beta	gout	RILONACEPT	pathwayBased	3	Completed	01/03/2009	https://clinicaltrials.gov/study/NCT00855920	0.7	LoF	protect
qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen	IL-1b Inflammasome	IL1B	Interleukin-1 beta	gout	RILONACEPT	pathwayBased	2	Completed	01/11/2007	https://clinicaltrials.gov/study/NCT00610363	0.2	LoF	protect
qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen	IL-1b Inflammasome	IL1B	Interleukin-1 beta	gout	RILONACEPT	pathwayBased	3	Completed	01/07/2009	https://clinicaltrials.gov/study/NCT00958438	0.7	LoF	protect
qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen	IL-1b Inflammasome	IL1B	Interleukin-1 beta	gout	RILONACEPT	pathwayBased	3	Completed	01/03/2009	https://clinicaltrials.gov/study/NCT00856206	0.7	LoF	protect
qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen	IL-1b Inflammasome	IL1B	Interleukin-1 beta	gout	RILONACEPT	pathwayBased	3	Completed	01/02/2009	https://clinicaltrials.gov/study/NCT00829829	0.7	LoF	protect
qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen	IL-1b Inflammasome	IL1B	Interleukin-1 beta	gout	RILONACEPT	pathwayBased	3	Terminated	01/11/2011	https://clinicaltrials.gov/study/NCT01459796	0.7	LoF	protect
qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen	IL-1b Inflammasome	IL1B	Interleukin-1 beta	cryopyrin-associated periodic syndrome	RILONACEPT	pathwayBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=282f4099-e848-432a-bac1-e041c192a5ba	1	LoF	protect
qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen	IL-1b Inflammasome	IL1B	Interleukin-1 beta	cryopyrin-associated periodic syndrome	RILONACEPT	pathwayBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/rilonacept-regeneron-previously-arcalyst	1	LoF	protect
qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen	IL-1b Inflammasome	IL1B	Interleukin-1 beta	juvenile idiopathic arthritis	RILONACEPT	pathwayBased	2	Completed	01/11/2008	https://clinicaltrials.gov/study/NCT00534495	0.2	LoF	protect
qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen	IL-1b Inflammasome	IL1B	Interleukin-1 beta	Muckle-Wells syndrome	RILONACEPT	pathwayBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=282f4099-e848-432a-bac1-e041c192a5ba	1	LoF	protect
qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen	IL-1b Inflammasome	IL1B	Interleukin-1 beta	Muckle-Wells syndrome	RILONACEPT	pathwayBased	3	Completed	01/12/2005	https://clinicaltrials.gov/study/NCT00288704	0.7	LoF	protect
qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen	IL-1b Inflammasome	IL1B	Interleukin-1 beta	psoriatic arthritis	CANAKINUMAB	pathwayBased	4	Recruiting	15/11/2021	https://clinicaltrials.gov/study/NCT05080218	1	LoF	protect
qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen	IL-1b Inflammasome	IL1B	Interleukin-1 beta	Schnitzler syndrome	CANAKINUMAB	pathwayBased	2	Completed	01/01/2011	https://clinicaltrials.gov/study/NCT01276522	0.2	LoF	protect
qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen	IL-1b Inflammasome	IL1B	Interleukin-1 beta	Schnitzler syndrome	CANAKINUMAB	pathwayBased	2	Completed	01/07/2011	https://clinicaltrials.gov/study/NCT01390350	0.2	LoF	protect
qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen	IL-1b Inflammasome	IL1B	Interleukin-1 beta	Schnitzler syndrome	CANAKINUMAB	pathwayBased	2	Completed	01/05/2011	https://clinicaltrials.gov/study/NCT01245127	0.2	LoF	protect
qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen	IL-1b Inflammasome	IL1B	Interleukin-1 beta	adult-onset Still's disease	CANAKINUMAB	pathwayBased	3	Active, not recruiting	30/03/2021	https://clinicaltrials.gov/study/NCT04717635	0.7	LoF	protect
qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen	IL-1b Inflammasome	IL1B	Interleukin-1 beta	adult-onset Still's disease	CANAKINUMAB	pathwayBased	2	Terminated	21/06/2012	https://clinicaltrials.gov/study/NCT02204293	0.2	LoF	protect	Recruitment issues due to marketing authorization of study drug
qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen	IL-1b Inflammasome	IL1B	Interleukin-1 beta	mevalonate kinase deficiency	CANAKINUMAB	pathwayBased	2	Completed	01/03/2011	https://clinicaltrials.gov/study/NCT01303380	0.2	LoF	protect
qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen	IL-1b Inflammasome	IL1B	Interleukin-1 beta	mevalonate kinase deficiency	CANAKINUMAB	pathwayBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7d271f3b-e4f9-4d80-8dcf-28d49123f80e	1	LoF	protect
qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen	IL-1b Inflammasome	IL1B	Interleukin-1 beta	familial Mediterranean fever	CANAKINUMAB	pathwayBased	2	Completed	01/04/2010	https://clinicaltrials.gov/study/NCT01088880	0.2	LoF	protect
qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen	IL-1b Inflammasome	IL1B	Interleukin-1 beta	familial Mediterranean fever	CANAKINUMAB	pathwayBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7d271f3b-e4f9-4d80-8dcf-28d49123f80e	1	LoF	protect
qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen	IL-1b Inflammasome	IL1B	Interleukin-1 beta	familial Mediterranean fever	CANAKINUMAB	pathwayBased	2	Completed	01/12/2010	https://clinicaltrials.gov/study/NCT01148797	0.2	LoF	protect
qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen	IL-1b Inflammasome	IL1B	Interleukin-1 beta	osteoarthritis	CANAKINUMAB	pathwayBased	2	Completed	01/04/2010	https://clinicaltrials.gov/study/NCT01160822	0.2	LoF	protect
qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen	IL-1b Inflammasome	IL1B	Interleukin-1 beta	sickle cell anemia	CANAKINUMAB	pathwayBased	2	Completed	05/04/2017	https://clinicaltrials.gov/study/NCT02961218	0.2	LoF	protect
qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen	IL-1b Inflammasome	IL1B	Interleukin-1 beta	CINCA syndrome	CANAKINUMAB	pathwayBased	3	Terminated	26/01/2009	https://clinicaltrials.gov/study/NCT00770601	0.7	LoF	protect
qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen	IL-1b Inflammasome	IL1B	Interleukin-1 beta	osteoarthritis, knee	CANAKINUMAB	pathwayBased	2	Active, not recruiting	27/08/2021	https://clinicaltrials.gov/study/NCT04814368	0.2	LoF	protect
qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen	IL-1b Inflammasome	IL1B	Interleukin-1 beta	systemic juvenile idiopathic arthritis	CANAKINUMAB	pathwayBased	3	Completed	01/07/2009	https://clinicaltrials.gov/study/NCT00889863	0.7	LoF	protect
qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen	IL-1b Inflammasome	IL1B	Interleukin-1 beta	systemic juvenile idiopathic arthritis	CANAKINUMAB	pathwayBased	3	Completed	07/05/2015	https://clinicaltrials.gov/study/NCT02396212	0.7	LoF	protect
qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen	IL-1b Inflammasome	IL1B	Interleukin-1 beta	systemic juvenile idiopathic arthritis	CANAKINUMAB	pathwayBased	3	Terminated	01/07/2009	https://clinicaltrials.gov/study/NCT00886769	0.35	LoF	protect	recommendation by Data Monitoring Committee
qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen	IL-1b Inflammasome	IL1B	Interleukin-1 beta	systemic juvenile idiopathic arthritis	CANAKINUMAB	pathwayBased	3	Withdrawn	01/01/2013	https://clinicaltrials.gov/study/NCT01676948	0.7	LoF	protect
qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen	IL-1b Inflammasome	IL1B	Interleukin-1 beta	systemic juvenile idiopathic arthritis	CANAKINUMAB	pathwayBased	3	Completed	01/09/2009	https://clinicaltrials.gov/study/NCT00891046	0.7	LoF	protect
qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen	IL-1b Inflammasome	IL1B	Interleukin-1 beta	systemic juvenile idiopathic arthritis	CANAKINUMAB	pathwayBased	3	Completed	03/11/2014	https://clinicaltrials.gov/study/NCT02334748	0.7	LoF	protect
qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen	IL-1b Inflammasome	IL1B	Interleukin-1 beta	systemic juvenile idiopathic arthritis	CANAKINUMAB	pathwayBased	3	Completed	17/11/2014	https://clinicaltrials.gov/study/NCT02296424	0.7	LoF	protect
qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen	IL-1b Inflammasome	IL1B	Interleukin-1 beta	gout	CANAKINUMAB	pathwayBased	3	Withdrawn	01/09/2012	https://clinicaltrials.gov/study/NCT01593527	0.7	LoF	protect
qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen	IL-1b Inflammasome	IL1B	Interleukin-1 beta	gout	CANAKINUMAB	pathwayBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/ilaris	1	LoF	protect
qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen	IL-1b Inflammasome	IL1B	Interleukin-1 beta	gout	CANAKINUMAB	pathwayBased	3	Completed	01/11/2011	https://clinicaltrials.gov/study/NCT01470989	0.7	LoF	protect
qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen	IL-1b Inflammasome	IL1B	Interleukin-1 beta	gout	CANAKINUMAB	pathwayBased	3	Completed	01/12/2009	https://clinicaltrials.gov/study/NCT01029652	0.7	LoF	protect
qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen	IL-1b Inflammasome	IL1B	Interleukin-1 beta	gout	CANAKINUMAB	pathwayBased	3	Completed	01/05/2011	https://clinicaltrials.gov/study/NCT01356602	0.7	LoF	protect
qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen	IL-1b Inflammasome	IL1B	Interleukin-1 beta	gout	CANAKINUMAB	pathwayBased	2	Completed	01/04/2008	https://clinicaltrials.gov/study/NCT00663169	0.2	LoF	protect
qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen	IL-1b Inflammasome	IL1B	Interleukin-1 beta	gout	CANAKINUMAB	pathwayBased	3	Completed	25/08/2011	https://clinicaltrials.gov/study/NCT01431638	0.7	LoF	protect
qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen	IL-1b Inflammasome	IL1B	Interleukin-1 beta	gout	CANAKINUMAB	pathwayBased	2	Completed	05/06/2009	https://clinicaltrials.gov/study/NCT00927810	0.2	LoF	protect
qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen	IL-1b Inflammasome	IL1B	Interleukin-1 beta	gout	CANAKINUMAB	pathwayBased	2	Completed	01/12/2008	https://clinicaltrials.gov/study/NCT00819585	0.2	LoF	protect
qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen	IL-1b Inflammasome	IL1B	Interleukin-1 beta	gout	CANAKINUMAB	pathwayBased	2	Completed	01/11/2008	https://clinicaltrials.gov/study/NCT00798369	0.2	LoF	protect
qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen	IL-1b Inflammasome	IL1B	Interleukin-1 beta	gout	CANAKINUMAB	pathwayBased	3	Terminated	20/06/2011	https://clinicaltrials.gov/study/NCT01362608	0.7	LoF	protect
qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen	IL-1b Inflammasome	IL1B	Interleukin-1 beta	gout	CANAKINUMAB	pathwayBased	3	Completed	01/03/2010	https://clinicaltrials.gov/study/NCT01080131	0.7	LoF	protect
qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen	IL-1b Inflammasome	IL1B	Interleukin-1 beta	cryopyrin-associated periodic syndrome	CANAKINUMAB	pathwayBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7d271f3b-e4f9-4d80-8dcf-28d49123f80e	1	LoF	protect
qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen	IL-1b Inflammasome	IL1B	Interleukin-1 beta	cryopyrin-associated periodic syndrome	CANAKINUMAB	pathwayBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/ilaris	1	LoF	protect
qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen	IL-1b Inflammasome	IL1B	Interleukin-1 beta	juvenile idiopathic arthritis	CANAKINUMAB	pathwayBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/ilaris	1	LoF	protect
qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen	IL-1b Inflammasome	IL1B	Interleukin-1 beta	juvenile idiopathic arthritis	CANAKINUMAB	pathwayBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7d271f3b-e4f9-4d80-8dcf-28d49123f80e	1	LoF	protect
qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen	IL-1b Inflammasome	IL1B	Interleukin-1 beta	Muckle-Wells syndrome	CANAKINUMAB	pathwayBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7d271f3b-e4f9-4d80-8dcf-28d49123f80e	1	LoF	protect
qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen	IL-1b Inflammasome	IL1B	Interleukin-1 beta	pulmonary sarcoidosis	CANAKINUMAB	pathwayBased	2	Completed	19/12/2016	https://clinicaltrials.gov/study/NCT02888080	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	fibromyalgia	TRAMADOL	targetBased	3	Completed	01/05/2012	https://clinicaltrials.gov/study/NCT01598753	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	fibromyalgia	TRAMADOL	targetBased	3	Completed	01/05/2012	https://clinicaltrials.gov/study/NCT01598753	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	rotator cuff tear	TRAMADOL	targetBased	4	Completed	01/09/2011	https://clinicaltrials.gov/study/NCT02850211	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	rotator cuff tear	TRAMADOL	targetBased	4	Completed	01/09/2011	https://clinicaltrials.gov/study/NCT02850211	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	rotator cuff tear	TRAMADOL	targetBased	2	Completed	22/09/2016	https://clinicaltrials.gov/study/NCT03380533	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	rotator cuff tear	TRAMADOL	targetBased	2	Completed	22/09/2016	https://clinicaltrials.gov/study/NCT03380533	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	hip fracture	TRAMADOL	targetBased	4	Completed	21/04/2021	https://clinicaltrials.gov/study/NCT04837924	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	hip fracture	TRAMADOL	targetBased	4	Completed	21/04/2021	https://clinicaltrials.gov/study/NCT04837924	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	hip fracture	TRAMADOL	targetBased	2	Completed	01/01/2010	https://clinicaltrials.gov/study/NCT01630343	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	hip fracture	TRAMADOL	targetBased	2	Completed	01/01/2010	https://clinicaltrials.gov/study/NCT01630343	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis, knee	TRAMADOL	targetBased	3	Completed	01/04/2003	https://clinicaltrials.gov/study/NCT00833911	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis, knee	TRAMADOL	targetBased	3	Completed	01/04/2003	https://clinicaltrials.gov/study/NCT00833911	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis, knee	TRAMADOL	targetBased	2	Completed	30/08/2018	https://clinicaltrials.gov/study/NCT03850587	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis, knee	TRAMADOL	targetBased	2	Completed	30/08/2018	https://clinicaltrials.gov/study/NCT03850587	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pulpitis	TRAMADOL	targetBased	4	Completed	01/04/2014	https://clinicaltrials.gov/study/NCT02110966	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pulpitis	TRAMADOL	targetBased	4	Completed	01/04/2014	https://clinicaltrials.gov/study/NCT02110966	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pulpitis	TRAMADOL	targetBased	4	Completed	21/06/2021	https://clinicaltrials.gov/study/NCT05488925	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	pulpitis	TRAMADOL	targetBased	4	Completed	21/06/2021	https://clinicaltrials.gov/study/NCT05488925	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	ankylosing spondylitis	TRAMADOL	targetBased	4	Completed	01/03/2008	https://clinicaltrials.gov/study/NCT00647517	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	ankylosing spondylitis	TRAMADOL	targetBased	4	Completed	01/03/2008	https://clinicaltrials.gov/study/NCT00647517	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis	TRAMADOL	targetBased	4	Completed	01/03/2008	https://clinicaltrials.gov/study/NCT01019265	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis	TRAMADOL	targetBased	4	Completed	01/03/2008	https://clinicaltrials.gov/study/NCT01019265	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis	TRAMADOL	targetBased	4	Recruiting	01/01/2019	https://clinicaltrials.gov/study/NCT03781544	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis	TRAMADOL	targetBased	4	Recruiting	01/01/2019	https://clinicaltrials.gov/study/NCT03781544	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis	TRAMADOL	targetBased	4	Completed	01/10/2007	https://clinicaltrials.gov/study/NCT01728246	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis	TRAMADOL	targetBased	4	Completed	01/10/2007	https://clinicaltrials.gov/study/NCT01728246	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis	TRAMADOL	targetBased	4	Completed	01/08/2005	https://clinicaltrials.gov/study/NCT01063842	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis	TRAMADOL	targetBased	4	Completed	01/08/2005	https://clinicaltrials.gov/study/NCT01063842	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis	TRAMADOL	targetBased	4	Completed	01/05/2007	https://clinicaltrials.gov/study/NCT00635349	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis	TRAMADOL	targetBased	4	Completed	01/05/2007	https://clinicaltrials.gov/study/NCT00635349	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis	TRAMADOL	targetBased	2	Completed	21/07/2016	https://clinicaltrials.gov/study/NCT02845271	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis	TRAMADOL	targetBased	2	Completed	21/07/2016	https://clinicaltrials.gov/study/NCT02845271	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	toothache	TRAMADOL	targetBased	3	Completed	01/06/2013	https://clinicaltrials.gov/study/NCT01920386	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	toothache	TRAMADOL	targetBased	3	Completed	01/06/2013	https://clinicaltrials.gov/study/NCT01920386	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Inguinal hernia	TRAMADOL	targetBased	4	Completed	01/09/2012	https://clinicaltrials.gov/study/NCT01943760	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Inguinal hernia	TRAMADOL	targetBased	4	Completed	01/09/2012	https://clinicaltrials.gov/study/NCT01943760	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis, hip	HYDROMORPHONE HYDROCHLORIDE	targetBased	3	Completed		https://clinicaltrials.gov/study/NCT00399048	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis, hip	HYDROMORPHONE HYDROCHLORIDE	targetBased	3	Completed		https://clinicaltrials.gov/study/NCT00399048	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis, knee	HYDROMORPHONE HYDROCHLORIDE	targetBased	3	Completed		https://clinicaltrials.gov/study/NCT00399048	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis, knee	HYDROMORPHONE HYDROCHLORIDE	targetBased	3	Completed		https://clinicaltrials.gov/study/NCT00399048	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	sickle cell anemia	HYDROMORPHONE HYDROCHLORIDE	targetBased	4	Completed	15/03/2015	https://clinicaltrials.gov/study/NCT02222246	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	sickle cell anemia	HYDROMORPHONE HYDROCHLORIDE	targetBased	4	Completed	15/03/2015	https://clinicaltrials.gov/study/NCT02222246	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis	TRAMADOL HYDROCHLORIDE	targetBased	4	Completed	01/05/2007	https://clinicaltrials.gov/study/NCT00635349	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis	TRAMADOL HYDROCHLORIDE	targetBased	4	Completed	01/05/2007	https://clinicaltrials.gov/study/NCT00635349	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis	TRAMADOL HYDROCHLORIDE	targetBased	4	Completed	01/08/2005	https://clinicaltrials.gov/study/NCT01063842	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis	TRAMADOL HYDROCHLORIDE	targetBased	4	Completed	01/08/2005	https://clinicaltrials.gov/study/NCT01063842	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	toothache	TRAMADOL HYDROCHLORIDE	targetBased	3	Completed	01/06/2013	https://clinicaltrials.gov/study/NCT01920386	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	toothache	TRAMADOL HYDROCHLORIDE	targetBased	3	Completed	01/06/2013	https://clinicaltrials.gov/study/NCT01920386	0.7	GoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	scoliosis	CLEVIDIPINE	targetBased	2	Completed	01/06/2012	https://clinicaltrials.gov/study/NCT01645111	0.2	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	myelofibrosis	FEDRATINIB	targetBased	3	Completed	27/03/2019	https://clinicaltrials.gov/study/NCT03755518	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	myelofibrosis	FEDRATINIB	targetBased	2	Completed	01/11/2012	https://clinicaltrials.gov/study/NCT01692366	0.2	LoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	muscular disease	ALFACALCIDOL	targetBased	3	Completed	01/04/2012	https://clinicaltrials.gov/study/NCT02327091	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	osteoporosis	ALFACALCIDOL	targetBased	4	Completed	01/08/2011	https://clinicaltrials.gov/study/NCT01430104	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	osteoporosis	ALFACALCIDOL	targetBased	2	Recruiting	12/10/2017	https://clinicaltrials.gov/study/NCT03183557	0.2	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	osteoporosis	ALFACALCIDOL	targetBased	3	Completed	01/09/2004	https://clinicaltrials.gov/study/NCT00144456	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	osteoporosis	ALFACALCIDOL	targetBased	4	Unknown status	01/01/2013	https://clinicaltrials.gov/study/NCT01765010	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	osteoporosis	ALFACALCIDOL	targetBased	3	Completed	01/05/2000	https://clinicaltrials.gov/study/NCT00138983	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	scoliosis	ALFACALCIDOL	targetBased	2	Recruiting	20/09/2018	https://clinicaltrials.gov/study/NCT03582917	0.2	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	systemic lupus erythematosus	ALFACALCIDOL	targetBased	4	Completed	01/04/2007	https://clinicaltrials.gov/study/NCT00668330	1	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	postmenopausal osteoporosis	ALFACALCIDOL	targetBased	3	Completed	01/05/2005	https://clinicaltrials.gov/study/NCT00165698	0.7	GoF	protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	sarcopenia	ALFACALCIDOL	targetBased	4	Not yet recruiting	13/02/2024	https://clinicaltrials.gov/study/NCT06272227	1	GoF	protect
Thrombin 1536 HTS	F2_modulation	F2	Prothrombin	total joint arthroplasty	DABIGATRAN ETEXILATE MESYLATE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/pradaxa	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	systemic lupus erythematosus	BRENTUXIMAB VEDOTIN	targetBased	2	Terminated	01/07/2015	https://clinicaltrials.gov/study/NCT02533570	0.2	LoF	protect	Sponsor decision based on portfolio prioritization
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	diffuse scleroderma	BRENTUXIMAB VEDOTIN	targetBased	2	Recruiting	14/02/2024	https://clinicaltrials.gov/study/NCT05149768	0.2	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	diffuse scleroderma	BRENTUXIMAB VEDOTIN	targetBased	2	Completed	07/05/2019	https://clinicaltrials.gov/study/NCT03198689	0.2	LoF	protect
qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen	IL-1b Inflammasome	IL1B	Interleukin-1 beta	osteoarthritis	GEVOKIZUMAB	pathwayBased	2	Completed	01/07/2012	https://clinicaltrials.gov/study/NCT01683396	0.2	LoF	protect
qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen	IL-1b Inflammasome	IL1B	Interleukin-1 beta	osteoarthritis	GEVOKIZUMAB	pathwayBased	2	Completed	01/05/2013	https://clinicaltrials.gov/study/NCT01882491	0.2	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	Hypereosinophilic syndrome	RUXOLITINIB	targetBased	2	Recruiting	26/09/2002	https://clinicaltrials.gov/study/NCT00044304	0.2	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	discoid lupus erythematosus	RUXOLITINIB	targetBased	2	Completed	04/05/2022	https://clinicaltrials.gov/study/NCT04908280	0.2	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	discoid lupus erythematosus	RUXOLITINIB	targetBased	2	Recruiting	19/04/2024	https://clinicaltrials.gov/study/NCT06261021	0.2	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	myelofibrosis	RUXOLITINIB	targetBased	2	Completed	20/08/2020	https://clinicaltrials.gov/study/NCT04218071	0.2	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	myelofibrosis	RUXOLITINIB	targetBased	3	Completed	06/12/2013	https://clinicaltrials.gov/study/NCT01969838	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	myelofibrosis	RUXOLITINIB	targetBased	2	Completed	29/09/2016	https://clinicaltrials.gov/study/NCT02784496	0.2	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	myelofibrosis	RUXOLITINIB	targetBased	2	Active, not recruiting	28/08/2018	https://clinicaltrials.gov/study/NCT03427866	0.2	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	myelofibrosis	RUXOLITINIB	targetBased	2	Terminated	03/05/2021	https://clinicaltrials.gov/study/NCT04543279	0.2	LoF	protect	Low accrual
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	myelofibrosis	RUXOLITINIB	targetBased	2	Recruiting	16/12/2021	https://clinicaltrials.gov/study/NCT05037760	0.2	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	myelofibrosis	RUXOLITINIB	targetBased	2	Terminated	01/11/2013	https://clinicaltrials.gov/study/NCT01790295	0.2	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	myelofibrosis	RUXOLITINIB	targetBased	4	Completed	01/05/2012	https://clinicaltrials.gov/study/NCT01558739	1	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	myelofibrosis	RUXOLITINIB	targetBased	3	Completed	16/08/2011	https://clinicaltrials.gov/study/NCT01493414	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	myelofibrosis	RUXOLITINIB	targetBased	2	Completed	01/10/2013	https://clinicaltrials.gov/study/NCT01981850	0.2	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	myelofibrosis	RUXOLITINIB	targetBased	3	Recruiting	11/03/2021	https://clinicaltrials.gov/study/NCT04562389	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	myelofibrosis	RUXOLITINIB	targetBased	2	Active, not recruiting	20/10/2014	https://clinicaltrials.gov/study/NCT02251821	0.2	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	myelofibrosis	RUXOLITINIB	targetBased	3	Terminated	03/02/2016	https://clinicaltrials.gov/study/NCT02598297	0.7	LoF	protect	Unresolvable inability to recruit the patients.
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	myelofibrosis	RUXOLITINIB	targetBased	3	Completed	01/07/2009	https://clinicaltrials.gov/study/NCT00934544	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	myelofibrosis	RUXOLITINIB	targetBased	2	Completed	30/06/2011	https://clinicaltrials.gov/study/NCT01369498	0.2	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	myelofibrosis	RUXOLITINIB	targetBased	4	Recruiting	10/06/2022	https://clinicaltrials.gov/study/NCT05447260	1	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	myelofibrosis	RUXOLITINIB	targetBased	2	Completed	21/02/2013	https://clinicaltrials.gov/study/NCT01712308	0.2	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	myelofibrosis	RUXOLITINIB	targetBased	2	Active, not recruiting	27/02/2017	https://clinicaltrials.gov/study/NCT03069326	0.2	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	myelofibrosis	RUXOLITINIB	targetBased	2	Completed	01/03/2011	https://clinicaltrials.gov/study/NCT01340651	0.2	LoF	protect
Primary biochemical high-throughput screening assay for inhibitors of Rho kinase 2 (Rhok2)	ROCK2	ROCK2	Rho-associated protein kinase 2	diffuse scleroderma	BELUMOSUDIL	targetBased	2	Terminated	03/03/2021	https://clinicaltrials.gov/study/NCT04680975	0.2	LoF	protect	Sponsor decision due to slow enrollment and strategic consideration; not driven by any safety concerns.
Primary biochemical high-throughput screening assay for inhibitors of Rho kinase 2 (Rhok2)	ROCK2	ROCK2	Rho-associated protein kinase 2	diffuse scleroderma	BELUMOSUDIL	targetBased	2	Terminated	26/06/2019	https://clinicaltrials.gov/study/NCT03919799	0.2	LoF	protect	Sponsor decision due to slow enrollment and strategic consideration; not driven by any safety concerns.
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	myelofibrosis	PACRITINIB	targetBased	2	Active, not recruiting	04/06/2018	https://clinicaltrials.gov/study/NCT03645824	0.2	LoF	protect
Fluorescence-based biochemical primary high throughput screening assay to identify activators of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	TNNI3	Troponin I, cardiac muscle	muscular disease	LEVOSIMENDAN	targetBased	2	Unknown status	01/09/2012	https://clinicaltrials.gov/study/NCT01721434	0.2	GoF	protect
Fluorescence-based biochemical primary high throughput screening assay to identify inhibitors of the calcium sensitivity of cardiac Regulated Thin Filaments (RTF)	TNNI3	TNNI3	Troponin I, cardiac muscle	muscular disease	LEVOSIMENDAN	targetBased	2	Unknown status	01/09/2012	https://clinicaltrials.gov/study/NCT01721434	0.2	GoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	ankylosing spondylitis	TOFACITINIB CITRATE	targetBased	2	Recruiting	26/04/2023	https://clinicaltrials.gov/study/NCT05814939	0.2	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	psoriatic arthritis	TOFACITINIB CITRATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=68e3d6b2-7838-4d2d-a417-09d919b43e13	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis, hip	MORPHINE SULFATE	targetBased	4	Unknown status	01/09/2009	https://clinicaltrials.gov/study/NCT01281891	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis, hip	MORPHINE SULFATE	targetBased	4	Unknown status	01/09/2009	https://clinicaltrials.gov/study/NCT01281891	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	bone fracture	MORPHINE SULFATE	targetBased	4	Completed	01/12/2018	https://clinicaltrials.gov/study/NCT03693404	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	bone fracture	MORPHINE SULFATE	targetBased	4	Completed	01/12/2018	https://clinicaltrials.gov/study/NCT03693404	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	hip fracture	MORPHINE SULFATE	targetBased	4	Completed	01/10/2008	https://clinicaltrials.gov/study/NCT01904071	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	hip fracture	MORPHINE SULFATE	targetBased	4	Completed	01/10/2008	https://clinicaltrials.gov/study/NCT01904071	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis, knee	MORPHINE SULFATE	targetBased	2	Unknown status	01/08/2015	https://clinicaltrials.gov/study/NCT02967302	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis, knee	MORPHINE SULFATE	targetBased	2	Unknown status	01/08/2015	https://clinicaltrials.gov/study/NCT02967302	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis, knee	MORPHINE SULFATE	targetBased	4	Completed	01/04/2008	https://clinicaltrials.gov/study/NCT00901628	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis, knee	MORPHINE SULFATE	targetBased	4	Completed	01/04/2008	https://clinicaltrials.gov/study/NCT00901628	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis, knee	MORPHINE SULFATE	targetBased	2	Completed	01/04/2014	https://clinicaltrials.gov/study/NCT02860949	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis, knee	MORPHINE SULFATE	targetBased	2	Completed	01/04/2014	https://clinicaltrials.gov/study/NCT02860949	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	sickle cell anemia	MORPHINE SULFATE	targetBased	4	Completed	15/03/2015	https://clinicaltrials.gov/study/NCT02222246	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	sickle cell anemia	MORPHINE SULFATE	targetBased	4	Completed	15/03/2015	https://clinicaltrials.gov/study/NCT02222246	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	sickle cell anemia	MORPHINE SULFATE	targetBased	4	Terminated	01/03/2011	https://clinicaltrials.gov/study/NCT00880373	1	GoF	protect	The funding withdrawal and early termination of the trial is based upon lack of suitable recruitment figures in order to reach the required trial endpoints.
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	sickle cell anemia	MORPHINE SULFATE	targetBased	4	Terminated	01/03/2011	https://clinicaltrials.gov/study/NCT00880373	1	GoF	protect	The funding withdrawal and early termination of the trial is based upon lack of suitable recruitment figures in order to reach the required trial endpoints.
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	sickle cell anemia	MORPHINE SULFATE	targetBased	2	Completed	01/11/2019	https://clinicaltrials.gov/study/NCT04301336	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	sickle cell anemia	MORPHINE SULFATE	targetBased	2	Completed	01/11/2019	https://clinicaltrials.gov/study/NCT04301336	0.2	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	gout	ARHALOFENATE	targetBased	2	Completed	01/03/2014	https://clinicaltrials.gov/study/NCT02063997	0.2		protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	gout	ARHALOFENATE	targetBased	2	Completed	01/03/2014	https://clinicaltrials.gov/study/NCT02063997	0.2		protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	gout	ARHALOFENATE	targetBased	2	Completed	01/03/2014	https://clinicaltrials.gov/study/NCT02063997	0.2		protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	gout	ARHALOFENATE	targetBased	2	Completed	01/03/2014	https://clinicaltrials.gov/study/NCT02063997	0.2		protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	gout	ARHALOFENATE	targetBased	2	Completed	01/03/2014	https://clinicaltrials.gov/study/NCT02063997	0.2		protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	gout	ARHALOFENATE	targetBased	2	Completed	01/03/2014	https://clinicaltrials.gov/study/NCT02063997	0.2		protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	gout	ARHALOFENATE	targetBased	2	Completed	01/06/2011	https://clinicaltrials.gov/study/NCT01399008	0.2		protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	gout	ARHALOFENATE	targetBased	2	Completed	01/06/2011	https://clinicaltrials.gov/study/NCT01399008	0.2		protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	gout	ARHALOFENATE	targetBased	2	Completed	01/06/2011	https://clinicaltrials.gov/study/NCT01399008	0.2		protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	gout	ARHALOFENATE	targetBased	2	Completed	01/06/2011	https://clinicaltrials.gov/study/NCT01399008	0.2		protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	gout	ARHALOFENATE	targetBased	2	Completed	01/06/2011	https://clinicaltrials.gov/study/NCT01399008	0.2		protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	gout	ARHALOFENATE	targetBased	2	Completed	01/06/2011	https://clinicaltrials.gov/study/NCT01399008	0.2		protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	fibromyalgia	DROXIDOPA	targetBased	2	Completed	01/01/2009	https://clinicaltrials.gov/study/NCT01323374	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	fibromyalgia	FAXELADOL	targetBased	2	Completed	19/09/2005	https://clinicaltrials.gov/study/NCT03783910	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	fibromyalgia	FAXELADOL	targetBased	2	Completed	19/09/2005	https://clinicaltrials.gov/study/NCT03783910	0.2	GoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	juvenile dermatomyositis	BARICITINIB	targetBased	2	Recruiting	10/11/2022	https://clinicaltrials.gov/study/NCT05524311	0.2	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	myositis	BARICITINIB	targetBased	2	Completed	07/10/2021	https://clinicaltrials.gov/study/NCT04208464	0.2	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	systemic lupus erythematosus	BARICITINIB	targetBased	3	Completed	02/08/2018	https://clinicaltrials.gov/study/NCT03616964	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	systemic lupus erythematosus	BARICITINIB	targetBased	2	Completed	24/03/2016	https://clinicaltrials.gov/study/NCT02708095	0.2	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	systemic lupus erythematosus	BARICITINIB	targetBased	3	Terminated	09/09/2019	https://clinicaltrials.gov/study/NCT03843125	0.35	LoF	protect	Study terminated due to insufficient evidence to support a positive benefit: risk profile. Safety findings were consistent with previously published OLUMIANT data
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	systemic lupus erythematosus	BARICITINIB	targetBased	3	Terminated	02/08/2018	https://clinicaltrials.gov/study/NCT03616912	0.35	LoF	protect	Study terminated due to insufficient evidence to support a positive benefit: risk profile in systemic lupus erythematosus patients.
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	systemic scleroderma	BARICITINIB	targetBased	4	Recruiting	08/03/2022	https://clinicaltrials.gov/study/NCT05300932	1	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	dermatomyositis	BARICITINIB	targetBased	2	Withdrawn	01/06/2022	https://clinicaltrials.gov/study/NCT05361109	0.2	LoF	protect	Difficulty recruiting subjects
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	dermatomyositis	BARICITINIB	targetBased	3	Recruiting	31/08/2022	https://clinicaltrials.gov/study/NCT04972760	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	psoriatic arthritis	BARICITINIB	targetBased	4	Recruiting	15/11/2021	https://clinicaltrials.gov/study/NCT05080218	1	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	Aicardi-Goutieres syndrome	BARICITINIB	targetBased	2	Completed	03/06/2019	https://clinicaltrials.gov/study/NCT03921554	0.2	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	systemic juvenile idiopathic arthritis	BARICITINIB	targetBased	3	Recruiting	12/02/2020	https://clinicaltrials.gov/study/NCT04088396	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	juvenile idiopathic arthritis	BARICITINIB	targetBased	3	Completed	17/12/2018	https://clinicaltrials.gov/study/NCT03773978	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	juvenile idiopathic arthritis	BARICITINIB	targetBased	3	Recruiting	05/04/2019	https://clinicaltrials.gov/study/NCT03773965	0.7	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	postmenopausal osteoporosis	BAZEDOXIFENE ACETATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e1b75458-2e5b-46b9-92c6-fa6daba3770f	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	postmenopausal osteoporosis	BAZEDOXIFENE ACETATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e1b75458-2e5b-46b9-92c6-fa6daba3770f	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	postmenopausal osteoporosis	BAZEDOXIFENE ACETATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bfdd5d5b-7569-4848-afa2-e820fbe3c8fb	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	postmenopausal osteoporosis	BAZEDOXIFENE ACETATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bfdd5d5b-7569-4848-afa2-e820fbe3c8fb	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	postmenopausal osteoporosis	BAZEDOXIFENE ACETATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e16705d8-4472-4f83-96ac-69fa2be066cb	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	postmenopausal osteoporosis	BAZEDOXIFENE ACETATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e16705d8-4472-4f83-96ac-69fa2be066cb	1		protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	postmenopausal osteoporosis	BAZEDOXIFENE ACETATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=bfdd5d5b-7569-4848-afa2-e820fbe3c8fb	1		protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	postmenopausal osteoporosis	BAZEDOXIFENE ACETATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e16705d8-4472-4f83-96ac-69fa2be066cb	1		protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	postmenopausal osteoporosis	BAZEDOXIFENE ACETATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=e1b75458-2e5b-46b9-92c6-fa6daba3770f	1		protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	osteoporosis	BAZEDOXIFENE ACETATE	targetBased	3	Completed	01/07/2001	https://clinicaltrials.gov/study/NCT00481169	0.7		protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	osteoporosis	BAZEDOXIFENE ACETATE	targetBased	3	Completed	01/12/2001	https://clinicaltrials.gov/study/NCT00205777	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	osteoporosis	BAZEDOXIFENE ACETATE	targetBased	3	Completed	01/07/2001	https://clinicaltrials.gov/study/NCT00481169	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	osteoporosis	BAZEDOXIFENE ACETATE	targetBased	3	Completed	01/07/2001	https://clinicaltrials.gov/study/NCT00481169	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	osteoporosis	BAZEDOXIFENE ACETATE	targetBased	3	Completed	01/12/2001	https://clinicaltrials.gov/study/NCT00205777	0.7		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	osteoporosis	BAZEDOXIFENE ACETATE	targetBased	3	Completed	01/12/2001	https://clinicaltrials.gov/study/NCT00205777	0.7		protect
Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2 Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity	KEAP1	KEAP1	Kelch-like ECH-associated protein 1	psoriatic arthritis	DIMETHYL FUMARATE	targetBased	2	Withdrawn	01/05/2015	https://clinicaltrials.gov/study/NCT02475304	0.2	LoF	protect	Difficulties to enrol patients
Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of myeloid cell leukemia sequence 1 (MCL1) interactions with BIM-BH3 peptide.	MCL1	MCL1	Induced myeloid leukemia cell differentiation protein Mcl-1 , MCL1 apoptosis regulator, BCL2 family member, Myeloid cell leukemia ES variant	myelofibrosis	OBATOCLAX MESYLATE	targetBased	2	Completed	01/07/2006	https://clinicaltrials.gov/study/NCT00360035	0.2	LoF	protect
uHTS of Mcl-1/Bid interaction inhibitors	MCL1	MCL1	Induced myeloid leukemia cell differentiation protein Mcl-1 , MCL1 apoptosis regulator, BCL2 family member, Myeloid cell leukemia ES variant	myelofibrosis	OBATOCLAX MESYLATE	targetBased	2	Completed	01/07/2006	https://clinicaltrials.gov/study/NCT00360035	0.2	LoF	protect
uHTS of Mcl-1/Noxa interaction inhibitors	MCL1	MCL1	Induced myeloid leukemia cell differentiation protein Mcl-1 , MCL1 apoptosis regulator, BCL2 family member, Myeloid cell leukemia ES variant	myelofibrosis	OBATOCLAX MESYLATE	targetBased	2	Completed	01/07/2006	https://clinicaltrials.gov/study/NCT00360035	0.2	LoF	protect
Multiplexed high-throughput screen for small molecule regulators of Bcl-2 family protein interactions, specifically Bim-Bfl-1	BCL2A1_modulators	BCL2A1	Bcl-2-related protein A1	myelofibrosis	OBATOCLAX MESYLATE	targetBased	2	Completed	01/07/2006	https://clinicaltrials.gov/study/NCT00360035	0.2	LoF	protect
Primary biochemical high throughput screening assay to identify inhibitors of BCL2-related protein, long isoform (BCLXL).	BCL2L1_modulators	BCL2L1	Bcl-2-like protein 1	myelofibrosis	OBATOCLAX MESYLATE	targetBased	2	Completed	01/07/2006	https://clinicaltrials.gov/study/NCT00360035	0.2	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	spinal cord injury	NERISPIRDINE	targetBased	2	Completed	01/10/2004	https://clinicaltrials.gov/study/NCT00093275	0.2	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	spinal cord injury	NERISPIRDINE	targetBased	2	Completed	01/10/2004	https://clinicaltrials.gov/study/NCT00093275	0.2	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	spinal cord injury	NERISPIRDINE	targetBased	2	Completed	01/10/2004	https://clinicaltrials.gov/study/NCT00093275	0.2	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	spinal cord injury	NERISPIRDINE	targetBased	2	Completed	01/10/2004	https://clinicaltrials.gov/study/NCT00093275	0.2	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	spinal cord injury	NERISPIRDINE	targetBased	2	Completed	01/10/2004	https://clinicaltrials.gov/study/NCT00093275	0.2	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	spinal cord injury	NERISPIRDINE	targetBased	2	Completed	01/10/2004	https://clinicaltrials.gov/study/NCT00093275	0.2	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	spinal cord injury	NERISPIRDINE	targetBased	2	Completed	01/10/2004	https://clinicaltrials.gov/study/NCT00093275	0.2	LoF	protect
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	PTH1R	Parathyroid hormone/parathyroid hormone-related peptide receptor	postmenopausal osteoporosis	PARATHYROID HORMONE	targetBased	4	Completed	01/11/2007	https://clinicaltrials.gov/study/NCT00583518	1	GoF	protect
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	PTH1R	Parathyroid hormone/parathyroid hormone-related peptide receptor	postmenopausal osteoporosis	PARATHYROID HORMONE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/natpar	1	GoF	protect
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	PTH1R	Parathyroid hormone/parathyroid hormone-related peptide receptor	osteoporosis	PARATHYROID HORMONE	targetBased	3	Completed	10/01/2005	https://clinicaltrials.gov/study/NCT00172120	0.7	GoF	protect
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	PTH1R	Parathyroid hormone/parathyroid hormone-related peptide receptor	osteoporosis	PARATHYROID HORMONE	targetBased	3	Completed	01/09/1999	https://clinicaltrials.gov/study/NCT00000427	0.7	GoF	protect
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	PTH1R	Parathyroid hormone/parathyroid hormone-related peptide receptor	osteoporosis	PARATHYROID HORMONE	targetBased	2	Completed	01/10/1999	https://clinicaltrials.gov/study/NCT00005005	0.2	GoF	protect
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	PTH1R	Parathyroid hormone/parathyroid hormone-related peptide receptor	osteoporosis	PARATHYROID HORMONE	targetBased	2	Completed	01/09/1987	https://clinicaltrials.gov/study/NCT00005006	0.2	GoF	protect
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	PTH1R	Parathyroid hormone/parathyroid hormone-related peptide receptor	osteoporosis	PARATHYROID HORMONE	targetBased	4	Recruiting	01/07/2019	https://clinicaltrials.gov/study/NCT03994172	1	GoF	protect
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	PTH1R	Parathyroid hormone/parathyroid hormone-related peptide receptor	osteoporosis	PARATHYROID HORMONE	targetBased	4	Completed	01/04/2007	https://clinicaltrials.gov/study/NCT00479037	1	GoF	protect
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	PTH1R	Parathyroid hormone/parathyroid hormone-related peptide receptor	osteoporosis	PARATHYROID HORMONE	targetBased	3	Completed	27/04/2000	https://clinicaltrials.gov/study/NCT00172081	0.7	GoF	protect
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	PTH1R	Parathyroid hormone/parathyroid hormone-related peptide receptor	osteoporosis	PARATHYROID HORMONE	targetBased	4	Completed	01/09/2005	https://clinicaltrials.gov/study/NCT00221299	1	GoF	protect
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	PTH1R	Parathyroid hormone/parathyroid hormone-related peptide receptor	osteoporosis	PARATHYROID HORMONE	targetBased	2	Completed	01/05/2008	https://clinicaltrials.gov/study/NCT00683163	0.2	GoF	protect
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	PTH1R	Parathyroid hormone/parathyroid hormone-related peptide receptor	osteoporosis	PARATHYROID HORMONE	targetBased	2	Completed	01/08/1999	https://clinicaltrials.gov/study/NCT00004993	0.2	GoF	protect
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	PTH1R	Parathyroid hormone/parathyroid hormone-related peptide receptor	osteoporosis	PARATHYROID HORMONE	targetBased	3	Completed	16/10/2001	https://clinicaltrials.gov/study/NCT00172133	0.7	GoF	protect
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	PTH1R	Parathyroid hormone/parathyroid hormone-related peptide receptor	osteoporosis	PARATHYROID HORMONE	targetBased	2	Completed	18/05/1995	https://clinicaltrials.gov/study/NCT00172107	0.2	GoF	protect
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	PTH1R	Parathyroid hormone/parathyroid hormone-related peptide receptor	osteoporosis	PARATHYROID HORMONE	targetBased	3	Completed	10/01/2004	https://clinicaltrials.gov/study/NCT00172172	0.7	GoF	protect
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	PTH1R	Parathyroid hormone/parathyroid hormone-related peptide receptor	osteoporosis	PARATHYROID HORMONE	targetBased	3	Completed	01/07/2006	https://clinicaltrials.gov/study/NCT00365456	0.7	GoF	protect
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	PTH1R	Parathyroid hormone/parathyroid hormone-related peptide receptor	osteoporosis	PARATHYROID HORMONE	targetBased	2	Completed	01/05/2009	https://clinicaltrials.gov/study/NCT00853723	0.2	GoF	protect
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	PTH1R	Parathyroid hormone/parathyroid hormone-related peptide receptor	osteoporosis	PARATHYROID HORMONE	targetBased	2	Completed	01/06/1999	https://clinicaltrials.gov/study/NCT00021827	0.2	GoF	protect
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	PTH1R	Parathyroid hormone/parathyroid hormone-related peptide receptor	osteoporosis	PARATHYROID HORMONE	targetBased	2	Completed	01/08/1999	https://clinicaltrials.gov/study/NCT00000400	0.2	GoF	protect
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	PTH1R	Parathyroid hormone/parathyroid hormone-related peptide receptor	bone fracture	PARATHYROID HORMONE	targetBased	4	Unknown status	01/03/2012	https://clinicaltrials.gov/study/NCT01687374	1	GoF	protect
Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn6) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )]	FGB_inhibitors	FGB	Fibrinogen beta chain [Cleaved into: Fibrinopeptide B; Fibrinogen beta chain]	osteoarthritis	FIBRINOGEN, HUMAN	targetBased	4	Completed	01/09/2010	https://clinicaltrials.gov/study/NCT01235715	1		protect
Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn7) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )]	FGB_inhibitors	FGB	Fibrinogen beta chain [Cleaved into: Fibrinopeptide B; Fibrinogen beta chain]	osteoarthritis	FIBRINOGEN, HUMAN	targetBased	4	Completed	01/09/2010	https://clinicaltrials.gov/study/NCT01235715	1		protect
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	S1PR1	Sphingosine 1-phosphate receptor 1	dermatomyositis	SIPONIMOD	targetBased	2	Terminated	15/06/2010	https://clinicaltrials.gov/study/NCT01148810	0.2	GoF	protect	Trial was prematurely terminated due to enrollment challenges.
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	S1PR1	Sphingosine 1-phosphate receptor 1	polymyositis	SIPONIMOD	targetBased	2	Terminated	24/04/2013	https://clinicaltrials.gov/study/NCT01801917	0.2	GoF	protect
qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS	TXNRD1	TXNRD1	Thioredoxin reductase 1, cytoplasmic	rheumatic disease	AUROTHIOGLUCOSE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=M01CB04	1	LoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	rotator cuff tear	CLOMIPHENE	targetBased	2	Recruiting	09/03/2023	https://clinicaltrials.gov/study/NCT04944836	0.2		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	rotator cuff tear	CLOMIPHENE	targetBased	2	Recruiting	09/03/2023	https://clinicaltrials.gov/study/NCT04944836	0.2		protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis, knee	CEBRANOPADOL	targetBased	2	Completed	01/05/2011	https://clinicaltrials.gov/study/NCT01357837	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis, knee	CEBRANOPADOL	targetBased	2	Completed	01/05/2011	https://clinicaltrials.gov/study/NCT01357837	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis, knee	CEBRANOPADOL	targetBased	2	Completed	04/12/2012	https://clinicaltrials.gov/study/NCT01709214	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis, knee	CEBRANOPADOL	targetBased	2	Completed	04/12/2012	https://clinicaltrials.gov/study/NCT01709214	0.2	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	osteoarthritis, knee	CEBRANOPADOL	targetBased	2	Completed	04/12/2012	https://clinicaltrials.gov/study/NCT01709214	0.2	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	osteoarthritis, knee	CEBRANOPADOL	targetBased	2	Completed	01/05/2011	https://clinicaltrials.gov/study/NCT01357837	0.2	GoF	protect
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	rotator cuff tear	CLOMIPHENE CITRATE	targetBased	2	Recruiting	09/03/2023	https://clinicaltrials.gov/study/NCT04944836	0.2		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	rotator cuff tear	CLOMIPHENE CITRATE	targetBased	2	Recruiting	09/03/2023	https://clinicaltrials.gov/study/NCT04944836	0.2		protect
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	PTH1R	Parathyroid hormone/parathyroid hormone-related peptide receptor	postmenopausal osteoporosis	ABALOPARATIDE	targetBased	4	Recruiting	01/02/2021	https://clinicaltrials.gov/study/NCT04467983	1	GoF	protect
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	PTH1R	Parathyroid hormone/parathyroid hormone-related peptide receptor	postmenopausal osteoporosis	ABALOPARATIDE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/eladynos	1	GoF	protect
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	PTH1R	Parathyroid hormone/parathyroid hormone-related peptide receptor	postmenopausal osteoporosis	ABALOPARATIDE	targetBased	3	Completed	05/08/2019	https://clinicaltrials.gov/study/NCT04064411	0.7	GoF	protect
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	PTH1R	Parathyroid hormone/parathyroid hormone-related peptide receptor	postmenopausal osteoporosis	ABALOPARATIDE	targetBased	3	Completed	01/04/2011	https://clinicaltrials.gov/study/NCT01343004	0.7	GoF	protect
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	PTH1R	Parathyroid hormone/parathyroid hormone-related peptide receptor	osteoporosis	ABALOPARATIDE	targetBased	3	Completed	03/05/2018	https://clinicaltrials.gov/study/NCT03512262	0.7	GoF	protect
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	PTH1R	Parathyroid hormone/parathyroid hormone-related peptide receptor	osteoporosis	ABALOPARATIDE	targetBased	2	Completed	01/04/2007	https://clinicaltrials.gov/study/NCT00542425	0.2	GoF	protect
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	PTH1R	Parathyroid hormone/parathyroid hormone-related peptide receptor	osteoporosis	ABALOPARATIDE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208743lbl.pdf	1	GoF	protect
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	PTH1R	Parathyroid hormone/parathyroid hormone-related peptide receptor	osteoporosis	ABALOPARATIDE	targetBased	3	Completed	01/04/2011	https://clinicaltrials.gov/study/NCT01343004	0.7	GoF	protect
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	PTH1R	Parathyroid hormone/parathyroid hormone-related peptide receptor	osteoporosis	ABALOPARATIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=712143d9-e21e-4013-bb3b-3426a21060a8	1	GoF	protect
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	PTH1R	Parathyroid hormone/parathyroid hormone-related peptide receptor	osteoporosis	ABALOPARATIDE	targetBased	4	Active, not recruiting	10/01/2020	https://clinicaltrials.gov/study/NCT04167163	1	GoF	protect
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	PTH1R	Parathyroid hormone/parathyroid hormone-related peptide receptor	osteoporosis	ABALOPARATIDE	targetBased	2	Completed	25/09/2012	https://clinicaltrials.gov/study/NCT01674621	0.2	GoF	protect
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	PTH1R	Parathyroid hormone/parathyroid hormone-related peptide receptor	osteoporosis	ABALOPARATIDE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/eladynos	1	GoF	protect
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	PTH1R	Parathyroid hormone/parathyroid hormone-related peptide receptor	bone fracture	ABALOPARATIDE	targetBased	4	Withdrawn	01/06/2024	https://clinicaltrials.gov/study/NCT04626141	1	GoF	protect	Study withdrawn due to staffing/enrollment related challenges.
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	PTH1R	Parathyroid hormone/parathyroid hormone-related peptide receptor	bone fracture	ABALOPARATIDE	targetBased	2	Recruiting	18/05/2022	https://clinicaltrials.gov/study/NCT04760782	0.2	GoF	protect
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	PTH1R	Parathyroid hormone/parathyroid hormone-related peptide receptor	fracture of pelvis	ABALOPARATIDE	targetBased	2	Completed	17/09/2020	https://clinicaltrials.gov/study/NCT04249232	0.2	GoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	systemic lupus erythematosus	FILGOTINIB	targetBased	2	Completed	06/10/2017	https://clinicaltrials.gov/study/NCT03285711	0.2	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	ankylosing spondylitis	FILGOTINIB	targetBased	2	Completed	07/03/2017	https://clinicaltrials.gov/study/NCT03117270	0.2	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	ankylosing spondylitis	FILGOTINIB	targetBased	3	Withdrawn	01/12/2020	https://clinicaltrials.gov/study/NCT04483687	0.7	LoF	protect	Development program terminated
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	ankylosing spondylitis	FILGOTINIB	targetBased	3	Withdrawn	01/12/2020	https://clinicaltrials.gov/study/NCT04483700	0.7	LoF	protect	Development program terminated
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	psoriatic arthritis	FILGOTINIB	targetBased	2	Completed	09/03/2017	https://clinicaltrials.gov/study/NCT03101670	0.2	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	psoriatic arthritis	FILGOTINIB	targetBased	3	Terminated	03/12/2019	https://clinicaltrials.gov/study/NCT04115748	0.7	LoF	protect	Development program terminated
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	psoriatic arthritis	FILGOTINIB	targetBased	3	Terminated	13/11/2019	https://clinicaltrials.gov/study/NCT04115839	0.7	LoF	protect	Development program terminated
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	psoriatic arthritis	FILGOTINIB	targetBased	2	Terminated	26/07/2017	https://clinicaltrials.gov/study/NCT03320876	0.2	LoF	protect	development program for filgotinib for participants with psoriatic arthritis has been stopped
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	cutaneous lupus erythematosus	FILGOTINIB	targetBased	2	Completed	24/05/2017	https://clinicaltrials.gov/study/NCT03134222	0.2	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	spondyloarthropathy	FILGOTINIB	targetBased	3	Active, not recruiting	05/04/2023	https://clinicaltrials.gov/study/NCT05785611	0.7	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	spinal muscular atrophy, type III	AMIFAMPRIDINE PHOSPHATE	targetBased	2	Terminated	07/03/2019	https://clinicaltrials.gov/study/NCT03819660	0.2	LoF	protect	Development of indication not being pursued
Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	spinal muscular atrophy, type III	AMIFAMPRIDINE PHOSPHATE	targetBased	2	Terminated	07/03/2019	https://clinicaltrials.gov/study/NCT03819660	0.2	LoF	protect	Development of indication not being pursued
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	spinal muscular atrophy	AMIFAMPRIDINE PHOSPHATE	targetBased	2	Completed	21/01/2019	https://clinicaltrials.gov/study/NCT03781479	0.2	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	spinal muscular atrophy	AMIFAMPRIDINE PHOSPHATE	targetBased	2	Completed	21/01/2019	https://clinicaltrials.gov/study/NCT03781479	0.2	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	spinal muscular atrophy, type III	AMIFAMPRIDINE PHOSPHATE	targetBased	2	Terminated	07/03/2019	https://clinicaltrials.gov/study/NCT03819660	0.2	LoF	protect	Development of indication not being pursued
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	KCNQ1	Potassium voltage-gated channel subfamily KQT member 1	spinal muscular atrophy, type III	AMIFAMPRIDINE PHOSPHATE	targetBased	2	Terminated	07/03/2019	https://clinicaltrials.gov/study/NCT03819660	0.2	LoF	protect	Development of indication not being pursued
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	spinal muscular atrophy, type III	AMIFAMPRIDINE PHOSPHATE	targetBased	2	Terminated	07/03/2019	https://clinicaltrials.gov/study/NCT03819660	0.2	LoF	protect	Development of indication not being pursued
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	spinal muscular atrophy, type III	AMIFAMPRIDINE PHOSPHATE	targetBased	2	Terminated	07/03/2019	https://clinicaltrials.gov/study/NCT03819660	0.2	LoF	protect	Development of indication not being pursued
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	spinal muscular atrophy, type III	AMIFAMPRIDINE PHOSPHATE	targetBased	2	Terminated	07/03/2019	https://clinicaltrials.gov/study/NCT03819660	0.2	LoF	protect	Development of indication not being pursued
Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	spinal muscular atrophy	AMIFAMPRIDINE PHOSPHATE	targetBased	2	Completed	21/01/2019	https://clinicaltrials.gov/study/NCT03781479	0.2	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Wildtype qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	spinal muscular atrophy	AMIFAMPRIDINE PHOSPHATE	targetBased	2	Completed	21/01/2019	https://clinicaltrials.gov/study/NCT03781479	0.2	LoF	protect
qHTS for Inhibitors of KCHN2 3.1: Mutant qHTS	KCNH2	KCNH2	Potassium voltage-gated channel subfamily H member 2 , Voltage-gated inwardly rectifying potassium channel KCNH2	spinal muscular atrophy	AMIFAMPRIDINE PHOSPHATE	targetBased	2	Completed	21/01/2019	https://clinicaltrials.gov/study/NCT03781479	0.2	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	spinal muscular atrophy	AMIFAMPRIDINE PHOSPHATE	targetBased	2	Completed	21/01/2019	https://clinicaltrials.gov/study/NCT03781479	0.2	LoF	protect
Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels	KCNQ2	KCNQ2	Potassium voltage-gated channel subfamily KQT member 2	spinal muscular atrophy	AMIFAMPRIDINE PHOSPHATE	targetBased	2	Completed	21/01/2019	https://clinicaltrials.gov/study/NCT03781479	0.2	LoF	protect
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	S1PR1	Sphingosine 1-phosphate receptor 1	cutaneous lupus erythematosus	KRP203	targetBased	2	Completed	01/02/2011	https://clinicaltrials.gov/study/NCT01294774	0.2	GoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	systemic lupus erythematosus	UPADACITINIB	targetBased	2	Completed	27/07/2020	https://clinicaltrials.gov/study/NCT04451772	0.2	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	systemic lupus erythematosus	UPADACITINIB	targetBased	2	Completed	25/07/2019	https://clinicaltrials.gov/study/NCT03978520	0.2	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	ankylosing spondylitis	UPADACITINIB	targetBased	3	Active, not recruiting	26/11/2019	https://clinicaltrials.gov/study/NCT04169373	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	ankylosing spondylitis	UPADACITINIB	targetBased	2	Completed	24/10/2017	https://clinicaltrials.gov/study/NCT03178487	0.2	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	psoriatic arthritis	UPADACITINIB	targetBased	3	Active, not recruiting	27/04/2017	https://clinicaltrials.gov/study/NCT03104400	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	psoriatic arthritis	UPADACITINIB	targetBased	3	Active, not recruiting	01/05/2017	https://clinicaltrials.gov/study/NCT03104374	0.7	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	psoriatic arthritis	UPADACITINIB	targetBased	4	Recruiting	15/11/2021	https://clinicaltrials.gov/study/NCT05080218	1	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	juvenile idiopathic arthritis	UPADACITINIB	targetBased	3	Recruiting	02/10/2023	https://clinicaltrials.gov/study/NCT05609630	0.7	LoF	protect
Identification of agents that induce E-selectin on human endothelial cells Measured in Cell-Based System Using Imaging - 2152-01_Activator_SinglePoint_HTS_Activity	SELE	SELE	E-selectin	sickle cell anemia	RIVIPANSEL	targetBased	3	Completed	17/06/2015	https://clinicaltrials.gov/study/NCT02187003	0.7	LoF	protect
Primary HTS assay for chemical inhibitors of TNF alpha stimulated E-Selectin expression	E-selectinExpression	SELE	E-Selectin	sickle cell anemia	RIVIPANSEL	targetBased	3	Completed	17/06/2015	https://clinicaltrials.gov/study/NCT02187003	0.7	LoF	protect
High Throughput Screen to Identify Compounds that increase expression of NF-kB in Human Neuronal Cells - Primary Screen	NFKB1	NFKB1	Nuclear factor NF-kappa-B p105 subunit	Duchenne muscular dystrophy	EDASALONEXENT	pathwayBased	3	Terminated	14/03/2019	https://clinicaltrials.gov/study/NCT03917719	0.35	LoF	protect	The Phase 3 PolarisDMD trial did not meet the primary endpoint. As a result, activities related to the development of edasalonexent have stopped including the CAT-1004-302 Open-Label Study of Edasalonexent in Boys With Duchenne Muscular Dystrophy
uHTS identification of cystic fibrosis induced NFkb Inhibitors in a fluoresence assay	NFKB1	NFKB1	Cystic fibrosis transmembrane conductance regulator	Duchenne muscular dystrophy	EDASALONEXENT	pathwayBased	3	Terminated	14/03/2019	https://clinicaltrials.gov/study/NCT03917719	0.35	LoF	protect	The Phase 3 PolarisDMD trial did not meet the primary endpoint. As a result, activities related to the development of edasalonexent have stopped including the CAT-1004-302 Open-Label Study of Edasalonexent in Boys With Duchenne Muscular Dystrophy
High Throughput Screen to Identify Compounds that increase expression of NF-kB in Human Neuronal Cells - Primary Screen	NFKB1	NFKB1	Nuclear factor NF-kappa-B p105 subunit	Duchenne muscular dystrophy	EDASALONEXENT	pathwayBased	3	Completed	02/10/2018	https://clinicaltrials.gov/study/NCT03703882	0.7	LoF	protect
uHTS identification of cystic fibrosis induced NFkb Inhibitors in a fluoresence assay	NFKB1	NFKB1	Cystic fibrosis transmembrane conductance regulator	Duchenne muscular dystrophy	EDASALONEXENT	pathwayBased	3	Completed	02/10/2018	https://clinicaltrials.gov/study/NCT03703882	0.7	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	rotator cuff tear	HYDROCODONE BITARTRATE	targetBased	4	Withdrawn	01/01/2015	https://clinicaltrials.gov/study/NCT02153177	1	GoF	protect	The study was withdrawn prior to any participants being enrolled.
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	rotator cuff tear	HYDROCODONE BITARTRATE	targetBased	2	Completed	22/01/2019	https://clinicaltrials.gov/study/NCT03818919	0.2	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	osteoarthritis	HYDROCODONE BITARTRATE	targetBased	2	Completed	01/09/2002	https://clinicaltrials.gov/study/NCT02222740	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	rotator cuff tear	HYDROCODONE BITARTRATE	targetBased	4	Withdrawn	01/01/2015	https://clinicaltrials.gov/study/NCT02153177	1	GoF	protect	The study was withdrawn prior to any participants being enrolled.
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	rotator cuff tear	HYDROCODONE BITARTRATE	targetBased	4	Withdrawn	01/01/2015	https://clinicaltrials.gov/study/NCT02153177	1	GoF	protect	The study was withdrawn prior to any participants being enrolled.
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	rotator cuff tear	HYDROCODONE BITARTRATE	targetBased	2	Completed	22/01/2019	https://clinicaltrials.gov/study/NCT03818919	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	rotator cuff tear	HYDROCODONE BITARTRATE	targetBased	2	Completed	22/01/2019	https://clinicaltrials.gov/study/NCT03818919	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis	HYDROCODONE BITARTRATE	targetBased	2	Completed	01/09/2002	https://clinicaltrials.gov/study/NCT02222740	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis	HYDROCODONE BITARTRATE	targetBased	2	Completed	01/09/2002	https://clinicaltrials.gov/study/NCT02222740	0.2	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	osteoarthritis	DIFELIKEFALIN	targetBased	2	Completed	01/08/2015	https://clinicaltrials.gov/study/NCT02524197	0.2	GoF	protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	systemic lupus erythematosus	IBERDOMIDE	targetBased	2	Completed	31/08/2017	https://clinicaltrials.gov/study/NCT03161483	0.2		protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	systemic lupus erythematosus	IBERDOMIDE	targetBased	2	Completed	16/09/2014	https://clinicaltrials.gov/study/NCT02185040	0.2		protect
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	RBX1	E3 ubiquitin-protein ligase RBX1	sarcoidosis	IBERDOMIDE	targetBased	2	Withdrawn	01/11/2014	https://clinicaltrials.gov/study/NCT02192489	0.2		protect	Administrative
uHTS Luminescent assay for identification of inhibitors of NALP3 in yeast	NLRP3	NLRP3	NACHT, LRR and PYD domains-containing protein 3, NACHT, LRR and PYD domains-containing protein 3	Schnitzler syndrome	DAPANSUTRILE	targetBased	2	Terminated	15/05/2018	https://clinicaltrials.gov/study/NCT03595371	0.2	LoF	protect	The study was terminated due to study design issues that did not allow for determination of efficacy and safety in subjects with Schnitzler Syndrome who are currently well controlled on anakinra therapy.
Toxoplasma gondii inhibition HTS in the presence of IFN-y	IFNG	IFNG	Interferon gamma	adult-onset Still's disease	EMAPALUMAB	targetBased	3	Recruiting	15/12/2021	https://clinicaltrials.gov/study/NCT05001737	0.7	LoF	protect
Toxoplasma gondii inhibition HTS in the presence of IFN-y	IFNG	IFNG	Interferon gamma	systemic juvenile idiopathic arthritis	EMAPALUMAB	targetBased	3	Recruiting	15/12/2021	https://clinicaltrials.gov/study/NCT05001737	0.7	LoF	protect
Toxoplasma gondii inhibition HTS in the presence of IFN-y	IFNG	IFNG	Interferon gamma	systemic lupus erythematosus	EMAPALUMAB	targetBased	3	Recruiting	15/12/2021	https://clinicaltrials.gov/study/NCT05001737	0.7	LoF	protect
qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode)	GLP1R	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	osteoarthritis, knee	LIRAGLUTIDE	targetBased	4	Completed	01/11/2016	https://clinicaltrials.gov/study/NCT02910570	1	GoF	protect
qHTS of GLP-1 Receptor Agonists	GLP1R agonists	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	osteoarthritis, knee	LIRAGLUTIDE	targetBased	4	Completed	01/11/2016	https://clinicaltrials.gov/study/NCT02910570	1	GoF	protect
qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs)	GLP1R PAMs	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	osteoarthritis, knee	LIRAGLUTIDE	targetBased	4	Completed	01/11/2016	https://clinicaltrials.gov/study/NCT02910570	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	diffuse scleroderma	LANIFIBRANOR	targetBased	2	Completed	29/10/2015	https://clinicaltrials.gov/study/NCT02503644	0.2	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	diffuse scleroderma	LANIFIBRANOR	targetBased	2	Completed	29/10/2015	https://clinicaltrials.gov/study/NCT02503644	0.2	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	diffuse scleroderma	LANIFIBRANOR	targetBased	2	Completed	29/10/2015	https://clinicaltrials.gov/study/NCT02503644	0.2	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	diffuse scleroderma	LANIFIBRANOR	targetBased	2	Completed	29/10/2015	https://clinicaltrials.gov/study/NCT02503644	0.2	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	diffuse scleroderma	LANIFIBRANOR	targetBased	2	Completed	29/10/2015	https://clinicaltrials.gov/study/NCT02503644	0.2	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	diffuse scleroderma	LANIFIBRANOR	targetBased	2	Completed	29/10/2015	https://clinicaltrials.gov/study/NCT02503644	0.2	GoF	protect
HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen	AKT1_inhibitors	AKT1	RAC-alpha serine/threonine-protein kinase	Proteus syndrome	MIRANSERTIB	targetBased	2	Recruiting	20/05/2022	https://clinicaltrials.gov/study/NCT04316546	0.2	LoF	protect
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	S1PR1	Sphingosine 1-phosphate receptor 1	systemic lupus erythematosus	CENERIMOD	targetBased	3	Not yet recruiting	01/07/2024	https://clinicaltrials.gov/study/NCT06475742	0.7		protect
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	S1PR1	Sphingosine 1-phosphate receptor 1	systemic lupus erythematosus	CENERIMOD	targetBased	3	Recruiting	13/12/2022	https://clinicaltrials.gov/study/NCT05648500	0.7		protect
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	S1PR1	Sphingosine 1-phosphate receptor 1	systemic lupus erythematosus	CENERIMOD	targetBased	2	Completed	21/12/2018	https://clinicaltrials.gov/study/NCT03742037	0.2		protect
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	S1PR1	Sphingosine 1-phosphate receptor 1	systemic lupus erythematosus	CENERIMOD	targetBased	3	Recruiting	26/06/2023	https://clinicaltrials.gov/study/NCT05672576	0.7		protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	discoid lupus erythematosus	DELGOCITINIB	targetBased	2	Terminated	09/07/2019	https://clinicaltrials.gov/study/NCT03958955	0.2	LoF	protect	Terminated due to recruitment challenges.
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	osteoporosis	ELDECALCITOL	targetBased	3	Completed	01/09/2004	https://clinicaltrials.gov/study/NCT00144456	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis, knee	OXYCODEGOL	targetBased	2	Completed	01/06/2012	https://clinicaltrials.gov/study/NCT01619839	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	osteoarthritis, knee	OXYCODEGOL	targetBased	2	Completed	01/06/2012	https://clinicaltrials.gov/study/NCT01619839	0.2	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	TLR9	Toll-like receptor 9	dermatomyositis	BAZLITORAN	targetBased	2	Completed	01/11/2015	https://clinicaltrials.gov/study/NCT02612857	0.2	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	AL amyloidosis	BELANTAMAB MAFODOTIN	targetBased	2	Recruiting	26/02/2021	https://clinicaltrials.gov/study/NCT04617925	0.2	LoF	protect
Nrf2 qHTS screen for inhibitors	nrf2Inhibitors	NFE2L2	Nuclear factor erythroid 2-related factor 2	Friedreich ataxia	OMAVELOXOLONE	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216718Orig1s000lbl.pdf	1	GoF	protect
qHTS of Nrf2 Activators	Nrf2 activators	NFE2L2	NFE2 like bZIP transcription factor 2, Nuclear factor erythroid 2-related factor 2	Friedreich ataxia	OMAVELOXOLONE	pathwayBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216718Orig1s000lbl.pdf	1	GoF	protect
Nrf2 qHTS screen for inhibitors	nrf2Inhibitors	NFE2L2	Nuclear factor erythroid 2-related factor 2	Friedreich ataxia	OMAVELOXOLONE	targetBased	2	Active, not recruiting	31/01/2015	https://clinicaltrials.gov/study/NCT02255435	0.2	GoF	protect
qHTS of Nrf2 Activators	Nrf2 activators	NFE2L2	NFE2 like bZIP transcription factor 2, Nuclear factor erythroid 2-related factor 2	Friedreich ataxia	OMAVELOXOLONE	pathwayBased	2	Active, not recruiting	31/01/2015	https://clinicaltrials.gov/study/NCT02255435	0.2	GoF	protect
qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen	IL-1b Inflammasome	IL1B	Interleukin-1 beta	osteoarthritis, hand	LUTIKIZUMAB	pathwayBased	2	Completed	01/03/2015	https://clinicaltrials.gov/study/NCT02384538	0.2	LoF	protect
qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen	IL-1b Inflammasome	IL1B	Interleukin-1 beta	osteoarthritis, knee	LUTIKIZUMAB	pathwayBased	2	Completed	04/06/2014	https://clinicaltrials.gov/study/NCT02087904	0.2	LoF	protect
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	PTH1R	Parathyroid hormone/parathyroid hormone-related peptide receptor	hip fracture	OSTABOLIN-C	targetBased	2	Withdrawn	01/12/2008	https://clinicaltrials.gov/study/NCT00787358	0.2	GoF	protect	Change in company direction
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	ESR1	Estrogen receptor, Estrogen receptor	postmenopausal osteoporosis		targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/fablyn	1		protect
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	ESR1	Estrogen receptor, Estrogen receptor	postmenopausal osteoporosis		targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/fablyn	1		protect
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	ESR2	Estrogen receptor beta	postmenopausal osteoporosis		targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/fablyn	1		protect

Partner with DrTarget for AI-Optimized Screening

We welcome collaborations with biotech companies, research institutions, and pharmaceutical partners looking to leverage AI for drug discovery. Get in touch to explore custom screening solutions and accelerate your research.